

Peter Rossing
Overlæge
Steno Diabetes Center Copenhagen
Besøgsadresse:
Niels Steensens Vej 2-4
NSK
2820
Gentofte
Danmark
E-mail: peter.rossing@regionh.dk
Telefon: 30913383



Primære forskningsområder

diabetisk nefropati, kardiovaskulær sygdom, neuropati og metabolomics

Ansættelse

Overlæge
Steno Diabetes Center Copenhagen
Region Hovedstaden
Gentofte, Danmark
1 jan. 2017 → nu

Steno Diabetes Center A/S

Gentofte, Danmark
fortid → 1 jan. 2016

Professor i endokrinologi med fokus på diabetisk karsygdom

University of Copenhagen
Copenhagen, Danmark

Publikationer

Association of Coding Variants in Hydroxysteroid 17-beta Dehydrogenase 14 (HSD17B14) with Reduced Progression to End Stage Kidney Disease in Type 1 Diabetes

Mychaleckyj, J., Valo, E., Ichimura, T., Ahluwalia, T., Dina, C., Miller, R., Shabalin, I., Gyorgy, B., Cao, J., Onengut-Gumuscu, S., Satake, E., Smiles, A., Haukka, J., Tregouet, D-A., Costacou, T., O'Neil, K., Paterson, A., Forsblom, C., Keenan, H., Pezzolesi, M., Pragnell, M., Galecki, A., Rich, S., Sandholm, N., Klein, R., Klein, B., Susztak, K., Orchard, T., Korstanje, R., King, G., Hadjadj, S., Rossing, P., Bonventre, J., Groop, P-H., Warram, J. & Krolewski, A., okt. 2021, I: Journal of the American Society of Nephrology : JASN. 32, 10, s. 2634-2651 18 s.

New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race

Chronic Kidney Disease Epidemiology Collaboration, 23 sep. 2021, (E-pub ahead of print) I: The New England journal of medicine.

Early Response in Albuminuria and Long-Term Kidney Protection during Treatment with an Endothelin Receptor Antagonist: A Prespecified Analysis from the SONAR Trial

Heerspink, H., Xie, D., Bakris, G., Correa-Rotter, R., Hou, F-F., Kitzman, D., Kohan, D., Makino, H., McMurray, J., Perkovic, V., Rossing, P., Parving, H-H. & de Zeeuw, D., 22 sep. 2021, (E-pub ahead of print) I: Journal of the American Society of Nephrology.

A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

DAPA-CKD Trial Committees and Investigators, 21 sep. 2021, (E-pub ahead of print) I: Kidney International.

Effect of liraglutide on expression of inflammatory genes in type 2 diabetes

Zobel, E. H., Ripa, R. S., von Scholten, B. J., Rotbain Curovic, V., Kjaer, A., Hansen, T. W., Rossing, P. & Størling, J., 17 sep. 2021, I: Scientific Reports. 11, 1, s. 18522 18522.

Ceramides and phospholipids are downregulated with liraglutide treatment: results from the LiraFlame randomized controlled trial

Zobel, E. H., Wretling, A., Ripa, R. S., Rotbain Curovic, V., von Scholten, B. J., Suvitaival, T., Hansen, T. W., Kjær, A., Legido-Quigley, C. & Rossing, P., sep. 2021, I: *BMJ open diabetes research & care*. 9, 1, e002395.

Circulating Free Fatty Acid and Phospholipid Signature Predicts Early Rapid Kidney Function Decline in Patients With Type 1 Diabetes

Afshinnia, F., Rajendiran, T. M., He, C., Byun, J., Montemayor, D., Darshi, M., Tumova, J., Kim, J., Limonte, C. P., Miller, R. G., Costacou, T., Orchard, T. J., Ahluwalia, T. S., Rossing, P., Snell-Bergeon, J. K., de Boer, I. H., Natarajan, L., Michailidis, G., Sharma, K. & Pennathur, S., sep. 2021, I: *Diabetes Care*. 44, 9, s. 2098-2106 9 s.

Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease

Chertow, G., Vart, P., Jongs, N., Toto, R., Gorriz, J. L., Hou, F. F., McMurray, J., Correa-Rotter, R., Rossing, P., Sjöström, C. D., Stefánsson, B., Langkilde, A. M., Wheeler, D. & Heerspink, H., sep. 2021, I: *Journal of the American Society of Nephrology : JASN*. 32, 9, s. 2352-2361 10 s.

Prognostic and comparative performance of cardiovascular risk markers in patients with type 2 diabetes: 2型糖尿病患者心血管危险标志物的预后和比较表现

Busch, N., Jensen, M. T., Goetze, J. P., Schou, M., Biering-Sørensen, T., Fritz-Hansen, T., Andersen, H. U., Vilsbøll, T., Rossing, P. & Jørgensen, P. G., sep. 2021, I: *Journal of Diabetes*. 13, 9, s. 754-763 10 s.

Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes

FIGARO-DKD Investigators, 28 aug. 2021, (E-pub ahead of print) I: *The New England journal of medicine*.

Medical therapies for prevention of cardiovascular and renal events in patients with atrial fibrillation and diabetes mellitus

Fauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P. & Camm, A. J., 19 aug. 2021, (E-pub ahead of print) I: *Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology*.

Liraglutide reduces cardiac adipose tissue in type 2 diabetes: A secondary analysis of the LIRAFLAME randomized placebo-controlled trial

Rasmussen, I. K. B., Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Jensen, J. K., Kjaer, A., Hansen, T. W. & Rossing, P., 13 aug. 2021, (E-pub ahead of print) I: *Diabetes, Obesity and Metabolism*.

HbA1c and beyond

Rossing, P., 12 aug. 2021, (E-pub ahead of print) I: *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*.

Distinct Molecular Signatures of Clinical Clusters in People with Type 2 Diabetes: an IMIRHAPSODY Study

Slieker, R. C., Donnelly, L. A., Fitipaldi, H., Bouland, G. A., Giordano, G. N., Åkerlund, M., Gerl, M. J., Ahlqvist, E., Ali, A., Dragan, I., Elders, P., Festa, A., Hansen, M. K., van der Heijden, A. A., Aly, D. M., Kim, M., Kuznetsov, D., Mehl, F., Kloose, C., Simons, K., Pavo, I., Pullen, T. J., Suvitaival, T., Wretling, A., Rossing, P., Lyssenko, V., Quigley, C. L., Groop, L., Thorens, B., Franks, P. W., Ibberson, M., Rutter, G. A., Beulens, J. W., 't Hart, L. M. & Pearson, E. R., 10 aug. 2021, (E-pub ahead of print) I: *Diabetes*.

Effect of Liraglutide on Vascular Inflammation Evaluated by [64Cu]DOTATATE

Zobel, E. H., Ripa, R. S., von Scholten, B. J., Curovic, V. R., Diaz, L. J., Hansen, T. W., Rossing, P. & Kjaer, A., 8 aug. 2021, I: *Diagnostics*. 11, 8, 1431.

Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

DAPA-CKD Trial Committees and Investigators, 5 aug. 2021, (E-pub ahead of print) I: *JACC. Heart failure*.

Effects of Empagliflozin on Myocardial Flow Reserve in Patients With Type 2 Diabetes Mellitus: The SIMPLE Trial

Jürgens, M., Schou, M., Hasbak, P., Kjær, A., Wolsk, E., Zerahn, B., Wiberg, M., Brandt-Jacobsen, N. H., Gæde, P., Rossing, P., Faber, J., Inzucchi, S. E., Gustafsson, F. & Kistorp, C., 3 aug. 2021, I: *Journal of the American Heart Association*. 10, 15, s. e020418 e020418.

Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial
DAPA-CKD Trial Committees and Investigators, 1 aug. 2021, I: Diabetes Care. 44, 8, s. 1894-1897 4 s.

Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors for diabetes after solid organ transplantation

Ertuglu, L. A., Porrini, E., Hornum, M., Demiray, A., Afsar, B., Ortiz, A., Covic, A., Rossing, P. & Kanbay, M., aug. 2021, I: Transplant international : official journal of the European Society for Organ Transplantation. 34, 8, s. 1341-1359 19 s.

Faecal biomarkers in type 1 diabetes with and without diabetic nephropathy

Winther, S. A., Mannerla, M. M., Frimodt-Møller, M., Persson, F., Hansen, T. W., Lehto, M., Hörkkö, S., Blaut, M., Forsblom, C., Groop, P-H. & Rossing, P., 26 jul. 2021, I: Scientific Reports. 11, 1, s. 15208 15208.

Sodium-Glucose Cotransporter 2 Inhibitors for Diabetes Mellitus Control After Kidney Transplantation: Review of the Current Evidence

Kanbay, M., Demiray, A., Afsar, B., Karakus, K. E., Ortiz, A., Hornum, M., Covic, A., Sarafidis, P. & Rossing, P., 14 jul. 2021, (E-pub ahead of print) I: Nephrology.

Finerenone Reduces New-Onset Atrial Fibrillation in Patients With Chronic Kidney Disease and Type 2 Diabetes

FIDELIO-DKD Investigators, 13 jul. 2021, I: Journal of the American College of Cardiology. 78, 2, s. 142-152 11 s.

The low-expression variant of FABP4 is associated with cardiovascular disease in type 1 diabetes

FinnDiane study group, 9 jul. 2021, (E-pub ahead of print) I: Diabetes.

Urinary peptidome and diabetic retinopathy in the DIRECT-Protect 1 and 2 trials

DIRECT Programme Study Group, 6 jul. 2021, (E-pub ahead of print) I: Diabetic Medicine. s. e14634 e14634.

Acute effects of dapagliflozin on renal oxygenation and perfusion in type 1 diabetes with albuminuria: A randomised, double-blind, placebo-controlled crossover trial

Laursen, J. C., Søndergaard-Heinrich, N., de Melo, J. M. L., Haddock, B., Rasmussen, I. K. B., Safavimanesh, F., Hansen, C. S., Størling, J., Larsson, H. B. W., Groop, P-H., Frimodt-Møller, M., Andersen, U. B. & Rossing, P., jul. 2021, I: EClinicalMedicine. 37, s. 100895 100895.

A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

DAPA-CKD Trial Committees and Investigators, jul. 2021, I: Kidney International. 100, 1, s. 215-224 10 s.

Effect of Liraglutide on Arterial Inflammation Assessed as [18F]FDG Uptake in Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Trial

Ripa, R. S., Zobel, E. H., von Scholten, B. J., Jensen, J. K., Binderup, T., Diaz, L. J., Curovic, V. R., Hansen, T. W., Rossing, P. & Kjaer, A., jul. 2021, I: Circulation. Cardiovascular Imaging. 14, 7, s. e012174 e012174.

Endothelial glycocalyx and cardio-renal risk factors in type 1 diabetes

Stougaard, E. B., Winther, S. A., Amadid, H., Frimodt-Møller, M., Persson, F., Hansen, T. W. & Rossing, P., jul. 2021, I: PLoS One. 16, 7, s. e0254859 e0254859.

Successful glucose lowering therapy triumphs in heart failure

Rossing, P., jul. 2021, I: EClinicalMedicine. 37, s. 100996 100996.

Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study

Slieker, R. C., Donnelly, L. A., Fitipaldi, H., Bouland, G. A., Giordano, G. N., Åkerlund, M., Gerl, M. J., Ahlqvist, E., Ali, A., Dragan, I., Festa, A., Hansen, M. K., Mansour Aly, D., Kim, M., Kuznetsov, D., Mehl, F., Klose, C., Simons, K., Pavo, I., Pullen, T. J., Suvitaival, T., Wretling, A., Rossing, P., Lyssenko, V., Legido-Quigley, C., Groop, L., Thorens, B., Franks, P. W., Ibberson, M., Rutter, G. A., Beulens, J. W. J., 't Hart, L. M. & Pearson, E. R., 10 jun. 2021, (E-pub ahead of print) I: Diabetologia.

A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes. Diabetes Care 2021;44:901-907

Vistisen, D., Andersen, G. S., Hulman, A., McGurnaghan, S. J., Colhoun, H. M., Henriksen, J. E., Thomsen, R. W., Persson, F., Rossing, P. & Jørgensen, M. E., jun. 2021, I: Diabetes Care. 44, 6

Metformin and carotid intima-media thickness in never-smokers with type 1 diabetes: The REMOVAL trial

REMOVAL Study Group, jun. 2021, I: Diabetes, Obesity and Metabolism. 23, 6, s. 1371-1378 8 s.

Non-invasive assessment of temporal changes in myocardial microvascular function in persons with type 2 diabetes and healthy controls

Rasmussen, I. K. B., Hasbak, P., von Scholten, B. J., Laursen, J. C., Zobel, E. H., Jorge Diaz, L., Holmvang, L., Ripa, R. S., u, D. O. C., Kjaer, A. & Hansen, T. W., jun. 2021, I: Diabetic Medicine. 38, 6, s. e14517

Persons with type 1 diabetes have low blood oxygen levels in the supine and standing body positions

Laursen, J. C., Clemmensen, K. K. B., Hansen, C. S., Diaz, L. J., Bordino, M., Groop, P. H., Fridmodt-Møller, M., Bernardi, L. & Rossing, P., 31 maj 2021, I: BMJ Open Diabetes Research and Care. 9, 1, e001944.

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes

Sivalingam, S., Larsen, E. L., van Raalte, D. H., Muskiet, M. H. A., Smits, M. M., Tonneijck, L., Joles, J. A., von Scholten, B. J., Zobel, E. H., Persson, F., Henriksen, T., Diaz, L. J., Hansen, T. W., Poulsen, H. E. & Rossing, P., 19 maj 2021, I: Scientific Reports. 11, 1, s. 10624 10624.

Biomarkers for early detection of kidney disease: a call for pathophysiological relevance

Siwy, J., Mischak, H., Beige, J., Rossing, P. & Stegmayr, B., maj 2021, I: Kidney International. 99, 5, s. 1240-1241 2 s.

Genome-Wide Association Study of Circulating Interleukin 6 Levels Identifies Novel Loci

CHARGE Inflammation Working Group, 27 apr. 2021, I: Human Molecular Genetics. 30, 5, s. 393-409 17 s.

Meta-analysis uncovers genome-wide significant variants for rapid kidney function decline

Gorski, M., Jung, B., Li, Y., Matias-Garcia, P. R., Wuttke, M., Coassin, S., Thio, C. H. L., Kleber, M. E., Winkler, T. W., Wanner, V., Chai, J-F., Chu, A. Y., Cocca, M., Feitosa, M. F., Ghasemi, S., Hoppmann, A., Horn, K., Li, M., Nutile, T., Scholz, M., Sieber, K. B., Teumer, A., Tin, A., Wang, J., Tayo, B. O., Ahluwalia, T. S., Almgren, P., Bakker, S. J. L., Banas, B., Bansal, N., Biggs, M. L., Boerwinkle, E., Bottinger, E. P., Brenner, H., Carroll, R. J., Chalmers, J., Chee, M-L., Chee, M-L., Cheng, C-Y., Coresh, J., de Borst, M. H., Degenhardt, F., Eckardt, K-U., Endlich, K., Franke, A., Freitag-Wolf, S., Gampawar, P., Gansevoort, R. T., Ghanbari, M., Rossing, P. & LifeLines Cohort study, 1 apr. 2021, I: Kidney International. 99, 4, s. 926-939 14 s.

A narrative review of new treatment options for chronic kidney disease in type 2 diabetes

Persson, F., Borg, R. & Rossing, P., apr. 2021, I: Annals of Translational Medicine. 9, 8, s. 716

A Validated Prediction Model for End-Stage Kidney Disease in Type 1 Diabetes

Vistisen, D., Andersen, G. S., Hulman, A., McGurnaghan, S. J., Colhoun, H. M., Henriksen, J. E., Thomsen, R. W., Persson, F., Rossing, P. & Jørgensen, M. E., apr. 2021, I: Diabetes Care. 44, 4, s. 901-907 7 s.

Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial

LEADER Trial Investigators, apr. 2021, I: Diabetes Care. 44, 4, s. 1020-1026 7 s.

Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?

Vlahou, A., Hallinan, D., Apweiler, R., Argiles, A., Beige, J., Benigni, A., Bischoff, R., Black, P. C., Boehm, F., Céraline, J., Chrousos, G. P., Delles, C., Evenepoel, P., Fridolin, I., Glorieux, G., van Gool, A. J., Heidegger, I., Ioannidis, J. P. A., Jankowski, J., Jankowski, V., Jeronimo, C., Kamat, A. M., Masereeuw, R., Mayer, G., Mischak, H., Ortiz, A., Remuzzi, G., Rossing, P., Schanstra, J. P., Schmitz-Dräger, B. J., Spasovski, G., Staessen, J. A., Stamatialis, D., Stenvinkel, P., Wanner, C., Williams, S. B., Zannad, F., Zoccali, C. & Vanholder, R., apr. 2021, I: Hypertension. 77, 4, s. 1029-1035 7 s.

Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

DAPA-CKD Trial Committees and Investigators, 31 mar. 2021, I: *European Heart Journal*. 42, 13, s. 1216-1227 12 s.

A primer on metabolic memory: why existing diabetes treatments fail

Copur, S., Rossing, P., Afsar, B., Sag, A. A., Siriopol, D., Kuwabara, M., Ortiz, A. & Kanbay, M., mar. 2021, I: *Clinical kidney journal*. 14, 3, s. 756-767 12 s.

Plasma trimethylamine N-oxide and its metabolic precursors and risk of mortality, cardiovascular and renal disease in individuals with type 2-diabetes and albuminuria

Winther, S. A., Øllgaard, J. C., Hansen, T. W., von Scholten, B. J., Reinhard, H., Ahluwalia, T. S., Wang, Z., Gæde, P., Parving, H-H., Hazen, S., Pedersen, O. & Rossing, P., mar. 2021, I: *PLoS One*. 16, 3, s. e0244402 e0244402.

Finerenone and Cardiovascular Outcomes in Patients with Chronic Kidney Disease and Type 2 Diabetes

FIDELIO-DKD Investigators, 9 feb. 2021, I: *Circulation*. 143, 6, s. 540-552 13 s.

Effect of Dapagliflozin on Clinical Outcomes in Patients with Chronic Kidney Disease, With and Without Cardiovascular Disease

McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa-Rotter, R., Chertow, G. M., Greene, T., Held, C., Hou, F. F., Mann, J. F. E., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A. M., Heerspink, H. J. L. & DAPA-CKD Trial Committees and Investigators, 2 feb. 2021, I: *Circulation*. 143, 5, s. 438-448 11 s.

Comparison of Natriuretic Peptides as Risk Markers for All-Cause Mortality and Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes

Tofte, N., Theilade, S., Winther, S. A., Birkelund, S., Goetze, J. P., Hansen, T. W. & Rossing, P., feb. 2021, I: *Diabetes Care*. 44, 2, s. 595-603 9 s.

Prognostic Value of Early Systolic Lengthening by Strain Imaging in Type 2 Diabetes

Brainin, P., Biering-Sørensen, T., Jensen, M. T., Møgelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jørgensen, P. G., feb. 2021, I: *Journal of the American Society of Echocardiography*. 34, 2, s. 127-135 9 s.

Genome-wide association study on coronary artery disease in type 1 diabetes suggests beta-defensin 127 as a risk locus

Antikainen, A. A. V., Sandholm, N., Trégolet, D-A., Charmet, R., McKnight, A. J., Ahluwalia, T. S., Syreeni, A., Valo, E., Forsblom, C., Gordin, D., Harjutsalo, V., Hadjadj, S., Maxwell, A. P., Rossing, P. & Groop, P-H., 21 jan. 2021, I: *Cardiovascular Research*. 117, 2, s. 600-612 13 s., cvaa045.

Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

DAPA-CKD Trial Committees and Investigators, jan. 2021, I: *The Lancet Diabetes and Endocrinology*. 9, 1, s. 22-31 10 s.

Linking Kidney and Cardiovascular Complications in Diabetes-Impact on Prognostication and Treatment: The 2019 Edwin Bierman Award Lecture

Rossing, P., Persson, F., Frimodt-Møller, M. & Hansen, T. W., jan. 2021, I: *Diabetes*. 70, 1, s. 39-50 12 s.

Relationship between Peripheral Neuropathy, Diastolic Function, and Adverse Cardiovascular Outcome in Individuals with Type 1 Diabetes Mellitus without Known Cardiovascular Disease: Results from The Thousand & 1 Study

Hansen, G. M., Jørgensen, P. G., Andersen, H. U., Rossing, P. & Jensen, M. T., jan. 2021, I: *Diabetes, Obesity and Metabolism*. 23, 1, s. 158-165 8 s.

Serum glycated albumin predicts all-cause mortality in dialysis patients with diabetes mellitus: meta-analysis and systematic review of a predictive biomarker

Copur, S., Siriopol, D., Afsar, B., Comert, M. C., Uzunkopru, G., Sag, A. A., Ortiz, A., Covic, A., van Raalte, D. H., Cherney, D. Z., Rossing, P. & Kanbay, M., jan. 2021, I: *Acta Diabetologica*. 58, 1, s. 81-91 11 s.

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., Perreault, L., Rosas, S. E., Rossing, P., Sola, L., Vallon, V., Wanner, C. & Perkovic, V., jan. 2021, I: American journal of kidney diseases : the official journal of the National Kidney Foundation. 77, 1, s. 94-109 16 s.

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Tuttle, K. R., Brosius, F. C., Cavender, M. A., Fioretto, P., Fowler, K. J., Heerspink, H. J. L., Manley, T., McGuire, D. K., Molitch, M. E., Mottl, A. K., Perreault, L., Rosas, S. E., Rossing, P., Sola, L., Vallon, V., Wanner, C. & Perkovic, V., jan. 2021, I: Diabetes. 70, 1, s. 1-16 16 s.

Copeptin and renal function decline, cardiovascular events and mortality in type 1 diabetes

Heinrich, N. S., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S., Jeppesen, J. L., Persson, F., Hansen, T. W., Goetze, J. P. & Rossing, P., 26 dec. 2020, (E-pub ahead of print) I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial

Rossing, P., Strand, J., Avogaro, A., Becka, M., Kanefendt, F. & Otto, C., 26 dec. 2020, (E-pub ahead of print) I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Assessment of the sublingual microcirculation with the GlycoCheck system: Reproducibility and examination conditions

Eickhoff, M. K., Winther, S. A., Hansen, T. W., Diaz, L. J., Persson, F., Rossing, P. & Frimodt-Møller, M., 23 dec. 2020, I: PLoS One. 15, 12, s. e0243737

Mineralocorticoid Receptor Antagonists for Diabetic Kidney Disease

Rossing, P., 7 dec. 2020, I: Clinical journal of the American Society of Nephrology : CJASN. 15, 12, s. 1696-1698 3 s.

Investigating new treatment opportunities for patients with chronic kidney disease in type 2 diabetes: the role of finerenone

FIDELIO-DKD and FIGARO-DKD Investigators, 6 dec. 2020, (E-pub ahead of print) I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

A New Panel Estimated GFR, Including β 2-Microglobulin and β -Trace Protein and Not Including Race, Developed in a Diverse Population

CKD-EPI GFR Collaborators, 4 dec. 2020, (E-pub ahead of print) I: American journal of kidney diseases : the official journal of the National Kidney Foundation.

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., Filippatos, G. & FIDELIO-DKD Investigators, 3 dec. 2020, I: The New England journal of medicine. 383, 23, s. 2219-2229 11 s.

TMAO: Trimethylamine-N-Oxide or Time to Minimize Intake of Animal Products?

Winther, S. A. & Rossing, P., 1 dec. 2020, I: The Journal of clinical endocrinology and metabolism. 105, 12

Concomitant diabetes with atrial fibrillation and anticoagulation management considerations

Kreutz, R., Camm, A. J. & Rossing, P., dec. 2020, I: European heart journal supplements : journal of the European Society of Cardiology. 22, Suppl O, s. O78-O86

Gut microbiota profile and selected plasma metabolites in type 1 diabetes without and with stratification by albuminuria

Winther, S. A., Henriksen, P., Vogt, J. K., Hansen, T. H., Ahonen, L., Suvitaival, T., Hein Zobel, E., Frimodt-Møller, M., Hansen, T. W., Hansen, T., Parving, H-H., Legido-Quigley, C., Rossing, P. & Pedersen, O., dec. 2020, I: Diabetologia. 63, 12, s. 2713-2724 12 s.

Visit-to-visit variability of clinical risk markers in relation to long-term complications in type 1 diabetes

Rotbain Curovic, V., Theilade, S., Winther, S. A., Tofte, N., Tarnow, L., Jorsal, A., Parving, H-H., Persson, F., Hansen, T. W. & Rossing, P., 11 nov. 2020, (E-pub ahead of print) I: Diabetic Medicine Online. s. e14459

Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline

Navaneethan, S. D., Zoungas, S., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Liew, A., Michos, E. D., Olowu, W. A., Sadusky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Lytvyn, L., Craig, J. C., Tunnicliffe, D. J., Howell, M., Tonelli, M., Cheung, M., Earley, A., Rossing, P., de Boer, I. H. & Khunti, K., 10 nov. 2020, (E-pub ahead of print) I: Annals of Internal Medicine.

Cardiovascular and renal outcomes by baseline albuminuria status and renal function - results from the LEADER randomized trial

LEADER Trial Investigators, 1 nov. 2020, I: Diabetes, Obesity and Metabolism. 22, 11, s. 2077-2088 12 s.

Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1-7 randomised controlled trials

Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, P., Seufert, J., Tadayon, S. & Vilsbøll, T., 1 nov. 2020, I: The Lancet Diabetes and Endocrinology. 8, 11, s. 880-893 14 s.

Diabetes mellitus in chronic kidney disease: Biomarkers beyond HbA1c to estimate glycemic control and diabetes-dependent morbidity and mortality

Copur, S., Onal, E. M., Afsar, B., Ortiz, A., van Raalte, D. H., Cherney, D. Z., Rossing, P. & Kanbay, M., nov. 2020, I: Journal of Diabetes and its Complications. 34, 11, s. 107707 107707.

Improved Time in Range Over 1 Year Is Associated With Reduced Albuminuria in Individuals With Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes

Ranjan, A. G., Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S. & Nørgaard, K., nov. 2020, I: Diabetes Care. 43, 11, s. 2882-2885 4 s.

Changes in cardiac microvascular function in persons with type 2 diabetes in relation to kidney function

Rasmussen, I. K. B., Hasbak, P., von Scholten, B. J., Laursen, J. C., Zobel, E. H., Holmvang, L., Ripa, R. S., Rossing, P., Kjær, A. & Hansen, T. W., 22 okt. 2020.

MR-proANP and incident cardiovascular disease in patients with type 2 diabetes with and without heart failure with preserved ejection fraction

Jensen, J., Schou, M., Kistorp, C., Faber, J., Hansen, T. W., Jensen, M. T., Andersen, H. U., Rossing, P., Vilsbøll, T. & Jørgensen, P. G., 16 okt. 2020, I: Cardiovascular Diabetology. 19, 1, s. 180 180.

Dapagliflozin in Patients with Chronic Kidney Disease

Heerspink, H. J. L., Stefánsson, B. V., Correa-Rotter, R., Chertow, G. M., Greene, T., Hou, F-F., Mann, J. F. E., McMurray, J. J. V., Lindberg, M., Rossing, P., Sjöström, C. D., Toto, R. D., Langkilde, A-M., Wheeler, D. C., DAPA-CKD Trial Committees and Investigators, Hornum, M. & Hansen, D., 8 okt. 2020, I: The New England journal of medicine. 383, 15, s. 1436-1446 11 s.

A Targeted Multiomics Approach to Identify Biomarkers Associated with Rapid eGFR Decline in Type 1 Diabetes

Limonte, C. P., Valo, E., Montemayor, D., Afshinnia, F., Ahluwalia, T. S., Costacou, T., Darshi, M., Forsblom, C., Hoofnagle, A. N., Groop, P-H., Miller, R. G., Orchard, T. J., Pennathur, S., Rossing, P., Sandholm, N., Snell-Bergeon, J. K., Ye, H., Zhang, J., Natarajan, L., de Boer, I. H. & Sharma, K., 1 okt. 2020, I: American Journal of Nephrology. 51, 10, s. 839-848 10 s.

The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics

Wheeler, D. C., Stefánsson, B. V., Batiushin, M., Bilchenko, O., Cherney, D. Z. I., Chertow, G. M., Douthat, W., Dwyer, J. P., Escudero, E., Pecoits-Filho, R., Furuland, H., Górriz, J. L., Greene, T., Haller, H., Hou, F. F., Kang, S. W., Isidoro, R., Khullar, D., Mark, P. B., McMurray, J. J. V., Kashihara, N., Nowicki, M., Persson, F., Correa-Rotter, R., Rossing, P., Toto, R. D., Umanath, K., Van Bui, P., Wittmann, I., Lindberg, M., Sjöström, C. D., Langkilde, A. M. & Heerspink, H. J. L., 1 okt.

2020, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 35, 10, s. 1700-1711 12 s.

Circulating Metabolites and Lipids Are Associated to Diabetic Retinopathy in Individuals With Type 1 Diabetes

Curovic, V. R., Suvitaival, T., Mattila, I., Ahonen, L., Trošt, K., Theilade, S., Hansen, T. W., Legido-Quigley, C. & Rossing, P., okt. 2020, I: Diabetes. 69, 10, s. 2217-2226 10 s.

Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment

de Boer, I. H., Caramori, M. L., Chan, J. C. N., Heerspink, H. J. L., Hurst, C., Khunti, K., Liew, A., Michos, E. D., Navaneethan, S. D., Olowu, W. A., Sadosky, T., Tandon, N., Tuttle, K. R., Wanner, C., Wilkens, K. G., Zoungas, S., Lytvyn, L., Craig, J. C., Tunnicliffe, D. J., Howell, M., Tonelli, M., Cheung, M., Earley, A. & Rossing, P., okt. 2020, I: Kidney International. 98, 4, s. 839-848 10 s.

KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease

Rossing, P., okt. 2020, I: Kidney International Supplements. 98, 4, s. S1-S115

Omics research in diabetic kidney disease: new biomarker dimensions and new understandings?

Tofte, N., Persson, F. & Rossing, P., okt. 2020, I: Journal of Nephrology. 33, 5, s. 931-948 18 s.

A prediction model for end-stage kidney disease in type 1 diabetes in the presence of competing risk of death

Vistisen, D., Andersen, G. S., Hulman, A., McGurnaghan, S. J., Colhoun, H. M., Henriksen, J. E., Thomsen, R. W., Persson, F., Rossing, P. & Jørgensen, M. E., 22 sep. 2020.

Irbesartan treatment does not influence plasma levels of the dicarbonyls methylglyoxal, glyoxal and 3-deoxyglucosone in participants with type 2 diabetes and microalbuminuria: An IRMA2 sub-study

Piazza, M., Hanssen, N. M. J., Persson, F., Scheijen, J. L., van de Waarenburg, M. P. H., van Greevenbroek, M. M. J., Rossing, P., Hovind, P., Stehouwer, C. D. A., Parving, H. H. & Schalkwijk, C. G., 22 sep. 2020, I: Diabetic Medicine. s. e14405

Carotid-Femoral Pulse Wave Velocity as a Risk Marker for Development of Complications in Type 1 Diabetes Mellitus

Tougaard, N. H., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S., Hansen, T. W., Rossing, P. & Frimodt-Møller, M., 21 sep. 2020, I: Journal of the American Heart Association. 9, 19, s. e017165

Non invasive assessment of changes in cardiac microvascular function in persons with type 2 diabetes

Rasmussen, I. K. B., Hasbak, P., von Scholten, B. J., Laursen, J. C., Zobel, E. H., Holmvang, L., Ripa, R. S., Rossing, P., Kjær, A. & Hansen, T. W., 21 sep. 2020.

Sex differences in the association between myocardial function and prognosis in type 1 diabetes without known heart disease: the Thousand & 1 Study

Lassen, M. C. H., Biering-Sørensen, T., Jørgensen, P. G., Andersen, H. U., Rossing, P. & Jensen, M. T., 4 sep. 2020, (E-pub ahead of print) I: European heart journal cardiovascular Imaging.

Hyperoxia improves autonomic function in individuals with long-duration type 1 diabetes and macroalbuminuria

Laursen, J. C., Hansen, C. S., Bordino, M., Vistisen, D., Zobel, E. H., Winther, S. A., Groop, P-H., Frimodt-Møller, M., Bernardi, L. & Rossing, P., sep. 2020, I: Diabetic Medicine. 37, 9, s. 1561-1568 8 s.

Performance of Indexed and Nonindexed Estimated GFR

Titan, S., Miao, S., Tighiouart, H., Chen, N., Shi, H., Zhang, L., Li, Z., Froissart, M., Rossing, P., Grubb, A., Fan, L., Mauer, M., Bakoush, O., Wyatt, C., Shlipak, M. G., Shafi, T., Inker, L. A. & Levey, A. S., sep. 2020, I: American journal of kidney diseases : the official journal of the National Kidney Foundation. 76, 3, s. 446-449 4 s.

Uncarboxylated Matrix Gla-Protein: A Biomarker of Vitamin K Status and Cardiovascular Risk

Jespersen, T., Møllehave, L. T., Thuesen, B. H., Skaaby, T., Rossing, P., Toft, U., Jørgensen, NR., Corfixen, BI., Jakobsen, J., Frimodt-Møller, M. & Linneberg, A., sep. 2020, I: Clinical Biochemistry. 83, s. 49-56 8 s.

Major decreases in the lipidome following liraglutide treatment: 21-25 September 2020.

Wretling, A., Zobel, E. H., Ripa, R. S., Von Scholten, B. J., Suvitaival, T., Hansen, T. W., Vestergaard, H., Kjær, A., Legido-Quigley, C. & Rossing, P., 25 aug. 2020, I: *Diabetologia*. 63, Suppl 1, s. S252-525.

Metabolites of the mitochondrial energy production are associated with future cardiovascular morbidity and mortality in type 1 diabetes

Tofte, N., Suvitaival, T., Trošt, K., Mattila, I., Theilade, S., Winther, S. A., Frimodt-Møller, M., Legido-Quigley, C. & Rossing, P., 25 aug. 2020, I: *Diabetologia*. 63, Suppl 1, s. S447-940.

Profiling of gut microbiota and plasma metabolites in persons with type 1 diabetes and kidney disease

Henriksen, P., Winther, S. A., Vogt, J. K., Hansen, T. H., Ahonen, L. L., Suvitaival, T., Frimodt-Møller, M., Hansen, T. W., Hansen, T., Parving, H-H. D., Legido-Quigley, C., Rossing, P. & Pedersen, O., 25 aug. 2020, I: *Diabetologia*. 63, Suppl 1, s. S384-795.

The circulating lipidome in diabetic retinopathy

Suvitaival, T., Curovic, V. R., Ahonen, L. L., Theilade, S., Hansen, T. W., Legido-Quigley, C. & Rossing, P., 25 aug. 2020, I: *Diabetologia*. 63, Suppl 1, s. S395-820.

SGLT 2 inhibitors in Type 1 diabetes

Stougaard, E. B., Amadid, H., Søndergaard, E., Jørgensen, M. E., Persson, F. & Rossing, P., 24 aug. 2020, I: *Ugeskrift for Læger*. 182, 35

Correction to: 2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD) (*Diabetologia*, (2020), 63, 2, (221-228), 10.1007/s00125-019-05039-w)

Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D'Alessio, D. A. & Davies, M. J., aug. 2020, I: *Diabetologia*. 63, 8, s. 1667-1 s.

Liver nucleotide biosynthesis is linked to protection from vascular complications in individuals with long-term type 1 diabetes

Jain, R., Özgümüş, T., Jensen, T. M., du Plessis, E., Keindl, M., Møller, C. L., Falhammar, H., Nyström, T., Catrina, S-B., Jörneskog, G., Jessen, L. E., Forsblom, C., Haukka, J. K., Groop, P-H., Rossing, P., Groop, L., Eliasson, M., Eliasson, B., Brismar, K., Al-Majdoub, M., Nilsson, P. M., Taskinen, M-R., Ferrannini, E., Spégel, P., Berg, T. J. & Lyssenko, V., 14 jul. 2020, I: *Scientific Reports*. 10, 1, s. 11561-11561.

Effect of dapagliflozin on cardiac function in people with type 2 diabetes and albuminuria – A double blind randomized placebo-controlled crossover trial

Eickhoff, M. K., Olsen, F. J., Frimodt-Møller, M., Diaz, L. J., Faber, J., Jensen, M. T., Rossing, P. & Persson, F., 1 jul. 2020, I: *Journal of Diabetes and its Complications*. 34, 7, 107590.

Plasma metabolomics identifies markers of impaired renal function: A meta-analysis of 3,089 persons with type 2 diabetes

Tofte, N., Vogelzangs, N., Mook-Kanamori, D., Brahimaj, A., Nano, J., Ahmadizar, F., Willems van Dijk, K., Frimodt-Møller, M., Arts, I., Beulens, J. W. J., Rutters, F., van der Heijden, A. A., Kavousi, M., Stehouwer, C. D. A., Nijpels, G., van Greevenbroek, M. M. J., van der Kallen, C. J. H., Rossing, P., Ahluwalia, T. S. & 't Hart, L. M., 1 jul. 2020, I: *The Journal of clinical endocrinology and metabolism*. 105, 7, s. 2275-2287 dgaa173.

Erratum. 2019 Update to: Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). (*Diabetes Care*, (2020) 43, (487-493), 10.2337/dci19-0066)

Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D'Alessio, D. A. & Davies, M. J., jul. 2020, I: *Diabetes Care*. 43, 7, s. 1670-1 s.

Lipoprotein(a) and renal function decline, cardiovascular disease and mortality in type 2 diabetes and microalbuminuria

Heinrich, N. S., von Scholten, B. J., Reinhard, H., Persson, F., Ahluwalia, T. S., Hansen, T. W., Parving, H-H., Jacobsen, P. K. & Rossing, P., jul. 2020, I: *Journal of Diabetes and its Complications*. 34, 7, s. 107593-107593.

Mendelian randomization analysis does not support causal associations of birth weight with hypertension risk and blood pressure in adulthood

Zheng, Y., Huang, T., Wang, T., Mei, Z., Sun, Z., Zhang, T., Ellervik, C., Chai, J-F., Sim, X., van Dam, R. M., Tai, E-S., Koh, W-P., Dorajoo, R., Saw, S-M., Sabanayagam, C., Wong, T. Y., Gupta, P., Rossing, P., Ahluwalia, T. S., Vinding, R. K., Bisgaard, H., Bønnelykke, K., Wang, Y., Graff, M., Voortman, T., van Rooij, F. J. A., Hofman, A., van Heemst, D., Noordam, R., Estampador, A. C., Varga, T. V., Enzenbach, C., Scholz, M., Thiery, J., Burkhardt, R., Orho-Melander, M., Schulz, C-A., Ericson, U., Sonestedt, E., Kubo, M., Akiyama, M., Zhou, A., Kilpeläinen, T. O., Hansen, T., Kleber, M. E., Delgado, G., McCarthy, M., Lemaitre, R. N., Felix, J. F., Jaddoe, V. W. V., Wu, Y., Mohlke, K. L., Lehtimäki, T., Wang, C. A., Pennell, C. E., Schunkert, H., Kessler, T., Zeng, L., Willenborg, C., Peters, A., Lieb, W., Grote, V., Rzehak, P., Koletzko, B., Erdmann, J., Munz, M., Wu, T., He, M., Yu, C., Lecoeur, C., Froguel, P., Corella, D., Moreno, L. A., Lai, C-Q., Pitkänen, N., Boreham, C. A., Ridker, P. M., Rosendaal, F. R., de Mutsert, R., Power, C., Paternoster, L., Sørensen, T. I. A., Tjønneland, A., Overvad, K., Djousse, L., Rivadeneira, F., Lee, N. R., Raitakari, O. T., Kähönen, M., Viikari, J., Langhendries, J-P., Escribano, J., Verduci, E., Dedoussis, G., König, I., Balkau, B., Coltell, O., Dallongeville, J., Meirhaeghe, A., Amouyel, P., Gottrand, F., Pahkala, K., Niinikoski, H., Hyppönen, E., März, W., Mackey, D. A., Gruszfeld, D., Tucker, K. L., Fumeron, F., Estruch, R., Ordovas, J. M., Arnett, D. K., Mook-Kanamori, D. O., Mozaffarian, D., Psaty, B. M., North, K. E., Chasman, D. I. & Qi, L., jul. 2020, I: *European Journal of Epidemiology*. 35, 7, s. 685-697 13 s.

Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes

PERL Study Group, 25 jun. 2020, I: *The New England journal of medicine*. 382, 26, s. 2493-2503 11 s.

Improved Time in Glucose Range over One Year Is Associated with Reduced Albuminuria in Sensor-Augmented Insulin Pump-Treated Type 1 Diabetes

Rosenlund, S. V., Hansen, T. W., Rossing, P., Andersen, S. P. & Nørgaard, K., 1 jun. 2020.

Metformin and cardiorenal outcomes in diabetes: a reappraisal

Petrie, J. R., Rossing, P. & Campbell, I. W., jun. 2020, I: *Diabetes, Obesity and Metabolism*. 22, 6, s. 904-915 12 s.

2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., Huikuri, H. V., Johansson, I., Jüni, P., Lettino, M., Marx, N., Mellbin, L. G., Östgren, C. J., Rocca, B., Roffi, M., Sattar, N., Seferović, P. M., Sousa-Uva, M., Valensi, P., Wheeler, D. C., Piepoli, M. F., Birkeland, K. I., Adamopoulos, S., Ajjan, R., Avogaro, A., Baigent, C., Brodmann, M., Bueno, H., Ceconi, C., Chioncel, O., Coats, A., Collet, J. P., Collins, P., Cosyns, B., Di Mario, C., Fisher, M., Fitzsimons, D., Halvorsen, S., Hansen, D., Hoes, A., Holt, R. I. G., Home, P., Katus, H. A., Khunti, K., Komajda, M., Lambrinou, E., Landmesser, U., Lewis, B. S., Linde, C., Lorusso, R., Mach, F., Mueller, C., Neumann, F. J., Persson, F., Petersen, S. E., Petronio, A. S., Richter, D. J., Rosano, G. M. C., Rossing, P., Rydén, L., Shlyakhto, E., Simpson, I. A., Touyz, R. M., Wijns, W., Wilhelm, M. & Williams, B., 1 maj 2020, I: *Revista Espanola de Cardiologia (Online)*. 73, 5, s. 404.e1-404.e59

Association between severe diabetic retinopathy and lectin pathway proteins - an 18-year follow-up study with newly diagnosed type 1 diabetes patients

Holt, C. B., Hoffmann-Petersen, I. T., Hansen, T. K., Parving, H-H., Thiel, S., Hovind, P., Tarnow, L., Rossing, P. & Østergaard, J. A., maj 2020, I: *Immunobiology*. 225, 3, s. 151939 151939.

Cardiovascular prognostic value of echocardiography and N terminal pro B-type natriuretic peptide in type 1 diabetes: The thousand & 1 study

Rørth, R., Jørgensen, P. G., Andersen, H. U., Christoffersen, C., Gøtze, J. P., Køber, L., Rossing, P. & Jensen, M. T., maj 2020, I: *European Journal of Endocrinology*. 182, 5, s. 481-488 8 s.

Epicardial adipose tissue: an emerging biomarker of cardiovascular complications in type 2 diabetes?

Christensen, R. H., von Scholten, B. J., Lehrskov, L. L., Rossing, P. & Jørgensen, P. G., maj 2020, I: *Therapeutic Advances in Endocrinology and Metabolism*. 11, s. 2042018820928824

Post-Systolic Shortening by Speckle Tracking Echocardiography Predicts Cardiac Events in Type 2 Diabetes

Brainin, P., Jensen, M. T., Biering-Sørensen, T., Møgelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jørgensen, P. G., maj 2020, I: *JACC. Cardiovascular imaging*. 13, 5, s. 1289-1291 3 s.

Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial
PRIORITY investigators, 1 apr. 2020, I: *The Lancet Diabetes and Endocrinology*. 8, 4, s. 301-312 12 s.

Relation of cardiac adipose tissue to coronary calcification and myocardial microvascular function in type 1 and type 2 diabetes

Zobel, E. H., Christensen, R. H., Winther, S. A., Hasbak, P., Hansen, C. S., von Scholten, B. J., Holmvang, L., Kjaer, A., Rossing, P. & Hansen, T. W., 10 feb. 2020, I: *Cardiovascular Diabetology*. 19, 1, 16.

Rationale and protocol of the Dapagliflozin And Prevention of Adverse outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial

DAPA-CKD Investigators , 7 feb. 2020, I: *Nephrology Dialysis Transplantation*. 35, 2, s. 274-282 9 s.

2019 update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D'Alessio, D. A. & Davies, M. J., feb. 2020, I: *Diabetes Care*. 43, 2, s. 487-493 7 s.

2019 update to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

Buse, J. B., Wexler, D. J., Tsapas, A., Rossing, P., Mingrone, G., Mathieu, C., D'Alessio, D. A. & Davies, M. J., feb. 2020, I: *Diabetologia*. 63, 2, s. 221-228 8 s.

Describing the fecal metabolome in cryogenically collected samples from healthy participants

Trošt, K., Ahonen, L., Suviavaara, T., Christiansen, N., Nielsen, T., Thiele, M., Jacobsen, S., Krag, A., Rossing, P., Hansen, T., Dragsted, L. O. & Legido-Quigley, C., 21 jan. 2020, I: *Scientific Reports*. 10, 1, 885.

Carotid-femoral pulse wave velocity is a risk marker for complications in persons with type 1 diabetes

Tougaard, N. H., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S., Hansen, T. W., Rossing, P. & Frimodt-Møller, M., 18 jan. 2020.

Changes in diabetes distress among people with type 2 diabetes during a risk screening programme for diabetic kidney disease - Longitudinal observations of the PRIORITY study

Joensen, L. E., Madsen, K. P., Frimodt-Møller, M., Tofte, N., Willaing, I., Lindhardt, M. & Rossing, P., 1 jan. 2020, I: *Journal of Diabetes and its Complications*. 34, 1, 107467.

Mitigating risk of aldosterone in diabetic kidney disease

Frimodt-Møller, M., Persson, F. & Rossing, P., 1 jan. 2020, I: *Current opinion in nephrology and hypertension*. 29, 1, s. 145-151 6 s.

The History of Prevention and Treatment of Diabetic Nephropathy

Rossing, P. & Parving, H-H. D., 1 jan. 2020, *Unveiling Diabetes - Historical Milestones in Diabetology*. Jørgens, V. & Porta, M. (red.). Basel: S. Karger AG, Bind 29. s. 242-256 15 s.

Liraglutide and vascular inflammation in type 2 diabetes as assessed by FDG-PET/CT: The LiraFlame study

Ripa, R. S., Zobel, E. H., Von Scholten, B. J., Diaz, L. J., Jensen, J. K., Curovic, V. R., Hansen, T. W., Rossing, P. & Kjær, A., 2020.

Long term effects of flexor tenotomies

Andersen, J. H., Rasmussen, A., Kirketerp-Møller, K., Engberg, S., Frimodt-Møller, M. & Rossing, P., 2020.

Long term effects of flexor tenotomies

Andersen, J. H., Rasmussen, A., Kirketerp-Møller, K., Engberg, S., Frimodt-Møller, M. & Rossing, P., 2020.

Metabolomic and Proteomic Techniques for Establishing Biomarkers and Improving Our Understanding of Pathophysiology in Diabetic Nephropathy

Siwy, J., Ahonen, L., Magalhães, P., Frantzi, M. & Rossing, P., 2020, *DIABETIC NEPHROPATHY: METHODS AND PROTOCOLS*. Gnudi, L. & Long, D. A. (red.). Bind 2067. s. 287-306 20 s. (Methods in molecular biology).

The importance of addressing multiple risk markers in type 2 diabetes: results from the LEADER trial

Zobel, E. H., Hansen, T. W., Persson, F., Rasmussen, S., Wolthers, B. & Rossing, P., 2020.

Linking glycaemic dysregulation in diabetes to symptoms, comorbidities, and genetics through EHR data mining

Kirk, I. K., Simon, C., Banasik, K., Holm, P. C., Haue, A. D., Jensen, P. B., Juhl Jensen, L., Rodríguez, C. L., Pedersen, M. K., Eriksson, R., Andersen, H. U., Almdal, T., Bork-Jensen, J., Grarup, N., Borch-Johnsen, K., Pedersen, O., Pociot, F., Hansen, T., Bergholdt, R., Rossing, P. & Brunak, S., 10 dec. 2019, I: *eLife*. 8, 19 s., e44941.

The effect of needle tenotomy on hammer, mallet and claw toe deformities in patients with diabetes, a retrospective study

Hedegaard Andersen, J., Rasmussen, A., Frimodt-Møller, M., Rossing, P., Kirketerp-Møller, K. & Engberg, S., 1 dec. 2019, I: *Journal of Clinical and Translational Endocrinology*. 18, 100208.

Echocardiography improves prediction of major adverse cardiovascular events in a population with type 1 diabetes and without known heart disease: the Thousand & 1 Study

Jensen, M. T., Sogaard, P., Gustafsson, I., Bech, J., Hansen, T. F., Almdal, T., Theilade, S., Biering-Sørensen, T., Jørgensen, P. G., Galatius, S., Andersen, H. U. & Rossing, P., dec. 2019, I: *Diabetologia*. 62, 12, s. 2354-2364 11 s.

Response to Comment on Pilemann-Lyberg et al. Uric Acid Is an Independent Risk Factor for Decline in Kidney Function, Cardiovascular Events, and Mortality in Patients With Type 1 Diabetes.

Pilemann-Lyberg, S., Hansen, T. W. & Rossing, P., dec. 2019, I: *Diabetes Care*. 42, 12, s. e188

Design of a randomised controlled trial of the effects of empagliflozin on myocardial perfusion, function and metabolism in type 2 diabetes patients at high cardiovascular risk (the SIMPLE trial)

Jürgens, M., Schou, M., Hasbak, P., Kjær, A., Wolsk, E., Zerahn, B., Wiberg, M., Brandt, N. H., Gæde, P. H., Rossing, P., Faber, J., Inzucchi, S., Gustafsson, F. & Kistorp, C. M., 27 nov. 2019, I: *BMJ Open*. 9, 11, e029098.

Metabolomic assessment reveals alteration in polyols and branched chain amino acids associated with present and future renal impairment in a discovery cohort of 637 persons with type 1 diabetes

Tofte, N., Suvitaival, T., Trošt, K., Mattila, I., Theilade, S., Winther, S. A., Ahluwalia, T. S., Frimodt-Møller, M., Legido-Quigley, C. & Rossing, P., 22 nov. 2019, I: *Frontiers in Endocrinology*. 10, s. 1-11 11 s., 818.

Genome wide association study of apparent treatment resistant hypertension in the CHARGE consortium: The CHARGE Pharmacogenetics Working Group

VA Million Veteran Program and the CHARGE Pharmacogenetics Working group, 15 nov. 2019, I: *American Journal of Hypertension*. 32, 12, s. 1146-1153 8 s.

Major adverse renal events (MARE): A proposal to unifying renal endpoints

Prischl, F. C., Rossing, P., Bakris, G., Mayer, G. & Wanner, C., 11 nov. 2019, (E-pub ahead of print) I: *Nephrology Dialysis Transplantation*.

Lipidomic analysis reveals sphingomyelin and phosphatidylcholine species associated with renal impairment and all-cause mortality in type 1 diabetes

Tofte, N., Suvitaival, T., Ahonen, L., Winther, S. A., Theilade, S., Frimodt-Møller, M., Ahluwalia, T. S. & Rossing, P., 8 nov. 2019, I: *Scientific Reports*. 9, 1, 10 s., 16398.

Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease

Rossing, P., Block, G. A., Chin, M. P., Goldsberry, A., Heerspink, H. J. L., McCullough, P. A., Meyer, C. J., Packham, D., Pergola, P. E., Spinowitz, B., Sprague, S. M., Warnock, D. G. & Chertow, G. M., 1 okt. 2019, I: *Kidney International*. 96, 4, s. 1030-1036 7 s.

Genome-Wide Association Study of Diabetic Kidney Disease Highlights Biology Involved in Glomerular Basement Membrane Collagen

SUMMIT Consortium, DCCT/EDIC Research Group, GENIE Consortium, 1 okt. 2019, I: Journal of the American Society of Nephrology. 30, 10, s. 2000-2016 17 s.

Inflammation Leads the Way on the ROADMAP to Diabetic Kidney Disease

Persson, F., Fridodt-Møller, M. & Rossing, P., 1 okt. 2019, I: Kidney International Reports. 4, 10, s. 1362-1365 4 s.

Prognostic value of ratio of transmitral early filling velocity to early diastolic strain rate in patients with Type 2 diabetes

Lassen, M. C. H., Jensen, M. T., Biering-Sørensen, T., Møgelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jørgensen, P. G., 1 okt. 2019, I: European heart journal cardiovascular Imaging. 20, 10, s. 1171-1178 8 s.

Progressive decline in estimated glomerular filtration rate in patients with diabetes after moderate loss in kidney function - even without albuminuria

Vistisen, D., Andersen, G. S., Hulman, A., Persson, F., Rossing, P. & Jørgensen, M. E., 1 okt. 2019, I: Diabetes Care. 42, 10, s. 1886-1894 9 s.

Abstracts

Bastrup Israelsen, M., Trošt, K., Stæhr Madsen, B., Suviataival, T., Hansen, C., Thiele, M., Rossing, P., Hansen, T., Legido-Quigley, C. & Krag, A., okt. 2019, I: Hepatology. 70, Suppl 1, s. 172-173 1 s., 267.

Assessment of the Sublingual Microcirculation with the GlycoCheck System: Reproducibility and Examination Conditions

Frimodt-Møller, M., Eickhoff, M. K., Winther, S. A., Diaz, L. J., Persson, F., Hansen, T. W. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 849 1 s., SA-PO331.

Hypoxia in individuals with type 1 diabetes and macroalbuminuria is associated with autonomic dysfunction

Laursen, J. C., Clemmensen, K. K. B., Hansen, C. S., Diaz, L. J., Groop, P-H., Fridodt-Møller, M., Bernardi, L. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 361 1 s., TH-PO92.

Individual Effects of Liraglutide on Cardiorenal Risk Markers: Results from the LEADER Trial

Persson, F., Zobel, E. H., Hansen, T., Rasmussen, S., Von Scholten, B. J., Wolthers, B. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 1096 1 s., PUB071.

Lipoprotein(a) and Decline in Renal Function, Incidence of Cardiovascular Disease, and Mortality in Individuals with Type 2 Diabetes and Microalbuminuria

S. Heinrich, N., von Scholten, B. J., Persson, F., Hansen, T., Parving, H-H. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 1094 1 s., PUB081.

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

Tofte, N., Lindhardt, M. K., Currie, G., Fridodt-Møller, M., von der Leyen, H., Delles, C., Mischak, H. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 1 72 s., FR-OR113 .

Polyols and Branched Chained Amino Acids Are Associated with Present and Future Renal Impairment in Type 1 Diabetes

Tofte, N., Suviataival, T., Trošt, K., Mattila, I., Theilade, S., Winther, S. A., Ahluwalia, T. S., Fridodt-Møller, M., Legido-Quigley, C. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 362 1 s., TH-PO934.

Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock?

Laursen, J. C., Hansen, C. S., Bordino, M., Zobel, E. H., Winther, S. A., Groop, P-H., Fridodt-Møller, M., Bernardi, L. & Rossing, P., okt. 2019. 1 s.

Spirolactone for the prevention of microalbuminuria in high risk type 2 diabetes: Results from the multicenter randomized double-blind controlled study "PRIORITY"

Lindhardt, M. K., Tofte, N., Frimodt-Møller, M., Currie, G., Delles, C., von der Leyen, H., Mischak, H. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 498 1 s., FR-PO247.

The association between vitamin D level and microvascular complications in persons with type 2 diabetes

Tougaard, N. H., Hansen, T. W. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 905 1 s., SA-PO557.

Trimethylamine-N-Oxide and Renal Complications, Cardiovascular Disease, and Mortality in Individuals with Type 2 Diabetes and Microalbuminuria

Winther, S. A., Øllgaard, J. C., Hansen, T. W., Von Scholten, B. J., Gæde, P., Parving, H-H., Pedersen, O. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 904 1 s., SA-PO551.

Urinary Glycolic Acid Predicts Kidney Function Decline in Type 1 Diabetic Subjects

Darshi, M., Kim, J. J., Ahluwalia, T. S., Rossing, P., Groop, P-H. & Sharma, K., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 358 1 s., TH-PO919.

Visit-to-Visit Variability of Albuminuria and eGFR as Risk Markers for Renal Complications, Cardiovascular Events, and Mortality in Type 1 Diabetes

Curovic, V. R., Theilade, S., Winther, S. A., Tofte, N., Jorsal, A., Parving, H-H., Persson, F., Hansen, T. & Rossing, P., okt. 2019, I: Journal of the American Society of Nephrology. 30, s. 904 1 s., SA-PO552.

Editorial: Novel Biomarkers for Type 2 Diabetes

Ahluwalia, T. S., Kilpeläinen, T. O., Singh, S. & Rossing, P., 27 sep. 2019, I: Frontiers in Endocrinology. 10, 649.

Association of Birth Weight With Type 2 Diabetes and Glycemic Traits: A Mendelian Randomization Study

BIRTH-GENE (BIG) Study Working Group, 20 sep. 2019, I: JAMA network open. 2, 9, 18 s., e1910915.

Targeted Clinical Metabolite Profiling Platform for the Stratification of Diabetic Patients

Ahonen, L., Jäntti, S., Suvitaival, T., Theilade, S., Risz, C., Kostianen, R., Rossing, P., Orešič, M. & Hyötyläinen, T., 14 sep. 2019, I: Metabolites. 9, 9, 184.

Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study

Gæde, P., Oellgaard, J., Kruuse, C., Rossing, P., Parving, H-H. & Pedersen, O., 1 sep. 2019, I: Diabetologia. 62, 9, s. 1575-1580 6 s.

Cell populations and molecular biomarkers in blood and urine characterise nephropathy in type 1 diabetes

Henriksen, P., Kyliuk-Price, D., Winther, S. A., Suvitaival, T., Legido-Quigley, C., Timmermann, D. B. & Rossing, P., 1 sep. 2019, I: Diabetologia. 62, Suppl 1, s. 478 1 s., 986.

Markers of Collagen Formation and Degradation Reflect Renal Function and Predict Adverse Outcomes in Patients With Type 1 Diabetes

Pilemann-Lyberg, S., Rasmussen, D. G. K., Hansen, T. W., Tofte, N., Winther, S. A., Nielsen, S. H., Theilade, S., Karsdal, M. A., Genovese, F. & Rossing, P., 1 sep. 2019, I: Diabetes Care. 42, 9, s. 1760-1768 9 s.

Circulating metabolites are associated with present and future renal impairment in type 1 Diabetes

Tofte, N., Suvitaival, T., Trošt, K., Mattila, I., Theilade, S., Winther, S. A., Ahluwalia, T. S., Frimodt-Møller, M., Legido-Quigley, C. & Rossing, P., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 30 1 s., 57.

Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy: Barcelona, Spain, 16 - 20 September 2019

Eickhoff, M. K., Frimodt-Møller, M., Mischak, H., Rossing, P. & Persson, F., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 40 1 s., 77.

Estimated GFR (eGFR) loss with glucagon like peptide 1 (GLP1) analogue treatment: Data from Sustain 6 and LEADER
Perkovic, V., Bain, S. C., Bakris, G. L., Buse, J. B., Gondolf, T., Idorn, T., Lausvig, N., Mahaffey, K. W., Marso, S. P., Nauck, M. A., Pratley, R. E., Rossing, P., Zinman, B. & Mann, J. F. E., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 484 1 s., 998.

Plasma metabolomics identifies markers of kidney function in 3,064 Europeans with type 2 diabetes: Barcelona, Spain, 16 - 20 September 2019

Ahluwalia, T. S., Tofte, N., Vogelzangs, N., Mook-Kanamori, D., Brahimaj, A., Frimodt-Møller, M., Arts, I., Beulens, J., van der Heijden, A., Stehouwer, C., Nijpels, G., van Greevenbroek, M., van der Kallen, C., Rossing, P. & t' Hart, L. M., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 456 1 s., 937.

Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock?

Laursen, J. C., Hansen, C. S., Bordino, M., Zobel, E. H., Winther, S. A., Groop, P-H., Frimodt-Møller, M., Bernardi, L. & Rossing, P., sep. 2019. 1 s.

Relative hypoxia in supine and standing position in type 1 diabetes: Impaired autonomic cardiorespiratory control around the clock? Barcelona, Spain, 16 - 20 September 2019

Laursen, J. C., Hansen, C. S., Bordino, M., Zobel, E. H., Winther, S. A., Groop, P-H., Frimodt-Møller, M., Bernardi, L. & Rossing, P., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 52 1 s., 98.

Renal function dominates the landscape of the metabolome in type 1 diabetes

Suvitaival, T., Tofte, N., Mattila, I., Trošt, K., Theilade, S., Winther, S. A., Ahluwalia, T. S., Frimodt-Møller, M., Rossing, P. & Legido-Quigley, C., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 455 1 s., 936.

Role of gastrointestinal inflammation in diabetic kidney disease

Mannerla, M., Winther, S. A., Frimodt-Møller, M., Persson, F., Hansen, T. W., Forsblom, C., Lehto, M., Groop, P-H. & Rossing, P., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 480 1 s., 991.

The utility of plasma concentration of Trimethylamine-N-Oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes

Winther, S. A., Øllgaard, J. C., Tofte, N., Tarnow, L., Wang, Z., Ahluwalia, T. S., Jorsal, A., Theilade, S., Parving, H. H., Hansen, T., Hazen, S. L., Pedersen, O. & Rossing, P., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 32 1 s., 60.

Visit-to-visit variability of HbA1c and systolic BP as risk markers for cardiovascular events, end stage renal disease, renal function decline and mortality in type 1 diabetes

Curovic, V. R., Theilade, S., Winther, S. A., Tofte, N., Tarnow, L., Jorsal, A., Parving, H. H., Persson, F., Hansen, T. W. & Rossing, P., sep. 2019, I: Diabetologia. 62, Suppl 1, s. 568 1 s., 1181.

Epicardial adipose tissue predicts incident cardiovascular disease and mortality in patients with type 2 diabetes

Christensen, R. H., von Scholten, B. J., Hansen, C. S., Jensen, M. T., Vilsbøll, T., Rossing, P. & Jørgensen, P. G., 30 aug. 2019, I: Cardiovascular Diabetology. 18, 1, 114.

An echocardiographic substrate for dyspnea identifies high risk patients with type 2 diabetes

Jørgensen, P. G., Schou, M., Biering-Sørensen, T., Mogelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jensen, M. T., 15 aug. 2019, I: International Journal of Cardiology. 289, s. 119-124 6 s.

Epicardial and pericardial adipose tissues are associated with reduced diastolic and systolic function in type 2 diabetes

Christensen, R. H., Hansen, C. S., von Scholten, B. J., Jensen, M. T., Pedersen, B. K., Schnohr, P., Vilsbøll, T., Rossing, P. & Jørgensen, P. G., 1 aug. 2019, I: Diabetes, Obesity and Metabolism. 21, 8, s. 2006-2011 6 s.

Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinol-Rationale, Design, and Baseline Data

PERL Study Group, 1 aug. 2019, I: Diabetes Care. 42, 8, s. 1454-1463 10 s.

Utility of Plasma Concentration of Trimethylamine N-Oxide in Predicting Cardiovascular and Renal Complications in Individuals With Type 1 Diabetes

Winther, S. A., Øllgaard, J. C., Tofte, N., Tarnow, L., Wang, Z., Ahluwalia, T. S., Jorsal, A., Theilade, S., Parving, H-H., Hansen, T. W., Hazen, S. L., Pedersen, O. & Rossing, P., aug. 2019, I: *Diabetes Care*. 42, 8, s. 1512-1520 9 s.

Efficacy of Long-Term Remote Ischemic Conditioning on Vascular and Neuronal Function in Type 2 Diabetes Patients With Peripheral Arterial Disease

Hansen, C. S., Jørgensen, M. E., Fleischer, J., Bøtker, H. E. & Rossing, P., 2 jul. 2019, I: *Journal of the American Heart Association*. 8, 13, s. 1-17 17 s., e011779.

Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial

PIONEER 5 Investigators, 1 jul. 2019, I: *The Lancet Diabetes and Endocrinology*. 7, 7, s. 515-527 13 s.

Myocardial flow reserve assessed by cardiac 82Rb positron emission tomography/computed tomography is associated with albumin excretion in patients with Type 1 diabetes

Zobel, E. H., Winther, S. A., Hasbak, P., von Scholten, B. J., Holmvang, L., Kjaer, A., Rossing, P. & Hansen, T. W., 1 jul. 2019, I: *European heart journal cardiovascular Imaging*. 20, 7, s. 796-803 8 s., jey174.

A catalog of genetic loci associated with kidney function from analyses of a million individuals

LifeLines Cohort study, 1 jun. 2019, I: *Nature Genetics*. 51, 6, s. 957-972 16 s.

Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial

Pollock, C., Stefánsson, B., Reyner, D., Rossing, P., Sjöström, C. D., Wheeler, D. C., Langkilde, A. M. & Heerspink, H. J. L., 1 jun. 2019, I: *The Lancet Diabetes and Endocrinology*. 7, 6, s. 429-441 13 s.

Cardiac Autonomic Function is Associated With Myocardial Flow Reserve in Type 1 Diabetes

Zobel, E. H., Hasbak, P., Winther, S. A., Stevns, C., Fleischer, J., von Scholten, B. J., Holmvang, L., Kjaer, A., Rossing, P. & Hansen, T. W., 1 jun. 2019, I: *Diabetes*. 68, 6, s. 1277-1286 10 s.

Improvements in albuminuria and chronic kidney disease progression with the appetite suppressant lorcaserin

Rossing, P., Persson, F. & Frimodt-Møller, M., 1 jun. 2019, I: *Kidney International*. 95, 6, s. 1287-1288 2 s.

Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes

Rotbain Curovic, V., Theilade, S., Winther, S. A., Tofte, N., Eugen-Olsen, J., Persson, F., Hansen, T. W., Jeppesen, J. & Rossing, P., 1 jun. 2019, I: *Diabetes Care*. 42, 6, s. 1112-1119 8 s.

Uric acid is an independent risk factor for decline in kidney function, cardiovascular events, and mortality in patients with type 1 diabetes

Pilemann-Lyberg, S., Hansen, T. W., Tofte, N., Winther, S. A., Theilade, S., Ahluwalia, T. S. & Rossing, P., 1 jun. 2019, I: *Diabetes Care*. 42, 6, s. 1088-1094 7 s.

A marker of type VI collagen formation (PRO-C6) is associated with higher arterial stiffness in type 1 diabetes

Frimodt-Møller, M., Hansen, T. W., Rasmussen, D. G. K., Theilade, S., Nielsen, S. H., Karsdal, M. A., Genovese, F. & Rossing, P., jun. 2019, I: *Acta Diabetologica*. 56, 6, s. 711-712 2 s.

Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy

Eickhoff, M. K., Frimodt-Møller, M., Mischak, H., Rossing, P. & Persson, F., jun. 2019, I: *Diabetes*. 68, Suppl 1, 1 s., 526-P.

Effects of semaglutide and liraglutide on urinary albumin-to-creatinine ration (UACR) -A pooled analysis of sustain 6 and leader

Perkovic, V., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Marso, S. P., Nauck, M. A., Pratley, R. E., Rasmussen, S., Rossing, P., Tornøe, K., Zinman, B. & Mann, J., jun. 2019, I: Nephrology Dialysis Transplantation. 34, Suppl 1, s. 205 FP483.

Effects of the glucagon-like peptide-1 (GLP-1) analogues semaglutide and liraglutide on renal outcomes - A pooled analysis of the sustain 6 and leader trials

Perkovic, V., Bain, S. C., Bakris, G. L., Buse, J. B., Idorn, T., Mahaffey, K. W., Marso, S. P., Nauck, M. A., Pratley, R. E., Rasmussen, S., Rossing, P., Tornøe, K., Zinman, B. & Mann, J., jun. 2019, I: Nephrology Dialysis Transplantation. 34, Suppl 1, s. 388 SaO010.

EGFR loss with glucagon-like-peptide-1 (GLP-1) analouge treatment: Data from sustain 6 and leader

Perkovic, V., Bain, S. C., Bakris, G. L., Buse, J. B., Gondolf, T., Idorn, T., Lausvig, N., Mahaffey, K. W., Marso, S. P., Nauck, M. A., Pratley, R. E., Rossing, P., Zinman, B. & Mann, J., jun. 2019, I: Nephrology Dialysis Transplantation. 34, Suppl 1, FP482 .

Obesity remains a major risk factor associated with vascular stiffening in type 2 diabetes

Currie, G., Flynn, J., Rossing, P. & Delles, C., jun. 2019, I: Journal of Hypertension. 37, Suppl 1, s. 65

Predictive value of echocardiography in Type 2 diabetes

Jørgensen, P. G., Biering-Sørensen, T., Mogelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jensen, M. T., jun. 2019, I: European heart journal cardiovascular Imaging. 20, 6, s. 687-693 7 s.

Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

Eickhoff, M. K., Dekkers, C. C. J., Kramers, B. J., Laverman, G. D., Fridmodt-Møller, M., Jørgensen, N. R., Faber, J., Danser, A. H. J., Gansevoort, R. T., Rossing, P., Persson, F. & Heerspink, H. J. L., 31 maj 2019, I: Journal of Clinical Medicine. 8, 6

Dapagliflozin improves the urinary CKD273 proteomic score when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy

Eickhoff, M. K., Fridmodt-Møller, M., Mischak, H., Rossing, P. & Persson, F., 24 maj 2019.

Identification of serum metabolites associated with renal impairment: A metabolomics study in Type 1 Diabetes

Tofte, N., Suvitaival, T., Trošt, K., Mattila, I., Theilade, S., Winther, S. A., Ahluwalia, T. S., Fridmodt-Møller, M., Legido-Quigley, C. & Rossing, P., 24 maj 2019.

Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes

Hansen, T. W., Fridmodt-Møller, M., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S. & Rossing, P., 24 maj 2019.

Soluble urokinase plasminogen activator receptor predicts cardiovascular events, kidney function decline, and mortality in patients with type 1 diabetes

Curovic, V. R., Theilade, S., Winther, S. A., Tofte, N., Eugen-Olsen, J., Persson, F., Hansen, T. W., Jeppesen, J. & Rossing, P., 24 maj 2019.

The utility of plasma concentration of Trimethylamine-N-Oxide in predicting cardiovascular and renal complications in individuals with type 1 diabetes

Winther, S. A., Øllgaard, J. C., Tofte, N., Tarnow, L., Wang, Z., Ahluwalia, T. S., Jorsal, A., Theilade, S., Parving, H-H. D., Hansen, T. W., Hazen, S. L., Pedersen, O. & Rossing, P., 24 maj 2019.

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

SONAR Committees and Investigators, 11 maj 2019, I: The Lancet. 393, 10184, s. 1937-1947 11 s.

Cardiac ventricular sizes are reduced in patients with long-term, normoalbuminuric type 1 diabetes compared to the non-diabetic background population

Hjortkjær, H. Ø., Jensen, T., Hilsted, J., Mogensen, U. M., Corinth, H., Rossing, P., Sigvardsen, P. E., Fuchs, A., Kühl, J. T., Nordestgaard, B. G., Køber, L. & Kofoed, K. F., 1 maj 2019, I: *Diabetes and Vascular Disease Research*. 16, 3, s. 289-296 8 s.

Correction to: Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J. & Buse, J. B., maj 2019, I: *Diabetologia*. 62, 5, s. 873 1 s.

MR-proANP effectively risk stratifies patients with type 2 diabetes regardless of presence of heart failure

Jensen, J., Schou, M., Kistorp, C., Faber, J., Hansen, T. W., M T, J., Andersen, H. U., Rossing, P., Vilsbøll, T. & Jørgensen, P. G., maj 2019, I: *European Journal of Heart Failure*. 21, Suppl 1, s. 223 P964.

Pleiotropic effects of liraglutide in patients with type 2 diabetes and moderate renal impairment: individual effects of treatment

Zobel, E. H., von Scholten, B. J., Goldman, B., Persson, F., Hansen, T. W. & Rossing, P., maj 2019, I: *Diabetes, Obesity and Metabolism*. 21, 5, s. 1261-1265 5 s.

Increasing ESKD in Diabetes in the Land Down Under: What Can Be Done, We Must Wonder

Rossing, P., Frimodt-Møller, M. & Persson, F., 1 mar. 2019, I: *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 73, 3, s. 293-296 4 s.

Reduction in Albuminuria With Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers

Heerspink, H. J. L., Sjöström, C. D., Inzucchi, S. E., Hallow, M. K., Cain, V. A., Rossing, P., Stefansson, B. V. & Sartipy, P., 1 mar. 2019, I: *Diabetes, Obesity and Metabolism*. 21, 3, s. 720-725 6 s.

Prevalence of heart failure and the diagnostic value of MR-proANP in outpatients with type 2 diabetes

Jensen, J., Schou, M., Kistorp, C., Faber, J., Hansen, T. W., Jensen, M. T., Andersen, H. U., Rossing, P., Vilsbøll, T. & Jørgensen, P. G., mar. 2019, I: *Diabetes, Obesity and Metabolism*. 21, 3, s. 736-740 5 s.

Urinary proteomics and precision medicine for chronic kidney disease: Current status and future perspectives

Persson, F. & Rossing, P., mar. 2019, I: *Proteomics - Clinical Applications*. 13, 2, 1800176.

A novel rare CUBN variant and three additional genes identified in Europeans with and without diabetes: results from an exome-wide association study of albuminuria

Ahluwalia, T. S., Schulz, C-A., Waage, J., Skaaby, T., Sandholm, N., van Zuydam, N., Charmet, R., Bork-Jensen, J., Almgren, P., Thuesen, B. H., Bedin, M., Brandslund, I., Christensen, C. K., Linneberg, A., Ahlqvist, E., Groop, P-H., Hadjadj, S., Tregouet, D-A., Jørgensen, M. E., Grarup, N., Pedersen, O., Simons, M., Groop, L., Orho-Melander, M., McCarthy, M. I., Melander, O., Rossing, P., Kilpeläinen, T. O. & Hansen, T., 1 feb. 2019, I: *Diabetologia*. 62, 2, s. 292-305 14 s.

Left ventricular remodelling and cardiac chamber sizes in long-term, normoalbuminuric type 1 diabetes patients with and without cardiovascular autonomic neuropathy

Hjortkjær, H. Ø., Jensen, T., Hilsted, J., Mogensen, U. M., Corinth, H., Rossing, P., Køber, L. & Kofoed, K. F., 1 feb. 2019, I: *Journal of Diabetes and its Complications*. 33, 2, s. 171-177 7 s.

Variations in Risk of End-Stage Renal Disease and Risk of Mortality in an International Study of Patients With Type 1 Diabetes and Advanced Nephropathy

Skupien, J., Smiles, A. M., Valo, E., Ahluwalia, T. S., Gyorgy, B., Sandholm, N., Croall, S., Lajer, M., McDonnell, K., Forsblom, C., Harjutsalo, V., Marre, M., Galecki, A. T., Tregouet, D-A., Wu, C. Y., Mychaleckyj, J. C., Nickerson, H., Pragnell, M., Rich, S. S., Pezzolesi, M. G., Hadjadj, S., Rossing, P., Groop, P-H. & Krolewski, A. S., 1 jan. 2019, I: *Diabetes Care*. 42, 1, s. 93-101 9 s.

Generalised arterial calcification in normoalbuminuric patients with type 1 diabetes with and without cardiovascular autonomic neuropathy

Hjortkjær, H. Ø., Jensen, T., Hilsted, J., Mogensen, U. M., Rossing, P., Køber, L. & Kofoed, K. F., jan. 2019, I: *Diabetes and Vascular Disease Research*. 16, 1, s. 98-102 5 s.

Guidelines and clinical practice at the primary level of healthcare in patients with type 2 diabetes mellitus with and without kidney disease in five European countries

Eder, S., Leierer, J., Kerschbaum, J., Rosivall, L., Wiecek, A., de Zeeuw, D., Mark, P. B., Heinze, G., Rossing, P., Heerspink, H. L. & Mayer, G., jan. 2019, I: *Diabetes and Vascular Disease Research*. 16, 1, s. 47-56 10 s.

Application of urinary proteomics as possible risk predictor of renal and cardiovascular complications in patients with type 2-diabetes and microalbuminuria

Oellgaard, J., Gæde, P., Persson, F., Rossing, P., Parving, H-H. & Pedersen, O., 1 dec. 2018, I: *Journal of Diabetes and its Complications*. 32, 12, s. 1133-1140 8 s.

Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

Chertow, G. M., Appel, G. B., Block, G. A., Chin, M. P., Coyne, D. W., Goldsberry, A., Kalantar-Zadeh, K., Meyer, C. J., Molitch, M. E., Pergola, P. E., Raskin, P., Silva, A. L., Spinowitz, B., Sprague, S. M. & Rossing, P., 1 dec. 2018, I: *Journal of Diabetes and its Complications*. 32, 12, s. 1113-1117 5 s.

Efficacy of a novel inhibitor of vascular adhesion protein-1 in reducing albuminuria in patients with diabetic kidney disease (ALBUM): a randomised, placebo-controlled, phase 2 trial

de Zeeuw, D., Renfurm, R. W., Bakris, G., Rossing, P., Perkovic, V., Hou, F. F., Nangaku, M., Sharma, K., Heerspink, H. J. L., Garcia-Hernandez, A. & Larsson, T. E., 1 dec. 2018, I: *The Lancet Diabetes and Endocrinology*. 6, 12, s. 925-933 8 s.

Urinary proteomics for prediction of mortality in patients with type 2 diabetes and microalbuminuria

Currie, G. E., von Scholten, B. J., Mary, S., Flores Guerrero, J-L., Lindhardt, M., Reinhard, H., Jacobsen, P. K., Mullen, W., Parving, H-H., Mischak, H., Rossing, P. & Delles, C., 1 dec. 2018, I: *Cardiovascular Diabetology*. 17, 50, s. 50 8 s.

Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J. & Buse, J. B., dec. 2018, I: *Diabetologia*. 61, 12, s. 2461-2498 37 s.

Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

Davies, M. J., D'Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J. & Buse, J. B., dec. 2018, I: *Diabetes Care*. 41, 12, s. 2669-2701 32 s.

Type 1 diabetes is associated with T-wave morphology changes. The Thousand & 1 Study

Isaksen, J. L., Graff, C., Ellervik, C., Jensen, J. S., Andersen, H. U., Rossing, P., Kanters, J. K. & Jensen, M. T., 1 nov. 2018, I: *Journal of Electrocardiology*. 51, 6, s. 72-77 6 s.

Cardiovascular autonomic neuropathy and bone metabolism in Type 1 diabetes

Hansen, C. S., Theilade, S., Lajer, M., Hansen, T. W. & Rossing, P., nov. 2018, I: *Diabetic Medicine*. 35, 11, s. 1596-1604 8 s.

Urinary tubular biomarkers as predictors of kidney function decline, cardiovascular events and mortality in microalbuminuric type 2 diabetic patients

Rotbain Curovic, V., Hansen, T. W., Eickhoff, M. K., von Scholten, B. J., Reinhard, H., Jacobsen, P. K., Persson, F., Parving, H-H. & Rossing, P., nov. 2018, I: *Acta Diabetologica*. 55, 11, s. 1143-1150 7 s.

Acute Hyperoxia and Slow Deep Breathing Improve Baroreflex Sensitivity in Long-Duration Type 1 Diabetes Irrespective of Macroalbuminuria

Laursen, J. C., Hansen, C. S., Bordino, M., Zobel, E. H., Winther, S. A., Groop, P-H., Frimodt-Møller, M. & Rossing, P., 27 okt. 2018, I: Journal of the American Society of Nephrology. 29, s. 776 1 s., SA-PO158.

Effect of Dapagliflozin on Cardiac Function and Biomarkers in Patients with Type 2 Diabetes and Albuminuria – A Randomized Study

Eickhoff, M. K., Olsen, F. J., Frimodt-Møller, M., Diaz, L. J., Faber, J. O., Jensen, M. T., Rossing, P. & Persson, F., 27 okt. 2018, I: Journal of the American Society of Nephrology. s. 770 1 s., SA-PO139.

Plasma Metabolomics Profiling in Auto-Antibody-Positive Individuals Progressing to Type 1 Diabetes

Suvitaival, T., Wesley, J. D., Ali, A., Trošt, K., Ahonen, L. L., Overgaard, A. J., Mattila, I., Hagopian, W., von Herrath, M., Rossing, P., Pociot, F. & Legido-Quigley, C., 27 okt. 2018.

Reduction in Albuminuria with Dapagliflozin Cannot Be Predicted by Baseline Clinical Characteristics or Changes in Most Other Risk Markers

Lambers Heerspink, H. J., Sjöström, D., Inzucchi, S. E., Hallow, M. K., Cain, V. A., Rossing, P., Stefansson, B. V. & Sartipy, P., 27 okt. 2018, I: Journal of the American Society of Nephrology. SA-OR081.

Cathepsin D: A Potential Biomarker for Diabetic Kidney Disease

Drel, V., Natarajan, L., Hoofnagle, A., De Boer, I., Darshi, M., Sharma, K., Vaisar, T., Kim, J., Valo, E., Zhang, J., Ahluwalia, T. S., Snell-Bergeon, J., Rossing, P. & Groop, P-H., 26 okt. 2018, I: Journal of the American Society of Nephrology.

Exome Wide Association Study Identifies a Rare Coding Variant in Cubilin Gene and Suggestive Variants in Additional Genes Associated with Albuminuria Among 33,985 Europeans with and Without Diabetes

Ahluwalia, T. S., Bredslund, I., Christensen, C. K., Linneberg, A., Ahlqvist, E., Groop, P-H., Hadjadj, S., Groop, L., Grarup, N., Orho-Melander, M., McCarthy, M. I., Schulz, C-A., Melander, O., Rossing, P., Kilpelainen, T. O., Hansen, T., Skaaby, T., Sandholm, N., Bork-Jensen, J., van Zuydam, N. R., Almgren, P., Thuesen, B. H. & Jørgensen, M. E., 26 okt. 2018, I: Journal of the American Society of Nephrology. FR-PO431.

Increasing Baseline Albuminuria Is Associated with a Continuously Increased Risk of Cardiovascular (CV) and Renal Outcomes in the LEADER Trial

mosenzon, O., Raz, I., Bain, S. C., Persson, F., Lambers Heerspink, H. J., Mann, J., Rossing, P., Idorn, T., Rasmussen, S. & von Scholten, B. J., 26 okt. 2018, I: Journal of the American Society of Nephrology.

Myocardial Flow Reserve Assessed by Cardiac 82Rb PET/CT Is Associated with Albumin Excretion in Patients with Type 1 Diabetes

Zobel, E. H., Winther, S. A., Von Scholten, B. J., Holmvang, L., Kjær, A., Rossing, P. & Hansen, T. W., 26 okt. 2018, I: Journal of the American Society of Nephrology. FR-PO429.

Plasma lipids are associated with diabetic kidney disease: a study of plasma lipidomics in type 1 diabetes

Tofte, N., Suvitaival, T., Ahonen, L. L., Theilade, S., Winther, S. A., Frimodt-Møller, M., Ahluwalia, T. S. & Rossing, P., 26 okt. 2018, I: Journal of the American Society of Nephrology. 29, s. 535 1 s., FR-PO445.

Plasma metabolomics identifies markers of impaired kidney function: A meta-analysis of 1,984 Europeans with type 2 diabetes

Tofte, N., Ahluwalia, T. S., Vogelzangs, N., Mook-Kanamori, D., Brahimaj, A., Nano, J., van Dijk, K. W., Frimodt-Møller, M., van der Kallen, C., Arts, I., Beulens, J., van der Heijden, A., Nijpels, G., van Greevenbroek, M., Stehouwer, C., Rossing, P. & t' Hart, L. M., 26 okt. 2018, I: Journal of the American Society of Nephrology. 29, s. 535 1 s., FR-PO446.

Pulse Wave Velocity Is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes

Frimodt-Møller, M., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S. & Rossing, P., 26 okt. 2018, I: Journal of the American Society of Nephrology. 29, 1, FR-PO430.

Soluble Urokinase Plasminogen Activator Receptor Predicts Kidney Function Decline and Mortality in Patients with Type 1 Diabetes

Rotbain Curovic, V., Theilade, S., Winther, S. A., Tofte, N., Eugen-Olsen, J., Persson, F., Hansen, T. W., Jeppesen, J. L. & Rossing, P., 26 okt. 2018, I: Journal of the American Society of Nephrology. 29, s. 537 1 s., FR-PO453.

Uric acid is an independent risk factor for mortality, cardiovascular event and decline in kidney function in patients with type 1 diabetes

Pilemann-Lyberg, S., Hansen, T. W., Tofte, N., Winther, S. A., Theilade, S., Ahluwalia, T. S. & Rossing, P., 26 okt. 2018, I: Journal of the American Society of Nephrology. 29, s. 537 1 s., FR-PO454.

Urine Metabolites Predict Kidney Function Decline in Type I Diabetic Subjects

Darshi, M., Groop, P-H., Natarajan, L., Sharma, K., Valo, E., Zhang, J., Kim, J. J., Saito, R., Montemayor, D., Ahluwalia, T. S., Snell-Bergeon, J. K. & Rossing, P., 26 okt. 2018, I: Journal of the American Society of Nephrology. FR-PO459.

Reduction in Albuminuria Is Associated with Cardiorenal Protection Independent of Baseline Albuminuria – A Post-Hoc Analysis of the LEADER Trial

Persson, F., Rossing, P., Bain, S. C., mosenzon, O., lambers heerspink, H., Mann, J., Raz, I., Idorn, T., Rasmussén, S. & von Scholten, B. J., 25 okt. 2018, I: Journal of the American Society of Nephrology. 29, s. 9 1 s., TH-OR034.

Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and Decline in Renal Function in Patients with Type 1 Diabetes

Hansen, T. W., Fridodt-Møller, M., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S. & Rossing, P., 19 okt. 2018.

Effect of dapagliflozin on renal and cardiac function in patients with type 2 diabetes and albuminuria: a randomised study

Eickhoff, M. K., Olsen, F. J., Fridodt-Møller, M., Diaz, L. J., Jensen, M. T., Rossing, P. & Persson, F., 4 okt. 2018, I: Diabetologia. 61, Suppl 1, s. S299-S300 1 s., 619.

Pulse Wave Velocity is an Independent Risk Factor for Cardiovascular Events, Mortality and progression in diabetic kidney disease in patients with type 1 diabetes

Hansen, T. W., Fridodt-Møller, M., Theilade, S., Winther, S. A., Tofte, N., Ahluwalia, T. S. & Rossing, P., 4 okt. 2018, I: Diabetologia. 61, Suppl 1, s. S548-S548 1 s., 1123.

The REMOVAL Trial: Metformin reduces progression of carotid intima media thickness in never smokers with type 1 diabetes

Petrie, J. R., Chaturvedi, N., Ford, I., Rossing, P. & Colhoun, H. M., 4 okt. 2018, I: Diabetologia. 61, Suppl1, s. S555 1 s., 1138.

Trajectories of estimated GFR in patients with and without albuminuria

Jørgensen, M. E., Vistisen, D., Andersen, G. S., Hulman, A., Persson, F. & Rossing, P., 4 okt. 2018, I: Diabetologia. 61, Suppl1, s. S92 1 s., 181.

Burden of Uncontrolled Metabolic Risk Factors and Left Ventricular Structure and Function in Patients With Type 2 Diabetes Mellitus

Jørgensen, P. G., Jensen, M. T., Biering-Sørensen, T., Mogelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jensen, J. S., 2 okt. 2018, I: Journal of the American Heart Association. 7, 19, s. e008856

Markers of collagen formation and degradation reflect renal function and predict adverse outcome in type 1 diabetes

Pilemann-Lyberg, S., Hansen, T. W., Tofte, N., Winther, S. A., Theilade, S., Rasmussen, D. G. K., Nielsen, S., Karsdal, M. A., Genovese, F. & Rossing, P., 2 okt. 2018, I: Diabetologia. 61, S1, s. S491 1 s., 999.

Acute hyperoxia deteriorates nerve conduction velocity in type 1 diabetes: A possible effect on oxidative stress?

Laursen, J. C., Hansen, C. S., Bordino, M., Zobel, E. H., Winther, S. A., Groop, P. -H., Fridodt-Møller, M., Bernardi, L. & Rossing, P., 1 okt. 2018, I: Diabetologia. 61, 1, s. S467 1 s., 948.

Hjertesvigt er en hyppig komplikation i forbindelse med diabetes mellitus

Hangaard, M. H., Rossing, P., Jensen, J. S. & Jensen, M. T., 1 okt. 2018, I: Ugeskrift for Læger. 180, 20A, V02170164 .

Soluble urokinase plasminogen activator receptor predicts cardiovascular events, mortality and kidney function decline in patients with type 1 diabetes

Curovic, V. R., Theilade, S., Winther, S. A., Tofte, N., Eugen-Olsen, J., Persson, F., Hansen, T. W., Jeppesen, J. & Rossing, P., 1 okt. 2018, I: *Diabetologia*. 61, 1, s. S577-S578 1 s., 1183.

Cardiac repolarization and depolarization in people with Type 1 diabetes with normal ejection fraction and without known heart disease: a case-control study

Isaksen, J. L., Graff, C., Ellervik, C., Jensen, J. S., Rossing, P., Kanters, J. K. & Jensen, M. T., okt. 2018, I: *Diabetic Medicine Online*. 35, 10, s. 1337-1344 7 s.

Collagen Type III Degradation Is Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes with Microalbuminuria

Genovesa, F., Hansen, T. W., Rasmussen, D. G. K., Nielsen, S. H., Reinhard, H., Von Scholten, B. J., Persson, F., Jacobsen, P. K., Parving, H-H. D., Karsdal, M. A. & Rossing, P., okt. 2018, I: *Diabetologia*. 61, s. S492-S492 1 s., 1001.

Efficacy of long-term remote ischaemic conditioning on vascular and neuronal function in type 2 diabetes patients with peripheral arterial disease

Hansen, C. S., Jørgensen, M. E., Fleischer, J., Bøtker, H. E. & Rossing, P., okt. 2018, I: *Diabetologia*. 61, Suppl 1, s. S480-S480 1 s., 973.

Myocardial flow reserve assessed by Cardiac 82Rb PET/CT is associated with albumin excretion in patients with type 1 diabetes

Hansen, T. W., Zobel, E. H., Hasbak, P., Winther, S. A., Kjær, A., Holmvang, L. & Rossing, P., 20 sep. 2018, I: *Journal of Hypertension*. 36, e suppl 3, s. S531-S531 1 s., A3993.

Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised Steno-2 study

Oellgaard, J., Gæde, P., Rossing, P., Rørth, R., Køber, L., Parving, H-H. & Pedersen, O., aug. 2018, I: *Diabetologia*. 61, 8, s. 1724-1733 9 s.

How Does Risk Screening for Kidney Disease Influence Diabetes Distress?

Joensen, L. E., Madsen, K. P., Frimodt-Møller, M., Tofte, N., Willaing, I., Lindhardt, M. K. & Rossing, P., 1 jul. 2018, I: *Diabetes*. 67, Supplement 1, 1 s.

A Genome-Wide Association Study of Diabetic Kidney Disease in Subjects With Type 2 Diabetes

van Zuydam, N. R., Ahlqvist, E., Sandholm, N., Deshmukh, H., Rayner, N. W., Abdalla, M., Ladenvall, C., Ziemek, D., Fauman, E., Robertson, N. R., McKeigue, P. M., Valo, E., Forsblom, C., Harjutsalo, V., Perna, A., Rurali, E., Marcovecchio, M. L., Igo, R. P., Salem, R. M., Perico, N., Lajer, M., Käräjämäki, A., Imamura, M., Kubo, M., Takahashi, A., Sim, X., Liu, J., van Dam, R. M., Jiang, G., Tam, C. H. T., Luk, A. O. Y., Lee, H. M., Lim, C. K. P., Szeto, C. C., So, W. Y., Chan, J. C. N., Ang, S. F., Dorajoo, R., Wang, L., Hua Clara, T. S., McKnight, A-J., Duffy, S., Pezzolesi, M. G., Marre, M., Gyorgy, B., Hadjadj, S., Ahluwalia, T. S., Linneberg, A., Rossing, P. & FINNDIANE Study centres, jul. 2018, I: *Diabetes*. 67, 7, s. 1414-1427 13 s.

Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria

Rasmussen, D. G. K., Hansen, T. W., von Scholten, B. J., Nielsen, S. H., Reinhard, H., Parving, H-H., Tepel, M., Karsdal, M. A., Jacobsen, P. K., Genovesa, F. & Rossing, P., jul. 2018, I: *Diabetes Care*. 41, 7, s. 1493-1500 7 s.

Stratification of type 2 diabetes based on routine clinical markers

Safai, N., Ali, A., Rossing, P. & Ridderstråle, M., jul. 2018, I: *Diabetes Research and Clinical Practice*. 141, s. 275-283 8 s.

Data Pipeline for Clinical Diabetes Metabolomics - From Targeted Mass-Spectra to Patient Stratification

Suvitaival, T., Ahonen, L., Ali, A., Legido-Quigley, C., Dragsted, L. O. & Rossing, P., 28 jun. 2018.

Development and comparison of sample preparation methods for LC-MS based lipidomics on fecal samples
Ahonen, L. L., Stanstrup, J., Mattila, I., Christiansen, N., Rossing, P. & Dragsted, L. O., 4 jun. 2018.

Altered somatosensory neurovascular response in patients with Becker muscular dystrophy

Lindberg, U., Kruuse, C., Witting, N., Lundgaard, S. J., Vissing, J., Rostrup, E., Larsson, H. B. W. & Rossing, P., jun. 2018, I: Brain and Behavior. 8, 6, s. e00985 9 s.

Characteristics of high- and low-risk individuals in the PRIORITY study: urinary proteomics and mineralocorticoid receptor antagonism for prevention of diabetic nephropathy in Type 2 diabetes

Tofte, N., Lindhardt, M., Adamova, K., Beige, J., Beulens, J. W. J., Birkenfeld, A. L., Currie, G., Delles, C., Dimos, I., Francová, L., Frimodt-Møller, M., Girman, P., Göke, R., Havrdova, T., Kooy, A., Mischak, H., Navis, G., Nijpels, G., Noutsou, M., Ortiz, A., Parvanova, A., Persson, F., Ruggenenti, P. L., Rutters, F., Rychlík, I., Spasovski, G., Speeckaert, M., Trillini, M., von der Leyen, H. & Rossing, P., 21 maj 2018, I: Diabetic Medicine. 35, 10, s. 1375-1382 8 s.

Higher Collagen VI Formation Is Associated With All-Cause Mortality in Patients With Type 2 Diabetes and Microalbuminuria.

Hansen, T. W., Rasmussen, D., Von Scholten, B. J., Nielsen, S., Reinhard, H., Parving, H-H. D., Tepel, M., Karsdal, M., Genovese, F. & Rossing, P., 17 maj 2018.

COLLAGEN TYPE III DEGRADATION IS ASSOCIATED WITH DETERIORATION OF KIDNEY FUNCTION IN PATIENTS WITH TYPE 2 DIABETES WITH MICROALBUMINURIA.

Frimodt-Møller, M., Genovese, F., Hansen, T., Rasmussen, D., Nielsen, S., Reinhard, H., von Scholten, B. J., Persson, F., Jacobsen, P., Parving, H-H., Karsdal, M. & Rossing, P., 1 maj 2018, I: Nephrology Dialysis Transplantation. 33, 1, 1 s., SP418.

Decreases in weight with bardoxolone methyl in obese patients with chronic kidney disease stage 4 and type 2 diabetes - post-hoc analyses from beacon

Rossing, P., Appel, G., Block, G., Chertow, G., Chin, M., Coyne, D., Goldsberry, A., Meyer, C., Molitch, M., Pergola, P., Spinowitz, B., Sprague, S. & Raskin, P., 1 maj 2018, I: Nephrology Dialysis Transplantation. 33, 1, 1 s., SP104.

Effect of bardoxolone methyl treatment on urinary albumin in patients with type 2 diabetes and chronic kidney disease - post-hoc analysis from beam and beacon

Rossing, P., Block, G., Chertow, G., Chin, M., Goldsberry, A., McCullough, P., Meyer, C., Packham, D., Spinowitz, B., Sprague, S., Warnock, D. & Pergola, P., 1 maj 2018, I: Nephrology Dialysis Transplantation. 33, 1, FP152.

Effect of dapagliflozin on albuminuria and the renin-angiotensin system when added to renin-angiotensin blockade in patients with type 2 diabetes and nephropathy

Eickhoff, M., Frimodt-Møller, M., Jorgensen, N. R., Rossing, P. & Persson, F., 1 maj 2018, I: Nephrology Dialysis Transplantation. 33, 1, SP417 .

Prevalence of heart failure with preserved and reduced left ventricular ejection fraction and diagnostic value of MR-proANP in 803 outpatients with type 2 diabetes

Jensen, J., Schou, M., Kistorp, C., Faber, J., Hansen, T. W., Jensen, M. T., Andersen, H. U., Rossing, P., Vilsboll, T., Jensen, J. S. & Jorgensen, P. G., 1 maj 2018, I: European Journal of Heart Failure. 20, S1, s. 432 1 s.

Serum uric acid and progression of diabetic nephropathy in type 1 diabetes

Pilemann-Lyberg, S., Lindhardt, M., Persson, F., Andersen, S. & Rossing, P., 1 maj 2018, I: Journal of Diabetes and its Complications. 32, 5, s. 470-473 3 s.

Aldosterone Blockade Added to Renin-Angiotensin System Blockade to Reduce Albuminuria-A Path for Improved Renoprotection?

Rossing, P. & Persson, F., maj 2018, I: Medecine/Sciences. 355, 5, s. 407-408 2 s.

Altered levels of plasma lipids are associated with diabetic kidney disease: a cross-sectional study of plasma lipidomics in type 1 diabetes

Tofte, N., Suvitaival, T., Ahonen, L. L., Theilade, S., Ahluwalia, T. S., Frimodt-Møller, M. & Rossing, P., maj 2018, I: Nephrology Dialysis Transplantation. 33, Suppl 1, 1 s., SP420 .

Subclassification of diabetes based on quantitative traits

Rossing, P., maj 2018, I: *Nature Reviews Nephrology*. 14, s. 355-356 1 s.

Novel risk genes identified in a genome-wide association study for coronary artery disease in patients with type 1 diabetes

Charmet, R., Duffy, S., Keshavarzi, S., Gyorgy, B., Marre, M., Rossing, P., McKnight, A. J., Maxwell, A. P., Ahluwalia, T. V. S., Paterson, A. D., Trégouët, D-A. & Hadjadj, S., 25 apr. 2018, I: *Cardiovascular Diabetology*. 17, 1, s. 61

Uric acid is not associated with diabetic nephropathy and other complications in type 1 diabetes

Pilemann-Lyberg, S., Hansen, T. W., Persson, F., Theilade, S., Singh Ahluwalia, T., Frystyk, J. & Rossing, P., 11 apr. 2018, I: *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 8 s.

Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives

Rossing, P., Persson, F. & Frimodt-Møller, M., apr. 2018, I: *Nephrologie & Therapeutique*. 14 Suppl 1, s. S31-S37

Associations between advanced glycation endproducts and matrix metalloproteinases and its inhibitor in individuals with type 1 diabetes

Peeters, S. A., Engelen, L., Buijs, J., Theilade, S., Rossing, P., Schalkwijk, C. G. & Stehouwer, C. D. A., 1 mar. 2018, I: *Journal of Diabetes and its Complications*. 32, 3, s. 325-329 4 s.

The effect of uric acid lowering treatment on albuminuria and renal function in Type 1 diabetes: a randomized clinical trial

Pilemann-Lyberg, S., Persson, F., Frystyk, J. & Rossing, P., mar. 2018, I: *Diabetic Medicine Online*. 35, 3, s. 392-393 1 s.

Predicting albuminuria response to spironolactone treatment with urinary proteomics in patients with type 2 diabetes and hypertension

Lindhardt, M., Persson, F., Oxlund, C. S., Jacobsen, I. A., Zürlbig, P., Mischak, H., Rossing, P. & Heerspink, H. J. L., feb. 2018, I: *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 33, 2, s. 296-303 7 s.

Diagnosis of diabetic kidney disease: state of the art and future perspective

Persson, F. & Rossing, P., 1 jan. 2018, I: *Kidney International Supplements*. 8, 1, s. 2-7 6 s.

Arterial-ventricular coupling in type 1 diabetes: arterial stiffness is associated with impaired global longitudinal strain in type 1 diabetes patients-the Thousand & 1 Study

Theilade, S., Rossing, P., Jensen, J. S. & Jensen, M. T., jan. 2018, I: *Acta Diabetologica*. 55, 1, s. 21-29 8 s.

Biomarkers of inflammation and endothelial dysfunction as predictors of pulse pressure and incident hypertension in type 1 diabetes: a 20 year life-course study in an inception cohort

Ferreira, I., Hovind, P., Schalkwijk, C. G., Parving, H-H., Stehouwer, C. D. A. & Rossing, P., jan. 2018, I: *Diabetologia*. 61, 1, s. 231-241 10 s.

A Prospective Cohort Study in Patients with Type 2 Diabetes Mellitus for Validation of Biomarkers (PROVALID) - Study Design and Baseline Characteristics

Eder, S., Leierer, J., Kerschbaum, J., Rosivall, L., Wiecek, A., de Zeeuw, D., Mark, P. B., Heinze, G., Rossing, P., Heerspink, H. L. & Mayer, G., 2018, I: *Kidney & blood pressure research*. 43, 1, s. 181-190 10 s.

Clinical Features and Natural Course of Diabetic Nephropathy

Rossing, P. & Frimodt-Møller, M., 2018, *Diabetic Nephropathy: Pathophysiology and Clinical Aspects*. Roelof, J. & Vogt, L. (red.). 1 udg. Springer International Publishing, s. 21-33

Effects of Dapagliflozin on Albuminuria, Renal Function, and Renin-Angiotensin-Aldosterone Hormones in Type 2 Diabetes

Eickhoff, M. K., Frimodt-Møller, M., Jørgensen, N. R., Rossing, P. & Persson, F., 2018, I: *Journal of the American Society of Nephrology*. s. 770 1 s., SA-PO138.

Growth differentiation factor-15 and fibroblast growth factor-23 are associated with mortality in type 2 diabetes - An observational follow-up study

Frimodt-Møller, M., von Scholten, B. J., Reinhard, H., Jacobsen, P. K., Hansen, T. W., Persson, F. I., Parving, H-H. & Rossing, P., 2018, I: P L o S One. 13, 4, s. e0196634

Plasma lipids are associated with diabetic kidney disease: a study of plasma lipidomics in type 1 diabetes

Tofte, N., Suvitaival, T., Ahonen, L. L., Theilade, S., Winther, S. A., Frimodt-Møller, M., Ahluwalia, T. S. & Rossing, P., 2018, I: Diabetologia. 61, suppl 1, s. S497-S497 1 s., 1011.

Noninvasive diagnosis of chronic kidney diseases using urinary proteome analysis

Siwy, J., Zürlbig, P., Argilés, A., Beige, J., Haubitz, M., Jankowski, J., Julian, B. A., Linde, P. G., Marx, D., Mischak, H., Mullen, W., Novak, J., Ortiz, A., Persson, F., Pontillo, C., Rossing, P., Rupprecht, H., Schanstra, J. P., Vlahou, A. & Vanholder, R., dec. 2017, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention

Petrykiv, S. I., Laverman, G. D., Persson, F., Vogt, L., Rossing, P., de Borst, M. H., Gansevoort, R. T., de Zeeuw, D. & Heerspink, H. J. L., 7 nov. 2017, I: Clinical journal of the American Society of Nephrology : CJASN. 12, 11, s. 1804-1813 9 s.

Fasting Plasma Trimethylamine-N-Oxide as a Risk Marker of Poor Renal Outcomes, Cardiovascular Disease, and Mortality in Patients with Type 1 Diabetes with Diabetic Nephropathy

Winther, S. A., Øllgaard, J. C., Parving, H-H. D., Hazen, S. L., Pedersen, O. & Rossing, P., 4 nov. 2017, I: Journal of the American Society of Nephrology. 28, s. 102-103 SA-OR113.

Symmetric and Asymmetric Dimethylarginine as Risk Markers of Cardiovascular Disease, All-Cause Mortality, and Deterioration in Kidney Function in Patients with Type 2 Diabetes and Microalbuminuria

Persson, F., Zobel, E. H., von Scholten, B. J., Hansen, T. W., Parving, H-H. D. & Rossing, P., 4 nov. 2017. 1 s.

A Novel Marker of Collagen Type VI Formation Is Prognostic for Cardiovascular Disease, All-Cause Mortality, and Deterioration of Kidney Function in Patients with Type 2 Diabetes with Microalbuminuria

Guldager, D. K. R., Hansen, T. W., Nielsen, S. H., Reinhard, H., Parving, H-H. D., Karsdal, M. A., Genovese, F. & Rossing, P., 3 nov. 2017. 1 s.

Collagen Type III Degradation Is Associated with Deterioration of Kidney Function in Patients with Type 2 Diabetes with Microalbuminuria

Genovese, F., Hansen, T. W., Guldager, D. K. R., Nielsen, S. H., Reinhard, H., Parving, H-H. D., Karsdal, M. A. & Rossing, P., 3 nov. 2017. 1 s.

GDF-15 and FGF-23 Are Associated with Mortality in Type 2 Diabetic Patients with Microalbuminuria

Frimodt-Møller, M., von Scholten, B. J., Reinhard, H., Hansen, T. W., Persson, F., Parving, H-H. D. & Rossing, P., 3 nov. 2017. 1 s.

Is Urinary KIM-1 a Predictor of EGFR Decline, Incident Cardiovascular Disease, and All Cause Mortality?

Eickhoff, M. K., von Scholten, B. J., Reinhard, H., Hansen, T. W., Persson, F., Parving, H-H. D. & Rossing, P., 3 nov. 2017. 1 s.

Reduced Sublingual Endothelial Glycocalyx in Type 1 Diabetic Patients with Diabetic Nephropathy

Winther, S. A., Frimodt-Møller, M., Zobel, E. H., Hansen, T. W. & Rossing, P., 3 nov. 2017, I: Journal of the American Society of Nephrology. 28, s. 575 1 s., FR-PO666.

Serum and Urine Markers of Collagen Type VI Formation (Pro-C6) and Type III Degradation (C3M) Reflect Renal Function in Type 1 Diabetes

Hansen, T. W., Guldager, D. K. R., Pilemann-Lyberg, S., Nielsen, S. H., Karsdal, M. A., Persson, F., Theilade, S., Genovese, F. & Rossing, P., 3 nov. 2017. 1 s.

The Effect of Uric Acid Lowering on Albuminuria and Renal Function in Type 1 Diabetes: A Randomized Clinical Trial
Pilemann-Lyberg, S., Persson, F., Frystyk, J. & Rossing, P., 2 nov. 2017. 1 s.

Plasma high-sensitivity troponin T predicts end-stage renal disease and cardiovascular and all-cause mortality in patients with type 1 diabetes and diabetic nephropathy

Galsgaard, J., Persson, F., Hansen, T. W., Jorsal, A., Tarnow, L., Parving, H-H. & Rossing, P., nov. 2017, I: *Kidney International*. 92, 5, s. 1242-1248 6 s.

Prediction of Chronic Kidney Disease Stage 3 by CKD273, a Urinary Proteomic Biomarker

Pontillo, C., Zhang, Z-Y., Schanstra, J. P., Jacobs, L., Zürlbig, P., Thijs, L., Ramírez-Torres, A., Heerspink, H. J. L., Lindhardt, M., Klein, R., Orchard, T., Porta, M., Bilous, R. W., Charturvedi, N., Rossing, P., Vlahou, A., Schepers, E., Glorieux, G., Mullen, W., Delles, C., Verhamme, P., Vanholder, R., Staessen, J. A., Mischak, H. & Jankowski, J., nov. 2017, I: *Kidney International Reports*. 2, 6, s. 1066-1075 10 s.

Urinary proteomics predict onset of microalbuminuria in normoalbuminuric type 2 diabetic patients, a sub-study of the DIRECT-Protect 2 study

Lindhardt, M., Persson, F. I., Zürlbig, P., Stalmach, A., Mischak, H., de Zeeuw, D., Lambers Heerspink, H., Klein, R., Orchard, T., Porta, M., Fuller, J., Bilous, R., Chaturvedi, N., Parving, H-H. & Rossing, P., nov. 2017, I: *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 32, 11, s. 1866-1873 7 s.

Presence of micro- and macroalbuminuria and the association with cardiac mechanics in patients with type 2 diabetes

Jørgensen, P. G., Biering-Sørensen, T., Mogelvang, R., Fritz-Hansen, T., Vilsbøll, T., Rossing, P. & Jensen, J. S., 3 okt. 2017, I: *European heart journal cardiovascular Imaging*. s. 0-8 8 s.

Toe-brachial index as a predictor of cardiovascular disease and all-cause mortality in people with type 2 diabetes and microalbuminuria

Zobel, E. H., von Scholten, B. J., Reinhard, H., Persson, F., Hansen, T. W., Parving, H. H., Jacobsen, P. K. & Rossing, P., okt. 2017, I: *Diabetologia*. 60, 10, s. 1883-1891 8 s.

Cluster analyses of patients with dysregulated type 2 diabetes based on routine clinical markers reveal cluster-specific prevalence of diabetes complications

Ali, A., Safai, N., Rossing, P. & Ridderstråle, M., 13 sep. 2017.

Reduced sublingual endothelial glycocalyx in type 1 diabetic patients with diabetic nephropathy

Winther, S. A., Frimodt-Møller, M., Zobel, E. H., Hansen, T. W. & Rossing, P., 13 sep. 2017, I: *Diabetologia*. 60, s. S499 1 s., 1084.

Risk of heart failure in intensively treated patients with type 2 diabetes and microalbuminuria: 21 years follow-up in the multifactorial Steno-2 intervention

Øllgaard, J. C., Gæde, P., Rørth, R., Rossing, P., Køber, L., Parving, H-H. D. & Pedersen, O., 13 sep. 2017. 1 s.

GDF-15 and FGF-23 are associated with mortality in type 2 diabetic patients with microalbuminuria

Frimodt-Møller, M., von Scholten, B. J., Reinhard, H., Hansen, T. W., Persson, F., Parving, H-H. D. & Rossing, P., 12 sep. 2017. 1 s.

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, mortality and deterioration in kidney function in patients with type 2 diabetes

Hansen, T. W., Zobel, E. H., von Scholten, B. J., Reinhard, H., Persson, F., Teerlink, T., Parving, H-H. D., Jacobsen, P. K. & Rossing, P., 12 sep. 2017. 1 s.

Higher plasma methylglyoxal levels are associated with incident cardiovascular disease in individuals with type 1 diabetes: a 12-year follow-up study

Hanssen, N. M. J., Scheijen, J. L. J., Jorsal, A., Parving, H-H., Tarnow, L., Rossing, P., Stehouwer, C. D. A. & Schalkwijk, C. G., 1 sep. 2017, s. S511. 1 s.

A urinary proteome-based classifier for the early detection of decline in glomerular filtration

Pontillo, C., Jacobs, L., Staessen, J. A., Schanstra, J. P., Rossing, P., Heerspink, H. J. L., Siwy, J., Mullen, W., Vlahou, A., Mischak, H., Vanholder, R., Zürlbig, P. & Jankowski, J., sep. 2017, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 32, 9, s. 1510-1516 6 s.

Diabetes and Hypertension: A Position Statement by the American Diabetes Association

de Boer, I. H., Bangalore, S., Benetos, A., Davis, A. M., Michos, E. D., Muntner, P., Rossing, P., Zoungas, S. & Bakris, G. L., sep. 2017, I: Diabetes Care. 40, 9, s. 1273-1284 12 s.

Cardiovascular and metabolic effects of metformin in patients with type 1 diabetes (REMOVAL): a double-blind, randomised, placebo-controlled trial

Petrie, J. R., Chaturvedi, N., Ford, I., Brouwers, M. C. G. J., Greenlaw, N., Tillin, T., Hramiak, I., Hughes, A. D., Jenkins, A. J., Klein, B. E. K., Klein, R., Ooi, T. C., Rossing, P., Stehouwer, C. D. A., Sattar, N., Colhoun, H. M. & REMOVAL Study Group, aug. 2017, I: The Lancet Diabetes and Endocrinology. 5, 8, s. 597-609 12 s.

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference

Baigent, C., Herrington, W. G., Coresh, J., Landray, M. J., Levin, A., Perkovic, V., Pfeffer, M. A., Rossing, P., Walsh, M., Wanner, C., Wheeler, D. C., Winkelmayer, W. C. & McMurray, J. J. V., aug. 2017, I: Kidney International. 92, 2, s. 297-305 9 s.

Symmetric and asymmetric dimethylarginine as risk markers of cardiovascular disease, all-cause mortality and deterioration in kidney function in persons with type 2 diabetes and microalbuminuria

Zobel, E. H., von Scholten, B. J., Reinhard, H., Persson, F., Teerlink, T., Hansen, T. W., Parving, H-H., Jacobsen, P. K. & Rossing, P., 11 jul. 2017, I: Cardiovascular Diabetology. 16, 1, s. e88

Effect of weight reductions on estimated kidney function: Post-hoc analysis of two randomized trials

von Scholten, B. J., Davies, M. J., Persson, F., Hansen, T. W., Madsbad, S., Endahl, L., Jepsen, C. H. & Rossing, P., jul. 2017, I: Journal of Diabetes and its Complications. 31, 7, s. 1164-1168 5 s.

Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes

Krolewski, A. S., Skupien, J., Rossing, P. & Warram, J. H., 1 jun. 2017, I: Kidney International. 91, 6, s. 1300-1311 12 s.

Liraglutide effects on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomised, placebo-controlled, double-blind, cross-over trial

von Scholten, B. J., Persson, F., Rosenlund, S., Eugen-Olsen, J., Pielak, T., Faber, J., Hansen, T. W. & Rossing, P., 1 jun. 2017, I: Diabetes, Obesity and Metabolism. 19, 6, s. 901-905

Variability in response to albuminuria-lowering drugs: true or random?

Petrykiv, S. I., de Zeeuw, D., Persson, F., Rossing, P., Gansevoort, R. T., Laverman, G. D. & Heerspink, H. J. L., 1 jun. 2017, I: British Journal of Clinical Pharmacology. 83, 6, s. 1197-1204 8 s.

Comparison of manual and automated sample preparation techniques for lipidomics

Ahonen, L. & Rossing, P., jun. 2017.

Incident microalbuminuria and complement factor mannan-binding lectin-associated protein 19 in people with newly diagnosed type 1 diabetes

Ostergaard, J. A., Thiel, S., Hoffmann-Petersen, I. T., Hovind, P., Parving, H-H., Tarnow, L., Rossing, P. & Hansen, T. K., apr. 2017, I: Diabetes - Metabolism: Research and Reviews (Online). 33, 5, s. e2895

Intensified multifactorial intervention in type 2 diabetics with microalbuminuria leads to long-term renal benefits

Oellgaard, J., Gaede, P., Rossing, P., Persson, F., Parving, H-H. & Pedersen, O., apr. 2017, I: Kidney International. 91, 4, s. 982-988 7 s.

Metformin in adults with type 1 diabetes: Design and methods of REducing with MetfOrmin Vascular Adverse Lesions (REMOVAL): An international multicentre trial

Petrie, J. R., Chaturvedi, N., Ford, I., Hramiak, I., Hughes, A. D., Jenkins, A. J., E Klein, B., Klein, R., Ooi, T. C., Rossing, P., Sattar, N., Stehouwer, C. D. A., Colhoun, H. M. & REMOVAL Trial Team, apr. 2017, I: Diabetes, Obesity and Metabolism. 19, 4, s. 509-516 8 s.

Effect of Pancreatic Hormones on pro-Atrial Natriuretic Peptide in Humans

Zois, N. E., Terzic, D., Færch, K., Plomgaard, P., Hansen, J. S., Rossing, P. & Goetze, J. P., mar. 2017, I: EBioMedicine. 17, s. 88-94 7 s.

Systems Biology-Derived Biomarkers to Predict Progression of Renal Function Decline in Type 2 Diabetes

Mayer, G., Heerspink, H. J. L., Aschauer, C., Heinzl, A., Heinze, G., Kainz, A., Sunzenauer, J., Perco, P., de Zeeuw, D., Rossing, P., Pena, M. J., Oberbauer, R. & SYSKID Consortium, mar. 2017, I: Diabetes Care. 40, 3, s. 391-397 7 s.

Effect of large weight reductions on measured and estimated kidney function

von Scholten, B. J., Persson, F., Svane, M. S., Hansen, T. W., Madsbad, S. & Rossing, P., 1 feb. 2017, I: BMC Nephrology. 18, 1, s. 52

The effect of liraglutide on renal function: A randomized clinical trial

von Scholten, B. J., Persson, F., Rosenlund, S., Hovind, P., Faber, J., Hansen, T. W. & Rossing, P., feb. 2017, I: Diabetes, Obesity and Metabolism. 19, 2, s. 239-247

The Genetic Landscape of Renal Complications in Type 1 Diabetes

Sandholm, N., van Zuydam, N. R., Ahlqvist, E., Juliusdottir, T., Deshmukh, H. A., Rayner, N. W., Di Camillo, B., Forsblom, C., Fadista, J., Ziemek, D., Salem, R. M., Hiraki, L. T., Pezzolesi, M. G., Tregouet, D., Dahlström, E., Valo, E., Oskolkov, N., Ladenvall, C., Marcovecchio, M. L., Cooper, J. D., Sambo, F., Malovini, A., Manfrini, M., McKnight, A. J., Lajer, M. S., Harjutsalo, V., Gordin, D., Parkkonen, M., Lyssenko, V., McKeigue, P. M., Rich, S. S., Brosnan, M. J., Fauman, E., Bellazzi, R., Rossing, P., Hadjadj, S., Krolewski, A. S., Paterson, A. D., Hirschhorn, J. N., Maxwell, A. P., Cobelli, C., Colhoun, H. M., Groop, L., McCarthy, M. I., Groop, P-H. & FinnDiane Study Group, Jaakko Tuomilehto, feb. 2017, I: Journal of the American Society of Nephrology : JASN. 28, 2, s. 557-574 18 s.

Pleiotropic effects of liraglutide treatment on renal risk factors in type 2 diabetes: Individual effects of treatment

Zobel, E. H., von Scholten, B. J., Lindhardt, M., Persson, F., Hansen, T. W. & Rossing, P., jan. 2017, I: Journal of Diabetes and its Complications. 31, 1, s. 162-168 7 s.

Circulating matrix metalloproteinases are associated with arterial stiffness in patients with type 1 diabetes: pooled analysis of three cohort studies

Peeters, S. A., Engelen, L., Buijs, J., Chaturvedi, N., Fuller, J. H., Jorsal, A., Parving, H-H., Tarnow, L., Theilade, S., Rossing, P., Schalkwijk, C. G. & Stehouwer, C. D. A., 2017, I: Cardiovascular Diabetology. 16, 1, s. e139

Epicardial, pericardial and total cardiac fat and cardiovascular disease in type 2 diabetic patients with elevated urinary albumin excretion rate

Christensen, R. H., von Scholten, B. J., Hansen, C. S., Heywood, S. E., Rosenmeier, J. B., Andersen, U. B., Hovind, P., Reinhard, H., Parving, H-H., Pedersen, B. K., Jørgensen, M. E., Jacobsen, P. K. & Rossing, P., 2017, I: European journal of preventive cardiology. 24, 14, s. 1517-1524

Higher Parathyroid Hormone Level Is Associated With Increased Arterial Stiffness in Type 1 Diabetes

Zobel, E. H., Theilade, S., Johan von Scholten, B., Persson, F., Tarnow, L., Lajer, M., Hansen, T. W. & Rossing, P., 2017, I: Diabetes Care. 40, 3, s. e32-e33

Higher Plasma Methylglyoxal Levels are Associated with Incident Cardiovascular Disease in Individuals with Type 1 Diabetes: a 12-Year Follow-Up Study

Hanssen, N. M. J., Scheijen, J. L. J. M., Jorsal, A., Parving, H-H., Tarnow, L., Rossing, P., Stehouwer, C. D. A. & Schalkwijk, C. G., 2017, I: Diabetes. 66, 8, s. 2278-83

Plasma matrix metalloproteinases are associated with incident cardiovascular disease and all-cause mortality in patients with type 1 diabetes: a 12-year follow-up study

Peeters, S. A., Engelen, L., Buijs, J., Jorsal, A., Parving, H-H., Tarnow, L., Rossing, P., Schalkwijk, C. G. & Stehouwer, C. D. A., 2017, I: Cardiovascular Diabetology. 16, 1, s. e55

Reduced sublingual endothelial glycocalyx in type 1 diabetic patients with diabetic nephropathy

Winther, S. A., Frimodt-Møller, M., Zobel, E. H., Hansen, T. W. & Rossing, P., 2017.

Reduced sublingual endothelial glycocalyx in type 1 diabetics with diabetic nephropathy

Winther, S. A., Frimodt-Møller, M., Zobel, E. H., Hansen, T. W. & Rossing, P., 2017.

Three-phase bone scintigraphy for diagnosis of Charcot neuropathic osteoarthropathy in the diabetic foot - does quantitative data improve diagnostic value?

Fosbøl, M., Reving, S., Petersen, E. H., Rossing, P., Lajer, M. & Zerahn, B., 2017, I: Clinical Physiology and Functional Imaging. 37, 1, s. 30-36

Trimethylamine N-oxide (TMAO) as a new potential therapeutic target for insulin resistance and cancer

Oellgaard, J., Winther, S. A., Hansen, T. S., Rossing, P. & von Scholten, B. J., 2017, I: Current Pharmaceutical Design. 23, 25, s. 3699-3712 14 s.

Global Changes in Food Supply and the Obesity Epidemic

Zobel, E. H., Hansen, T. W., Rossing, P. & von Scholten, B. J., dec. 2016, I: Current Obesity Reports. 5, 4, s. 449-455 7 s.

Methylglyoxal is associated with changes in kidney function among individuals with screen-detected Type 2 diabetes mellitus

Jensen, T. M., Vistisen, D., Fleming, T., Nawroth, P., Rossing, P., Jørgensen, M. E., Lauritzen, T., Sandbæk, A. & Witte, D. R., 15 nov. 2016, I: Diabetic Medicine Online. 33, 12, s. 1625-1631 7 s.

Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial

Gæde, P., Øllgaard, J. C., Carstensen, B., Rossing, P., Lund-Andersen, H., Parving, H-H. & Pedersen, O., nov. 2016, I: Diabetologia. 59, 11, s. 2298-307 10 s.

Cardiac Autonomic Function Is Associated With the Coronary Microcirculatory Function in Patients With Type 2 Diabetes

von Scholten, B. J., Hansen, C. S., Hasbak, P., Kjaer, A., Rossing, P. & Hansen, T. W., okt. 2016, I: Diabetes. 65, 10, s. 3129-38 10 s.

Cholesterol remnants and triglycerides are associated with decreased myocardial function in patients with type 2 diabetes

Jørgensen, P. G., Jensen, M. T., Biering-Sørensen, T., Mogelvang, R., Galatius, S., Fritz-Hansen, T., Rossing, P., Vilsbøll, T. & Jensen, J. S., 22 sep. 2016, I: Cardiovascular Diabetology. 15, 1, s. 137

Abnormal echocardiography in patients with type 2 diabetes and relation to symptoms and clinical characteristics

Jørgensen, P. G., Jensen, M. T., Mogelvang, R., von Scholten, B. J., Bech, J., Fritz-Hansen, T., Galatius, S., Biering-Sørensen, T., Andersen, H. U., Vilsbøll, T., Rossing, P. & Jensen, J. S., sep. 2016, I: Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease. 13, 5, s. 321-30 10 s.

Impact of type 2 diabetes and duration of type 2 diabetes on cardiac structure and function

Jørgensen, P. G., Jensen, M. T., Mogelvang, R., Fritz-Hansen, T., Galatius, S., Biering-Sørensen, T., Storgaard, H., Vilsbøll, T., Rossing, P. & Jensen, J. S., 5 jul. 2016, I: International Journal of Cardiology. 221, s. 114-121 8 s.

Serum metabolites predict response to angiotensin II receptor blockers in patients with diabetes mellitus

Pena, M. J., Heinzl, A., Rossing, P., Parving, H-H., Dallmann, G., Rossing, K., Andersen, S., Mayer, B. & Heerspink, H. J. L., 5 jul. 2016, I: Journal of Translational Medicine. 14, 1, s. 203

Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review

Persson, F. I., Lindhardt, M., Rossing, P. & Parving, H-H., jul. 2016, I: Journal of the renin-angiotensin-aldosterone system : JRAAS. 17, 3, s. pii: 1470320316652047

Self-reported dyspnea is associated with impaired global longitudinal strain in ambulatory type 1 diabetes patients with normal ejection fraction and without known heart disease - The Thousand & 1 Study

Jensen, M. T., Risum, N., Rossing, P. & Jensen, J. S., jul. 2016, I: Journal of Diabetes and its Complications. 30, 5, s. 928-34 7 s.

Urinary biomarkers are associated with incident cardiovascular disease, all-cause mortality and deterioration of kidney function in type 2 diabetic patients with microalbuminuria

von Scholten, B. J., Reinhard, H., Hansen, T. W., Oellgaard, J. C., Parving, H-H., Jacobsen, P. K. & Rossing, P., jul. 2016, I: Diabetologia. 59, 7, s. 1549-57 9 s.

Early myocardial impairment in type 1 diabetes patients without known heart disease assessed with tissue Doppler echocardiography: The Thousand & 1 study

Jensen, M. T., Sogaard, P., Andersen, H. U., Gustafsson, I., Bech, J., Hansen, T. F., Theilade, S., Almdal, T., Rossing, P. & Jensen, J. S., jun. 2016, I: Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease. 13, 4, s. 260-267

Plasma soluble urokinase plasminogen activator receptor (suPAR) level is associated with myocardial impairment assessed with advanced echocardiography in Type 1 Diabetes Patients with normal ejection fraction and without known heart disease or end stage renal disease

Theilade, S., Rossing, P., Eugen-Olsen, J., Jensen, J. S. & Jensen, M. T., jun. 2016, I: European journal of endocrinology / European Federation of Endocrine Societies. 174, 6, s. 745-753

Retinopathy is associated with impaired myocardial function assessed by advanced echocardiography in type 1 diabetes patients - The Thousand & 1 Study

Nouhravesh, N., Andersen, H. U., Jensen, J. S., Rossing, P. & Jensen, M. T., jun. 2016, I: Diabetes Research and Clinical Practice. 116, s. 263-9 7 s.

Cardiac time intervals and the association with 2D-speckle-tracking, tissue Doppler and conventional echocardiography: the Thousand&1 Study

Biering-Sørensen, T., Jensen, J. S., Andersen, H. U., Rossing, P. & Jensen, M. T., maj 2016, I: The international journal of cardiovascular imaging. 32, 5, s. 789-98 10 s.

Impaired coronary microcirculation in type 2 diabetic patients is associated with elevated circulating regulatory T cells and reduced number of IL-21R⁺ T cells

von Scholten, B. J., Rosendahl, A., Hasbak, P., Bergholdt, R., Kjaer, A., Rossing, P. & Hansen, T. W., 19 apr. 2016, I: Cardiovascular Diabetology. 15, s. 67

Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy in TType 2 diabetic patients with normoalbuminuria (PRIORITY): essential study design and rationale of a randomised clinical multicentre trial

Lindhardt, M., Persson, F., Currie, G., Pontillo, C., Beige, J., Delles, C., von der Leyen, H., Mischak, H., Navis, G., Noutsou, M., Ortiz, A., Ruggenenti, P. L., Rychlik, I., Spasovski, G. & Rossing, P., 2 mar. 2016, I: B M J Open. 6, 3, s. e010310

Cardiac (82)Rb PET/CT for fast and non-invasive assessment of microvascular function and structure in asymptomatic patients with type 2 diabetes

von Scholten, B. J., Hasbak, P., Christensen, T. E., Ghotbi, A. A., Kjaer, A., Rossing, P. & Hansen, T. W., feb. 2016, I: Diabetologia. 59, 2, s. 371-8 8 s.

Efficacy and Safety of Liraglutide Versus Placebo as Add-on to Glucose-Lowering Therapy in Patients With Type 2 Diabetes and Moderate Renal Impairment (LIRA-RENAL): A Randomized Clinical Trial

Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, P., Scott, D. A., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A. & Umpierrez, G. E., feb. 2016, I: *Diabetes Care*. 39, 2, s. 222-30 9 s.

Angiogenic microRNAs Linked to Incidence and Progression of Diabetic Retinopathy in Type 1 Diabetes

Zampetaki, A., Willeit, P., Burr, S., Yin, X., Langley, S. R., Kiechl, S., Klein, R., Rossing, P., Chaturvedi, N. & Mayr, M., 1 jan. 2016, I: *Diabetes*. 65, 1, s. 216-27 12 s.

Several Conventional Risk Markers Suggesting Presence of Albuminuria Are Weak Among Rural Africans With Hypertension

Rasmussen, J. B., Nordin, L. S., Thomsen, J. A., Rossing, P., Bygbjerg, I. C. & Christensen, D. L., jan. 2016, I: *Journal of Clinical Hypertension*. 18, 1, s. 27-30 4 s.

Statins are independently associated with increased HbA1c in type 1 diabetes - The Thousand & 1 Study

Jensen, M. T., Andersen, H. U., Rossing, P. & Jensen, J. S., jan. 2016, I: *Diabetes Research and Clinical Practice*. 111, s. 51-7 7 s.

Are human endogenous retroviruses triggers of autoimmune diseases? Unveiling associations of three diseases and viral loci

Nexø, B. A., Villesen, P., Nissen, K. K., Lindegaard, H. M., Rossing, P., Petersen, T., Tarnow, L., Hansen, B., Lorenzen, T., Hørslev-Petersen, K., Jensen, S. B., Bahrami, S., Lajer, M., Schmidt, K., Parving, H-H. D., Junker, P. & Laska, M. J., 2016, I: *Immunologic Research*. 64, 1, s. 55-63

Diabetic Nephropathy

Rossing, P., Fioretto, P., Feldt-Rasmussen, B. F. & Parving, H-H., 2016, *Brenner and Rector's The Kidney*. 10 udg. Elsevier, s. 1283-1321 39 s.

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis

Currie, G., Taylor, A. H. M., Fujita, T., Ohtsu, H., Lindhardt, M., Rossing, P., Boesby, L., Edwards, N. C., Ferro, C. J., Townend, J. N., van den Meiracker, A. H., Saklayen, M. G., Oveisi, S., Jardine, A. G., Delles, C., Preiss, D. J. & Mark, P. B., 2016, I: *BMC Nephrology*. 17, 1, s. 127

Glucose-Dependent Insulinotropic Polypeptide (GIP) Stimulates Osteopontin Expression in the Vasculature via Endothelin-1 and CREB

Berglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayali, S., Brøns, C., Forsblom, C., Jonsson, A., Zetterqvist, A. V., Nitulescu, M., McDavitt, C. R., Dunér, P., Stancáková, A., Kuusisto, J., Ahlqvist, E., Lajer, M., Tarnow, L., Madsbad, S., Rossing, P., Kieffer, T. J., Melander, O., Orho-Melander, M., Nilsson, P., Groop, P-H., Vaag, A., Lindblad, B., Gottsäter, A., Laakso, M., Goncalves, I., Groop, L. & Gomez, M. F., 2016, I: *Diabetes*. 65, 1, s. 239-254

High osteoprotegerin is associated with development of foot ulcer in type 1 diabetes

Zobel, E. H., von Scholten, B. J., Lajer, M., Jorsal, A., Tarnow, L., Rasmussen, L. M., Holstein, P., Parving, H-H., Hansen, T. W. & Rossing, P., 2016, I: *Journal of Diabetes and its Complications*. 30, 8, s. 1603-08

Markers of inflammation and endothelial dysfunction are associated with incident cardiovascular disease, all-cause mortality, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria

von Scholten, B. J., Reinhard, H., Hansen, T. W., Schalkwijk, C. G., Stehouwer, C., Parving, H-H., Jacobsen, P. K. & Rossing, P., 2016, I: *Journal of Diabetes and its Complications*. 30, 2, s. 248-55

Renin angiotensin system blockade reduces urinary levels of soluble urokinase plasminogen activator receptor (suPAR) in patients with type 2 diabetes

Persson, F., Theilade, S., Eugen-Olsen, J., Rossing, P. & Parving, H-H., 2016, I: *Journal of Diabetes and its Complications*. 30, 8, s. 1440-42

The Danish Adult Diabetes Registry

Jørgensen, M. E., Kristensen, J. K., Reventlov Husted, G., Cerqueira, C. & Rossing, P., 2016, I: *Clinical Epidemiology*. 8, s. 429-434 6 s.

Cuff inflations do not affect night-time blood pressure: comparison of 24 h ambulatory blood pressure measured by a cuff and a tonometric device in type 2 diabetes

Zobel, E. H., Theilade, S., Hansen, T. W., Lindhardt, M. K. & Rossing, P., dec. 2015, I: *Blood Pressure Monitoring*. 20, 6, s. 369-72 4 s.

Increased All-Cause Mortality in Patients With Type 1 Diabetes and High-Expression Mannan-Binding Lectin Genotypes: A 12-Year Follow-up Study

Østergaard, J. A., Thiel, S., Lajer, M., Steffensen, R., Parving, H-H., Flyvbjerg, A., Rossing, P., Tarnow, L. & Hansen, T. K., okt. 2015, I: *Diabetes Care*. 38, 10, s. 1898-903 6 s.

Plasma proteomics classifiers improve risk prediction for renal disease in patients with hypertension or type 2 diabetes

Pena, M. J., Jankowski, J., Heinze, G., Kohl, M., Heinzl, A., Bakker, S. J. L., Gansevoort, R. T., Rossing, P., de Zeeuw, D., Heerspink, H. J. L. & Jankowski, V., okt. 2015, I: *Journal of Hypertension*. 33, 10, s. 2123-32 10 s.

Effect of sensor-augmented pump treatment vs. multiple daily injections on albuminuria: a 1 year randomized study

Vestergaard Rosenlund, S., Willum Hansen, T., Rossing, P. & Andersen, S., 21 sep. 2015, I: *The Journal of clinical endocrinology and metabolism*. 100, 11, s. 4181-88 jc20152839.

The influence of pharmaceutically induced weight changes on estimates of renal function: A patient-level pooled analysis of seven randomised controlled trials of glucose lowering medication

von Scholten, B. J., Ørsted, D. D., Svendsen, A. L., Persson, F. & Rossing, P., 9 sep. 2015, I: *Journal of Diabetes and its Complications*. 29, 8, s. 1146-51 6 s.

Effect of 4 years subcutaneous insulin infusion treatment on albuminuria, kidney function and HbA1c compared with multiple daily injections: a longitudinal follow-up study

Vestergaard Rosenlund, S., Hansen, T. W., Andersen, S. & Rossing, P., 2 sep. 2015, I: *Diabetic Medicine Online*. 32, 11, s. 1445-52

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy: A Randomized Clinical Trial

Bakris, G. L., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., Kolkhof, P., Joseph, A., Pieper, A., Kimmeskamp-Kirschbaum, N., Ruilope, L. M. & Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group, 1 sep. 2015, I: *JAMA - Journal of the American Medical Association*. 314, 9, s. 884-94 11 s.

Diagnosis and Prediction of CKD Progression by Assessment of Urinary Peptides

Schanstra, J. P., Zürgbig, P., Alkhalaf, A., Argilés, A., Bakker, S. J. L., Beige, J., Bilo, H. J. G., Chatzikyrkou, C., Dakna, M., Dawson, J., Delles, C., Haller, H., Haubitz, M., Husi, H., Jankowski, J., Jerums, G., Kleefstra, N., Kuznetsova, T., Maahs, D. M., Menne, J., Mullen, W., Ortiz, A., Persson, F., Rossing, P., Ruggenenti, P., Rychlik, I., Serra, A. L., Siwy, J., Snell-Bergeon, J. K., Spasovski, G., Staessen, J. A., Vlahou, A., Mischak, H. & Vanholder, R., aug. 2015, I: *Journal of the American Society of Nephrology : JASN*. 26, 8, s. 1999-2010 12 s.

Genetic risk factors affecting mitochondrial function are associated with kidney disease in people with Type 1 diabetes

Swan, E. J., Salem, R. M., Sandholm, N., Tarnow, L., Rossing, P., Lajer, M., Groop, P. H., Maxwell, A. P., McKnight, A. J. & GENIE Consortium, aug. 2015, I: *Diabetic Medicine Online*. 32, 8, s. 1104-9 6 s.

Diabetic kidney disease

Thomas, M. C., Brownlee, M., Susztak, K., Sharma, K., Jandeleit-Dahm, K. A. M., Zoungas, S., Rossing, P., Groop, P-H. & Cooper, M. E., 30 jul. 2015, I: *Nature reviews. Disease primers*. 1, s. 15018

Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?

Mann, J. F. E., Rossing, P., Wicek, A., Rosivall, L., Mark, P. B. & Mayer, G., 24 jul. 2015, I: *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 30 Suppl 4, s. iv1-5

Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes

Pena, M. J., de Zeeuw, D., Mischak, H., Jankowski, J., Oberbauer, R., Woloszczuk, W., Benner, J., Dallmann, G., Mayer, B., Mayer, G., Rossing, P. & Lambers Heerspink, H. J., 24 jul. 2015, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 30 Suppl 4, s. iv86-95

Glucagon-like peptide 1 receptor agonist (GLP-1 RA): long-term effect on kidney function in patients with type 2 diabetes

von Scholten, B. J., Hansen, T. W., Goetze, J. P., Persson, F. & Rossing, P., jul. 2015, I: Journal of Diabetes and its Complications. 29, 5, s. 670-4 5 s.

Characterization of renal biomarkers for use in clinical trials: effect of preanalytical processing and qualification using samples from subjects with diabetes

Brott, D. A., Furlong, S. T., Adler, S. H., Hainer, J. W., Arani, R. B., Pinches, M., Rossing, P., Chaturvedi, N. & DIRECT Programme Steering Committee, 22 jun. 2015, I: Drug Design, Development and Therapy. 9, s. 3191-8 8 s.

IGFBP-4 fragments as markers of cardiovascular mortality in type 1 diabetes patients with and without nephropathy

Hjortebjerg, R., Tarnow, L., Jorsal, A., Parving, H-H. D., Rossing, P., Bjerre, M. & Frystyk, J., 5 jun. 2015, I: The Journal of clinical endocrinology and metabolism. 100, 8, s. 3032-40

Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes

Theilade, S., Hansen, T. W., Goetze, J. P. & Rossing, P., jun. 2015, I: American Journal of Hypertension. 28, 6, s. 772-9 8 s.

Identification of possible adverse drug reactions in clinical notes: The case of glucose-lowering medicines

Warrer, P., Jensen, P. B., Aagaard, L., Jensen, L. J., Brunak, S., Krag, M. H., Rossing, P., Almdal, T., Andersen, H. U. & Hansen, E. H., 20 maj 2015, I: Journal of Research in Pharmacy Practice. 4, 2, s. 64-72 9 s.

The renal protective effect of angiotensin receptor blockers depends on intra-individual response variation in multiple risk markers

Schievink, B., de Zeeuw, D., Parving, H-H., Rossing, P. & Lambers Heerspink, H. J., 14 apr. 2015, I: British Journal of Clinical Pharmacology. 80, 4, s. 678-86

Global Longitudinal Strain Is Not Impaired in Type 1 Diabetes Patients Without Albuminuria: The Thousand & 1 Study

Jensen, M. T., Sogaard, P., Andersen, H. U., Bech, J., Fritz Hansen, T., Biering-Sørensen, T., Jørgensen, P. G., Galatius, S., Madsen, J. K., Rossing, P. & Jensen, J. S., apr. 2015, I: JACC. Cardiovascular imaging. 8, 4, s. 400-10 11 s.

Pulse pressure is not an independent predictor of outcome in type 2 diabetes patients with chronic kidney disease and anemia-the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT)

Theilade, S., Claggett, B., Hansen, T. W., Skali, H., Lewis, E. F., Solomon, S. D., Parving, H-H., Pfeffer, M., McMurray, J. J. & Rossing, P., 26 mar. 2015, I: Journal of Hypertension. 30, s. 46-52

Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes

Theilade, S., Lyngbaek, S., Hansen, T. W., Eugen-Olsen, J., Fenger, M., Rossing, P. & Jeppesen, J. L., mar. 2015, I: Journal of Internal Medicine. 277, 3, s. 362-71 10 s.

SORBS1 gene, a new candidate for diabetic nephropathy: results from a multi-stage genome-wide association study in patients with type 1 diabetes

Germain, M., Pezzolesi, M. G., Sandholm, N., McKnight, A. J., Susztak, K., Lajer, M., Forsblom, C., Marre, M., Parving, H-H. D., Rossing, P., Toppila, I., Skupien, J., Roussel, R., Ko, Y-A., Ledo, N., Folkersen, L., Civelek, M., Maxwell, A. P., Tregouet, D-A., Groop, P-H., Tarnow, L. & Hadjadj, S., mar. 2015, I: Diabetologia. 58, 3, s. 543-8 6 s.

Time course and mechanisms of the anti-hypertensive and renal effects of liraglutide treatment

von Scholten, B. J., Lajer, M., Goetze, J. P., Persson, F. & Rossing, P., mar. 2015, I: Diabetic Medicine. 32, 3, s. 343-52 10 s.

Vitamin D analogue therapy, cardiovascular risk and kidney function in people with Type 1 diabetes mellitus and diabetic nephropathy: a randomized trial

Joergensen, C., Tarnow, L., Goetze, J. P. & Rossing, P., mar. 2015, I: Diabetic Medicine Online. 32, 3, s. 374-81 8 s.

Diabetic nephropathy in 2014: Improved cardiorenal prognosis in diabetic nephropathy

Parving, H-H. & Rossing, P., feb. 2015, I: Nature Reviews Nephrology. 11, 2, s. 68-70 3 s.

Improved prognosis of diabetic nephropathy in type 1 diabetes

Andrésdóttir, G., Jensen, M. L., Carstensen, B., Parving, H-H., Hovind, P., Hansen, T. W. & Rossing, P., feb. 2015, I: Kidney International. 87, 2, s. 417-26 10 s.

Effects of 12 weeks of treatment with fermented milk on blood pressure, glucose metabolism and markers of cardiovascular risk in patients with type 2 diabetes: a randomised double-blind placebo-controlled study

Hove, K. D., Brøns, C., Færch, K., Lund, S. S., Rossing, P. & Vaag, A., jan. 2015, I: European journal of endocrinology / European Federation of Endocrine Societies. 172, 1, s. 11-20 10 s.

Microalbuminuria: A parameter that has changed diabetes care

Parving, H-H., Persson, F. & Rossing, P., jan. 2015, I: Diabetes Research and Clinical Practice. 107, 1, s. 1-8 8 s.

Additive prognostic value of plasma N-terminal pro-brain natriuretic peptide and coronary artery calcification for cardiovascular events and mortality in asymptomatic patients with type 2 diabetes

von Scholten, B. J., Reinhard, H., Hansen, T. W., Lindhardt, M., Petersen, C. L., Wiinberg, N., Hansen, P. R., Parving, H-H., Jacobsen, P. K. & Rossing, P., 2015, I: Cardiovascular Diabetology. 14, s. 59

Elevated Urinary Connective Tissue Growth Factor in Diabetic Nephropathy Is Caused by Local Production and Tubular Dysfunction

Gerritsen, K. G. F., Leeuwis, J. W., Koeners, M. P., Bakker, S. J. L., van Oeveren, W., Aten, J., Tarnow, L., Rossing, P., Wetzels, J. F. M., Joles, J. A., Kok, R. J., Goldschmeding, R. & Nguyen, T. Q., 2015, I: Journal of Diabetes Research. 2015, s. 539787

Pulse wave reflection is associated with diabetes duration, albuminuria and cardiovascular disease in type 1 diabetes

Theilade, S., Lajer, M., Hansen, T. W. & Rossing, P., dec. 2014, I: Acta Diabetologica. 51, 6, s. 973-80 8 s.

Treatment with continuous subcutaneous insulin infusion is associated with lower arterial stiffness

Vestergaard Rosenlund, S., Theilade, S., Hansen, T. W., Andersen, S. & Rossing, P., dec. 2014, I: Acta Diabetologica. 51, 6, s. 955-62 8 s.

Association of the pattern recognition molecule H-ficolin with incident microalbuminuria in an inception cohort of newly diagnosed type 1 diabetic patients: an 18 year follow-up study

Østergaard, J. A., Thiel, S., Hovind, P., Holt, C. B., Parving, H-H., Flyvbjerg, A., Rossing, P. & Hansen, T. K., okt. 2014, I: Diabetologia. 57, 10, s. 2201-7 7 s.

Central hemodynamics are associated with cardiovascular disease and albuminuria in type 1 diabetes

Theilade, S., Hansen, T. W. & Rossing, P., sep. 2014, I: American Journal of Hypertension. 27, 9, s. 1152-9 8 s.

Urine and plasma metabolites predict the development of diabetic nephropathy in individuals with Type 2 diabetes mellitus

Pena, M. J., Lambers Heerspink, H. J., Hellemons, M. E., Friedrich, T., Dallmann, G., Lajer, M., Bakker, S. J. L., Gansevoort, R. T., Rossing, P., de Zeeuw, D. & Roscioni, S. S., sep. 2014, I: Diabetic Medicine Online. 31, 9, s. 1138-47 10 s.

Multicentre prospective validation of a urinary peptidome-based classifier for the diagnosis of type 2 diabetic nephropathy

Siwy, J., Schanstra, J. P., Argilés, A., Bakker, S. J. L., Beige, J., Boucek, P., Brand, K., Delles, C., Duranton, F., Fernandez-Fernandez, B., Jankowski, M-L., Al Khatib, M., Kunt, T., Lajer, M. S., Lichtinghagen, R., Lindhardt, M., Maahs, D. M., Mischak, H., Mullen, W., Navis, G., Noutsou, M., Ortiz, A., Persson, F., Petrie, J. R., Roob, J. M., Rossing, P., Ruggenti, P., Rychlik, I., Serra, A. L., Snell-Bergeon, J. K., Spasovski, G., Stojceva-Taneva, O., Trillini, M., von der

Leyen, H., Winkhofer-Roob, B. M., Züribig, P. & Jankowski, J., aug. 2014, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 29, 8, s. 1563-70 8 s.

Glomerular filtration rate estimation using cystatin C alone or combined with creatinine as a confirmatory test

Fan, L., Inker, L. A., Rossert, J., Froissart, M., Rossing, P., Mauer, M. & Levey, A. S., jun. 2014, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 29, 6, s. 1195-203 9 s.

Improved survival and renal prognosis of patients with type 2 diabetes and nephropathy with improved control of risk factors

Andrésdóttir, G., Jensen, M., Carstensen, B., Parving, H-H., Rossing, K., Hansen, T. W. & Rossing, P., jun. 2014, I: Diabetes Care. 37, 6, s. 1660-7 8 s.

Urinary alpha- and pi-glutathione s-transferases in adult patients with type 1 diabetes

von Scholten, B. J., Theilade, S., Lajer, M. & Rossing, P., maj 2014, I: Nephron. 4, 2, s. 127-33 7 s.

Prevalence of systolic and diastolic dysfunction in patients with type 1 diabetes without known heart disease: the Thousand & 1 Study

Jensen, M. T., Sogaard, P., Andersen, H. U., Bech, J., Hansen, T. F., Galatius, S., Jørgensen, P. G., Biering-Sørensen, T., Møgelvang, R., Rossing, P. & Jensen, J. S., apr. 2014, I: Diabetologia. 57, 4, s. 672-80 9 s.

Sequential RAAS blockade: is it worth the risk?

Persson, F. & Rossing, P., mar. 2014, I: Advances in Chronic Kidney Disease. 21, 2, s. 159-65 7 s.

SVAR: Det nytter at diagnosticere diabetes tidligt

Rossing, P., 1 jan. 2014, I: Ugeskrift for Laeger. 176, 21

Cause-specific mortality according to urine albumin creatinine ratio in the general population

Skaaby, T., Husemoen, L. L. N., Ahluwalia, T. S., Rossing, P., Jørgensen, T., Thuesen, B. H., Pisinger, C., Rasmussen, K. & Linneberg, A., 2014, I: P L o S One. 9, 3, s. e93212

Rationale, design, and baseline characteristics of ARTS-DN: a randomized study to assess the safety and efficacy of finerenone in patients with type 2 diabetes mellitus and a clinical diagnosis of diabetic nephropathy

Ruilope, L. M., Agarwal, R., Chan, J. C., Cooper, M. E., Gansevoort, R. T., Haller, H., Remuzzi, G., Rossing, P., Schmieder, R. E., Nowack, C., Ferreira, A. C., Pieper, A., Kimmeskamp-Kirschbaum, N. & Bakris, G. L., 2014, I: American Journal of Nephrology. 40, 6, s. 572-81 10 s.

Retinopathy and clinical outcomes in patients with type 2 diabetes mellitus, chronic kidney disease, and anemia

Bello, N. A., Pfeffer, M. A., Skali, H., McGill, J. B., Rossert, J., Olson, K. A., Weinrauch, L., Cooper, M. E., de Zeeuw, D., Rossing, P., McMurray, J. J. V. & Solomon, S. D., 2014, I: BMJ open diabetes research & care. 2, 1, s. e000011

Can ADAMTS13 lead us to the paradise of personalized medicine?

Rossing, P. & Lajer, M., okt. 2013, I: Diabetes. 62, 10, s. 3331-2 2 s.

Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment

Albalat, A., Stalmach, A., Bitsika, V., Siwy, J., Schanstra, J. P., Petropoulos, A. D., Vlahou, A., Jankowski, J., Persson, F., Rossing, P., Jaskolla, T. W., Mischak, H. & Husi, H., okt. 2013, I: Proteomics. 13, 20, s. 2967-75 9 s.

Clinical use of estimated glomerular filtration rate for evaluation of kidney function

Broberg, B., Lindhardt, M., Rossing, P., Ibsen, H., Persson, F. I. & Rasmussen, K., 30 sep. 2013, I: Ugeskrift for Laeger. 175, 40, s. 2333-2336 4 s.

Diabetes mellitus, hypertension and albuminuria in rural Zambia: a hospital-based survey

Rasmussen, J. B., Thomsen, J. A., Rossing, P., Parkinson, S., Christensen, D. L. & Bygbjerg, I. C., sep. 2013, I: Tropical medicine & international health : TM & IH. 18, 9, s. 1080-1084 5 s.

24-hour central aortic systolic pressure and 24-hour central pulse pressure are related to diabetic complications in type 1 diabetes - a cross-sectional study

Theilade, S., Lajer, M. S., Hansen, T. W., Joergensen, C., Persson, F., Andrésdóttir, G., Reinhard, H., Nielsen, S. E., Lacy, P., Williams, B. & Rossing, P., 27 aug. 2013, I: Cardiovascular Diabetology. 12, s. 122

Urinary adiponectin excretion rises with increasing albuminuria in type 1 diabetes

Jorsal, A., Petersen, E. H., Tarnow, L., Hess, G., Zdunek, D., Frystyk, J., Flyvbjerg, A., Lajer, M. & Rossing, P., 24 aug. 2013, I: Journal of Diabetes and its Complications. 27, 6, s. 604-8 5 s.

Uric acid lowering to prevent kidney function loss in diabetes: the preventing early renal function loss (PERL) allopurinol study

Maahs, D. M., Caramori, L., Cherney, D. Z. I., Galecki, A. T., Gao, C., Jalal, D., Perkins, B. A., Pop-Busui, R., Rossing, P., Mauer, M., Doria, A. & PERL Consortium, aug. 2013, I: Current Diabetes Reports. 13, 4, s. 550-9 10 s.

Urinary renin and angiotensinogen in type 2 diabetes: added value beyond urinary albumin?

Persson, F., Lu, X., Rossing, P., Garred, I. M., Danser, A. H. J. & Parving, H-H., aug. 2013, I: Journal of Hypertension. 31, 8, s. 1646-52 7 s.

Tonometric devices for central aortic systolic pressure measurements in patients with type 1 diabetes: comparison of the BPro and SphygmoCor devices

Theilade, S., Hansen, T. W., Joergensen, C., Lajer, M. & Rossing, P., jun. 2013, I: Blood Pressure Monitoring. 18, 3, s. 156-60 5 s.

Urinary sulphate excretion and progression of diabetic nephropathy in Type 1 diabetes

Andrésdóttir, G., Bakker, S. J. L., Hansen, H. P., Parving, H-H. & Rossing, P., maj 2013, I: Diabetic Medicine Online. 30, 5, s. 563-6 4 s.

Arterial stiffness is associated with cardiovascular, renal, retinal, and autonomic disease in type 1 diabetes

Theilade, S., Lajer, M. S., Persson, F., Joergensen, C. & Rossing, P., mar. 2013, I: Diabetes Care. 36, 3, s. 715-21 7 s.

Diabetic nephropathy: Could problems with bardoxolone methyl have been predicted?

Rossing, P., mar. 2013, I: Nature Reviews Nephrology. 9, 3, s. 128-30 3 s.

A urinary peptide biomarker set predicts worsening of albuminuria in type 2 diabetes mellitus

Roscioni, S. S., de Zeeuw, D., Hellemons, M. E., Mischak, H., Zürbig, P., Bakker, S. J. L., Gansevoort, R. T., Reinhard, H., Persson, F., Lajer, M., Rossing, P. & Lambers Heerspink, H. J., feb. 2013, I: Diabetologia. 56, 2, s. 259-67 9 s.

Common variant in the HMG2A gene increases susceptibility to nephropathy in patients with type 2 diabetes

Alkayyal, S., Lajer, M., Deshmukh, H., Ahlqvist, E., Colhoun, H., Isomaa, B., Rossing, P., Groop, L. & Lyssenko, V., feb. 2013, I: Diabetologia. 56, 2, s. 323-9 7 s.

RNA oxidation and albuminuria in type 1 diabetes patients

Broedbaek, K., Andersen, J. T., Jimenez-Solem, E., Petersen, M., Lajer, M., Henriksen, T., Weimann, A., Parving, H. H., Rossing, P. & Poulsen, H. E., 1 jan. 2013, I: Cardiovascular Endocrinology. 2, 4, s. 103-105 3 s.

Diabetes: Effect of vitamin D on diabetic kidney disease in T1DM

Rossing, P. & Joergensen, C., jan. 2013, I: Nature reviews. Endocrinology. 9, 1, s. 6-7 2 s.

Direct renin inhibition in chronic kidney disease

Persson, F., Rossing, P. & Parving, H-H., 2013, I: British Journal of Clinical Pharmacology. 76, 4, s. 580-86

Levels of NT-proBNP, markers of low-grade inflammation, and endothelial dysfunction during spironolactone treatment in patients with diabetic kidney disease

Nielsen, S., Schjoedt, K. J., Rossing, K., Persson, F., Schalkwijk, C. G., Stehouwer, C. DA., Parving, H-H. & Rossing, P., 2013, I: Journal of the Renin-Angiotensin-Aldosterone System. 14, 2, s. 161-6

Vitamin D status and 5-year changes in urine albumin creatinine ratio and parathyroid hormone in a general population
Skaaby, T., Husemoen, L. L. N., Pisinger, C., Jørgensen, T., Thuesen, B. H., Rasmussen, K., Fenger, M., Rossing, P. & Linneberg, A., 2013, I: Endocrine. 44, 2, s. 473-80

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis

Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J. G., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., Tonelli, M., Vassalotti, J. A., Yamagishi, K., Coresh, J., de Jong, P. E., Wen, C-P., Nelson, R. G. & Chronic Kidney Disease Prognosis Consortium, 10 nov. 2012, I: Lancet. 380, 9854, s. 1662-73 12 s.

Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without hypertension: a meta-analysis

Mahmoodi, B. K., Matsushita, K., Woodward, M., Blankestijn, P. J., Cirillo, M., Ohkubo, T., Rossing, P., Sarnak, M. J., Stengel, B., Yamagishi, K., Yamashita, K., Zhang, L., Coresh, J., de Jong, P. E., Astor, B. C. & Chronic Kidney Disease Prognosis Consortium, 10 nov. 2012, I: Lancet. 380, 9854, s. 1649-61 13 s.

Kvalitetssikring i behandling af en folkesygdom: diabetes

Rossing, P., Adolphsen, H., Stenkær Ravnkilde, S., Cerqueira, C. & Friborg, S., 15 okt. 2012, I: Ugeskrift for Laeger. 174, 42, s. 2551

Plasma NT-proBNP and white matter hyperintensities in type 2 diabetic patients

Reinhard, H., Garde, E., Skimminge, A., Akeson, P., Ramsøy, T., Winther, K., Parving, H-H., Rossing, P. & Jacobsen, P. K., 3 okt. 2012, I: Cardiovascular Diabetology. 11, 1, 9 s.

Discrepancy between tonometric ambulatory and cuff-based office blood pressure measurements in patients with type 1 diabetes

Theilade, S., Lajer, M. S., Joergensen, C., Persson, F. & Rossing, P., okt. 2012, I: Journal of Clinical Hypertension. 14, 10, s. 686-93 8 s.

Nyresygdom ved type 2-diabetes

Persson, F. & Rossing, P., 10 sep. 2012, I: Ugeskrift for Laeger. 174, 37, s. 2150-4 5 s.

Implementation of proteomic biomarkers: making it work

Mischak, H., Ioannidis, J. P. A., Argilés, A., Attwood, T. K., Bongcam-Rudloff, E., Broenstrup, M., Charonis, A., Chrousos, G. P., Delles, C., Dominiczak, A., Dylag, T., Ehrich, J. H. H., Egido, J., Findeisen, P., Jankowski, J., Johnson, R. W., Julien, B. A., Lankisch, T., Leung, H. Y., Maahs, D. M., Magni, F., Manns, M. P., Manolis, E., Mayer, G., Navis, G., Novak, J., Ortiz, A., Persson, F., Peter, K., Riese, H. H., Rossing, P., Sattar, N., Spasovski, G., Thongboonkerd, V., Vanholder, R., Schanstra, J. P. & Vlahou, A., sep. 2012, I: European Journal of Clinical Investigation. 42, 9, s. 1027-36 10 s.

Ambulatory tonometric blood pressure measurements in patients with diabetes

Theilade, S., Joergensen, C., Persson, F., Lajer, M. S. & Rossing, P., jun. 2012, I: Diabetes Technology and Therapeutics. 14, 6, s. 453-6 4 s.

Assessment of kidney function: UACR—two risk markers or a 24 h collection in a minute?

Rossing, P., 8 maj 2012, I: Nature Reviews Nephrology. 8, 6, s. 320-1 2 s.

The authors reply

Nielsen, S. E. & Rossing, P., 1 apr. 2012, I: Kidney International. 81, 7, 1 s.

Impact of aliskiren treatment on urinary aldosterone levels in patients with type 2 diabetes and nephropathy: an AVOID substudy

Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K. & Hans-Henrik, P., mar. 2012, I: Journal of the renin-angiotensin-aldosterone system : JRAAS. 13, 1, s. 118-21 4 s.

Cardiovascular autonomic neuropathy and subclinical cardiovascular disease in normoalbuminuric type 1 diabetic patients
Mogensen, U. M., Jensen, T., Køber, L., Kelbæk, H., Mathiesen, A. S., Dixen, U., Rossing, P., Hilsted, J. & Kofoed, K. F., 2012, I: *Diabetes*. 61, 7, s. 1822-30 9 s.

Effect of Irbesartan treatment on plasma and urinary markers of protein damage in patients with type 2 diabetes and microalbuminuria

Rabbani, N., Adaikalakoteswari, A., Rossing, K., Rossing, P., Tarnow, L., Parving, H-H. & Thornalley, P. J., 2012, I: *Amino Acids*. 42, 5, s. 1627-39 13 s.

High YKL-40 levels predict mortality in patients with type 2 diabetes

Persson, F., Rathcke, C. N., Gall, M-A., Parving, H-H., Vestergaard, H. & Rossing, P., 2012, I: *Diabetes Research and Clinical Practice*. 96, 1, s. 84-9 6 s.

Impact of glycaemic control on the effect of direct renin inhibition in the AVOID study

Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K. & Parving, H-H., 2012, I: *Journal of the Renin-Angiotensin-Aldosterone System*. 13, 2, s. 250-3 4 s.

Kvalitetssikring i forbindelse med en folkesygdom: diabetes

Rossing, P., Adolphsen, H., Ravnkilde, SS., Cerqueira, C. & Friborg, S., 2012, I: *Ugeskrift for Laeger*. 174, 42, s. 2551

New susceptibility loci associated with kidney disease in type 1 diabetes

Sandholm, N., Salem, R. M., McKnight, A. J., Brennan, E. P., Forsblom, C., Isakova, T., McKay, G. J., Williams, W. W., Sadlier, D. M., Mäkinen, V-P., Swan, E. J., Palmer, C., Boright, A. P., Ahlqvist, E., Deshmukh, H. A., Keller, B. J., Huang, H., Ahola, A. J., Fagerholm, E., Gordin, D., Harjutsalo, V., He, B., Heikkilä, O., Hietala, K., Kytö, J., Lahermo, P., Lehto, M., Lithovius, R., Osterholm, A-M., Parkkonen, M., Pitkaniemi, J., Rosengård-Bärlund, M., Saraheimo, M., Sarti, C., Söderlund, J., Soro-Paavonen, A., Syreeni, A., Thorn, L. M., Tikkanen, H., Tolonen, N., Tryggvason, K., Tuomilehto, J., Wadén, J., Gill, G. V., Prior, S., Guiducci, C., Mirel, D. B., Parving, H-H., Rossing, P., Tarnow, L. & DCCT/EDIC Research Group, 2012, I: *P L o S Genetics*. 8, 9, s. e1002921

NT-proBNP, echocardiographic abnormalities and subclinical coronary artery disease in high risk type 2 diabetic patients

Reinhard, H., Hansen, P. R., Wiinberg, N., Kjær, A., Petersen, C. L., Winther, K., Parving, H-H., Rossing, P. & Jacobsen, P. K., 2012, I: *Cardiovascular Diabetology*. 11, s. 19

Serum amyloid A and C-reactive protein levels may predict microalbuminuria and macroalbuminuria in newly diagnosed type 1 diabetic patients

Overgaard, A. J., McGuire, J. N., Hovind, P., Parving, H-H., Rossing, P. & Pociot, F., 2012, I: *Journal of Diabetes and its Complications*. 27, 1, s. 59-63 5 s.

Spirolactone diminishes urinary albumin excretion in patients with type 1 diabetes and microalbuminuria: a randomized placebo-controlled crossover study

Nielsen, S. E., Persson, F., Frandsen, E., Sugaya, T., Hess, G., Zdunek, D., Shjoedt, K. J., Parving, H-H. & Rossing, P., 2012, I: *Diabetic Medicine*. 29, 8, s. e184-90

The effect of RAAS blockade on markers of renal tubular damage in diabetic nephropathy: u-NGAL, u-KIM1 and u-LFABP

Nielsen, S., Rossing, K., Hess, G., Zdunek, D., Jensen, B. R., Parving, H-H. & Rossing, P., 2012, I: *Scandinavian Journal of Clinical & Laboratory Investigation*. 72, 2, s. 137-42 6 s.

Tubular markers are associated with decline in kidney function in proteinuric type 2 diabetic patients

Nielsen, S., Reinhard, H., Zdunek, D., Hess, G., Gutiérrez, O. M., Wolf, M., Parving, H-H., Jacobsen, P. K. & Rossing, P., 2012, I: *Diabetes Research and Clinical Practice*. 97, 1, s. 71-6 6 s.

Urinary proteomics for early diagnosis in diabetic nephropathy

Zürbig, P., Jerums, G., Hovind, P., Macisaac, R. J., Mischak, H., Nielsen, S., Panagiotopoulos, S., Persson, F. & Rossing, P., 2012, I: *Diabetes*. 61, 12, s. 3304-13 10 s.

Vitamin D levels and asymptomatic coronary artery disease in type 2 diabetic patients with elevated urinary albumin excretion rate

Joergensen, C., Reinhard, H., Schmedes, A., Hansen, P. R., Wiinberg, N., Petersen, C. L., Winther, K., Parving, H-H., Jacobsen, P. K. & Rossing, P., 2012, I: *Diabetes Care*. 35, 1, s. 168-72 5 s.

Experimental testing of skin reactions to insulin detemir in diabetes patients naïve to insulin detemir

O'goshi, K., Serup, J., Blaaup, B., Thomsen, H. K., Rossing, P. & Tarnow, L., nov. 2011, I: *Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)*. 17, 4, s. 411-9 9 s.

Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts

Astor, B. C., Matsushita, K., Gansevoort, R. T., van der Velde, M., Woodward, M., Levey, A. S., Jong, P. E. D., Coresh, J., Astor, B. C., Matsushita, K., Gansevoort, R. T., van der Velde, M., Woodward, M., Levey, A. S., de Jong, P. E., Coresh, J., El-Nahas, M., Eckardt, K-U., Kasiske, B. L., Wright, J., Appel, L., Greene, T., Levin, A., Djurdjev, O., Wheeler, D. C., Landray, M. J., Townend, J. N., Emberson, J., Clark, L. E., Macleod, A., Marks, A., Ali, T., Fluck, N., Prescott, G., Smith, D. H., Weinstein, J. R., Johnson, E. S., Thorp, M. L., Wetzels, J. F., Blankestijn, P. J., van Zuilan, A. D., Menon, V., Sarnak, M., Beck, G., Kronenberg, F., Kollerits, B., Froissart, M., Stengel, B., Rossing, P., Parving, H-H. & Chronic Kidney Disease Prognosis Consortium, jun. 2011, I: *Kidney International*. 79, 12, s. 1331-40 10 s.

Long-Term Effects of Irbesartan Treatment and Smoking on Nucleic Acid Oxidation in Patients With Type 2 Diabetes and Microalbuminuria: An Irbesartan in Patients With Type 2 Diabetes and Microalbuminuria (IRMA 2) substudy

Broedbaek, K., Henriksen, T., Weimann, A., Petersen, M., Andersen, J. T., Afzal, S., Jimenez-Solem, E., Persson, F., Parving, H-H., Rossing, P. & Poulsen, H. E., 1 maj 2011, I: *Diabetes Care*. 34, 5, s. 1192-8 7 s.

Vitamin D levels, microvascular complications, and mortality in type 1 diabetes

Joergensen, C., Hovind, P., Schmedes, A., Parving, H-H. & Rossing, P., 1 maj 2011, I: *Diabetes Care*. 34, 5, s. 1081-5 5 s.

Irbesartan treatment does not influence plasma levels of the advanced glycation end products N{varepsilon}(1-carboxymethyl)lysine and N{varepsilon}(1-carboxyethyl)lysine in patients with type 2 diabetes and microalbuminuria. A randomized controlled trial

Engelen, L., Persson, F., Ferreira, I., Rossing, P., Hovind, P., Teerlink, T., Stehouwer, C. D., Parving, H-H. & Schalkwijk, C. G., 8 mar. 2011, I: *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 26, 11, s. 3573-3577

Need for better diabetes treatment for improved renal outcome

Rossing, P. & de Zeeuw, D., mar. 2011, I: *Kidney International, Supplement*. 120, s. S28-32

Higher plasma levels of advanced glycation end products are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study

Nin, J. W., Jorsal, A., Ferreira, I., Schalkwijk, C. G., Prins, M. H., Parving, H-H., Tarnow, L., Rossing, P. & Stehouwer, C. D., feb. 2011, I: *Diabetes Care*. 34, 2, s. 442-7 6 s.

Serum uric acid as a new player in the development of diabetic nephropathy

Hovind, P., Rossing, P., Johnson, R. J. & Parving, H-H., 1 jan. 2011, I: *Journal of Renal Nutrition*. 21, 1, s. 124-7 4 s.

Aliskiren in combination with losartan reduces albuminuria independent of baseline blood pressure in patients with type 2 diabetes and nephropathy

Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K. & Parving, H-H., 2011, I: *American Society of Nephrology. Clinical Journal*. 6, 5, s. 1025-31 7 s.

Diabetic Nephropathy

Parving, H-H. D., Mauer, M., Fioretto, P., Rossing, P. & Ritz, E., 2011, *Brenner and Rector's The Kidney*. Taal et al., M. W. (red.). 9. udg. W. B. Saunders Company, s. 1411

Elevated NT-proBNP and coronary calcium score in relation to coronary artery disease in asymptomatic type 2 diabetic patients with elevated urinary albumin excretion rate

Reinhard, H., Hansen, P. R., Persson, F., Tarnow, L., Wiinberg, N., Kjær, A., Petersen, C. L., Winther, K., Parving, H-H., Rossing, P. & Jacobsen, P. K., 2011, I: *Nephrology, Dialysis, Transplantation*. 26, 10, s. 3242-9 8 s.

Endothelial progenitor cells in long-standing asymptomatic type 1 diabetic patients with or without diabetic nephropathy

Reinhard, H., Jacobsen, P. K., Lajer, M. S., Tarnow, L., Bording Astrup, A. S., Kim, W. Y., Pedersen, N., Billestrup, N., Mandrup-Poulsen, T., Parving, H-H. & Rossing, P., 2011, I: *Nephron Clinical Practice*. 118, 3, s. c309-14 6 s.

Fibulin-1 is a marker for arterial extracellular matrix alterations in type 2 diabetes

Cangemi, C., Skov, V., Poulsen, M. K., Funder, J. A., Twal, W. O., Gall, M-A., Hjortdal, V. E., Jespersen, M. L., Kruse, T. A., Aagard, J., Parving, H-H., Knudsen, S., Høilund-Carlsen, P-F., Rossing, P., Henriksen, J. E., Argraves, W. S. & Rasmussen, L. M., 2011, I: *Clinical Chemistry (Washington, DC)*. 57, 11, s. 1556-65 10 s.

initial angiotensin receptor blockade-induced decrease in albuminuria is associated with long-term renal outcome in type 2 diabetic patients with microalbuminuria: a post hoc analysis of the IRMA-2 trial

Hellemons, M. E., Persson, F., Bakker, S. J. L., Rossing, P., Parving, H-H., De Zeeuw, D. & Lambers Heerspink, H. J., 2011, I: *Diabetes Care*. 34, 9, s. 2078-83 6 s.

NT-proBNP levels, atherosclerosis and vascular function in asymptomatic type 2 diabetic patients with microalbuminuria: peripheral reactive hyperaemia index but not NT-proBNP is an independent predictor of coronary atherosclerosis

Reinhard, H., Wiinberg, N., Hansen, P. R., Kjær, A., Petersen, C. L., Winther, K., Parving, H-H., Rossing, P. & Jacobsen, P. K., 2011, I: *Cardiovascular Diabetology*. 10, s. 71

Omics-bioinformatics in the context of clinical data

Mayer, G., Heinze, G., Mischak, H., Hellemons, M. E., Heerspink, H. J. L., Bakker, S. J. L., de Zeeuw, D., Haiduk, M., Rossing, P. & Oberbauer, R., 2011, I: *Methods in molecular biology*. 719, s. 479-97 19 s.

Osteoprotegerin and coronary artery disease in type 2 diabetic patients with microalbuminuria

Reinhard, H., Nybo, M., Hansen, P. R., Wiinberg, N., Kjær, A., Petersen, C. L., Winther, K., Parving, H-H., Rasmussen, L. M., Rossing, P. & Jacobsen, P. K., 2011, I: *Cardiovascular Diabetology*. 10, s. 70

The CTGF -945GC polymorphism is not associated with plasma CTGF and does not predict nephropathy or outcome in type 1 diabetes

Dendooven, A., Nguyen, T. Q., Brosens, L., Li, D., Tarnow, L., Parving, H-H., Rossing, P. & Goldschmeding, R., 2011, I: *Journal of Negative Results in BioMedicine*. 10, s. 4

Tubular markers do not predict the decline in glomerular filtration rate in type 1 diabetic patients with overt nephropathy

Nielsen, S. E., Andersen, S., Zdunek, D., Hess, G., Parving, H-H. & Rossing, P., 2011, I: *Kidney International*. 79, 10, s. 1113-8 6 s.

Urinary Neutrophil Gelatinase-Associated Lipocalin and Progression of Diabetic Nephropathy in Type 1 Diabetic Patients in a Four-Year Follow-Up Study

Nielsen, S. E., Hansen, H. P., Jensen, B. R., Parving, H-H. & Rossing, P., 15 dec. 2010, I: *Nephron Clinical Practice*. 118, 2, s. c130-c135

Osteoprotegerin and mortality in type 2 diabetic patients

Reinhard, H., Lajer, M. S., Gall, M-A., Tarnow, L., Parving, H-H., Rasmussen, L. M. & Rossing, P., 1 dec. 2010, I: *Diabetes Care*. 33, 12, s. 2561-6 6 s.

Quantitative iTRAQ-Based Proteomic Identification of Candidate Biomarkers for Diabetic Nephropathy in Plasma of Type 1 Diabetic Patients

Overgaard, A. J., Thingholm, T. E., Larsen, M. R., Tarnow, L., Rossing, P., McGuire, J. N. & Pociot, F., dec. 2010, I: *Clinical Proteomics*. 6, 4, s. 105-114 10 s.

Impact of baseline renal function on the efficacy and safety of aliskiren added to losartan in patients with type 2 diabetes and nephropathy

Persson, F., Lewis, J. B., Lewis, E. J., Rossing, P., Hollenberg, N. K., Parving, H-H. & AVOID Study Investigators, 1 nov. 2010, I: Diabetes Care. 33, 11, s. 2304-9 6 s.

Urinary proteomic diagnosis of coronary artery disease: identification and clinical validation in 623 individuals

Delles, C., Schiffer, E., von Zur Muhlen, C., Peter, K., Rossing, P., Parving, H-H., Dymott, J. A., Neisius, U., Zimmerli, L. U., Snell-Bergeon, J. K., Maahs, D. M., Schmieder, R. E., Mischak, H. & Dominiczak, A. F., 1 nov. 2010, I: Journal of Hypertension. 28, 11, s. 2316-22 7 s.

Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy

Alkhalaf, A., Zürgbig, P., Bakker, S. J. L., Bilo, H. J. G., Cerna, M., Fischer, C., Fuchs, S., Janssen, B., Medek, K., Mischak, H., Roob, J. M., Rossing, K., Rossing, P., Rychlík, I., Sourij, H., Tiran, B., Winklhofer-Roob, B. M., Navis, G. J. & PREDICTIONS Group, 20 okt. 2010, I: P L o S One. 5, 10, s. e13421

Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: An inception cohort study (Diabetes (2009) 58 (1668-1671))

Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J. & Parving, H. H., 1 okt. 2010, I: Diabetes. 59, 10, 1 s.

Vitamin D levels and mortality in type 2 diabetes

Joergensen, C., Gall, M-A., Schmedes, A., Tarnow, L., Parving, H-H. & Rossing, P., 1 okt. 2010, I: Diabetes Care. 33, 10, s. 2238-43 6 s.

Urinary collagen fragments are significantly altered in diabetes: a link to pathophysiology

Maahs, D. M., Siwy, J., Argilés, A., Cerna, M., Delles, C., Dominiczak, A. F., Gayraud, N., Iphöfer, A., Jänsch, L., Jerums, G., Medek, K., Mischak, H., Navis, G. J., Roob, J. M., Rossing, K., Rossing, P., Rychlík, I., Schiffer, E., Schmieder, R. E., Wascher, T. C., Winklhofer-Roob, B. M., Zimmerli, L. U., Zürgbig, P. & Snell-Bergeon, J. K., 28 sep. 2010, I: P L o S One. 5, 9

Finding diabetic nephropathy biomarkers in the plasma peptidome by high-throughput magnetic bead processing and MALDI-TOF-MS analysis

Hansen, H. G., Overgaard, J., Lajer, M., Hubalek, F., Højrup, P., Pedersen, L., Tarnow, L., Rossing, P., Pociot, F. & McGuire, J. N., sep. 2010, I: Proteomics - Clinical Applications. 4, 8-9, s. 697-705 9 s.

Proteomic biomarkers in diabetic nephropathy—reality or future promise?

Mischak, H. & Rossing, P., sep. 2010, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 25, 9, s. 2843-5 3 s.

Recommendations for biomarker identification and qualification in clinical proteomics

Mischak, H., Allmaier, G., Apweiler, R., Attwood, T., Baumann, M., Benigni, A., Bennett, S. E., Bischoff, R., Bongcam-Rudloff, E., Capasso, G., Coon, J. J., D'Haese, P., Dominiczak, A. F., Dakna, M., Dihazi, H., Ehrich, J. H., Fernandez-Llama, P., Fliser, D., Frokiaer, J., Garin, J., Girolami, M., Hancock, W. S., Haubitz, M., Hochstrasser, D., Holman, R. R., Ioannidis, J. P. A., Jankowski, J., Julian, B. A., Klein, J. B., Kolch, W., Luider, T., Massy, Z., Mattes, W. B., Molina, F., Monsarrat, B., Novak, J., Peter, K., Rossing, P., Sánchez-Carbayo, M., Schanstra, J. P., Semmes, O. J., Spasovski, G., Theodorescu, D., Thongboonkerd, V., Vanholder, R., Veenstra, T. D., Weissinger, E., Yamamoto, T. & Vlahou, A., 25 aug. 2010, I: Science translational medicine. 2, 46, s. 46ps42

Higher plasma soluble Receptor for Advanced Glycation End Products (sRAGE) levels are associated with incident cardiovascular disease and all-cause mortality in type 1 diabetes: a 12-year follow-up study

Nin, J. W. M., Jorsal, A., Mercedes Ferreira, I. M., Schalkwijk, C. G., Prins, M. H., Parving, H-H., Tarnow, L., Rossing, P. & Stehouwer, C. D. A., 1 aug. 2010, I: Diabetes. 59, 8, s. 2027-32 6 s.

Optimal antiproteinuric dose of aliskiren in type 2 diabetes mellitus: a randomised crossover trial

Persson, F. I., Rossing, P., Reinhard, H., Juhl, T., Stehouwer, C. D. A., Schalkwijk, C., Danser, A. H. J., Boomsma, F., Frandsen, E. & Parving, H-H., 1 aug. 2010, I: Diabetologia. 53, 8, s. 1576-80 5 s.

Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy

Lajer, M. S., Jorsal, A., Tarnow, L., Parving, H-H. & Rossing, P., 1 jul. 2010, I: Diabetes Care. 33, 7, s. 1567-72 6 s.

Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type 1 diabetic patients

Nielsen, S. E., Sugaya, T., Hovind, P., Baba, T., Parving, H-H. & Rossing, P., 1 jun. 2010, I: Diabetes Care. 33, 6, s. 1320-4 5 s.

Systems biology to battle vascular disease

Dominiczak, A. F., Hergert-Rosenthal, S., Delles, C., Fliser, D., Fournier, I., Graber, A., Girolami, M., Holmes, E., Lang, F., Molina, F., Nicholson, J., Remuzzi, G., Rossing, P., Rudolph, K. L., Wolkenhauer, O., Xenarios, I., Zubarev, R., Zubov, D., Vlahou, A. & Schanstra, J. P., apr. 2010, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 25, 4, s. 1019-22 4 s.

Development and validation of GFR-estimating equations using diabetes, transplant and weight

Stevens, L. A., Schmid, C. H., Zhang, Y. L., Coresh, J., Manzi, J., Landis, R., Bakoush, O., Contreras, G., Genuth, S., Klintmalm, G. B., Poggio, E., Rossing, P., Rule, A. D., Weir, M. R., Kusek, J., Greene, T. & Levey, A. S., feb. 2010, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 25, 2, s. 449-57 9 s.

Urinary proteome analysis enables assessment of renoprotective treatment in type 2 diabetic patients with microalbuminuria

Andersen, S. P., Mischak, H., Zürlbig, P., Parving, H-H. & Rossing, P., 1 jan. 2010, I: B M C Nephrology. 11, s. 29

Plasma proteome analysis of patients with type 1 diabetes with diabetic nephropathy

Overgaard, A. J., Hansen, H. G., Lajer, M., Pedersen, L., Tarnow, L., Rossing, P., McGuire, J. N. & Pociot, F., 2010, I: Proteome Science. 8, s. 4

Soluble CD40 ligand is elevated in type 1 diabetic nephropathy but not predictive of mortality, cardiovascular events or kidney function

Lajer, M. S., Tarnow, L., Michelson, A. D., Jorsal, A., Frelinger, A. L., Parving, H-H., Rossing, P. & Tarnow, L., 2010, I: Platelets. 21, 7, s. 525-32 8 s.

Autoregulation of glomerular filtration rate during spironolactone treatment in hypertensive patients with type 1 diabetes: a randomized crossover trial

Schjoedt, K. J., Christensen, P. K., Jorsal, A., Boomsma, F., Rossing, P. & Parving, H-H., nov. 2009, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 24, 11, s. 3343-9 7 s.

Nephropathy in type 1 diabetes is associated with increased circulating activated platelets and platelet hyperreactivity

Tarnow, L., Michelson, A. D., Barnard, M. R., Frelinger, A. L., Aasted, B., Jensen, B. R., Parving, H-H., Rossing, P. & Tarnow, L., nov. 2009, I: Platelets. 20, 7, s. 513-9 7 s.

Effect of adjunct metformin treatment on levels of plasma lipids in patients with type 1 diabetes

Lund, S. S., Tarnow, L., Bording Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, L., Pietraszek, L., Frandsen, M-L. F., Rossing, P., Parving, H-H. D. & Vaag, A. A., 1 okt. 2009, I: Diabetes, Obesity and Metabolism. 11, 10, s. 966-77 12 s.

Tubular and glomerular injury in diabetes and the impact of ACE inhibition

Nielsen, S. E., Sugaya, T., Tarnow, L., Lajer, M. S., Schjoedt, K. J., Astrup, A. S., Baba, T., Parving, H-H. & Rossing, P., sep. 2009, I: Diabetes Care. 32, 9, s. 1684-8 5 s.

Hypertension og diabetes mellitus

Poulsen, P. L., Hansen, K. W., Gaede, P. H. & Rossing, P., 8 jun. 2009, I: Ugeskrift for Laeger. 171, 24, s. 2031-4 4 s.

Klinisk vurdering af ekskretorisk nyrefunktion

Petersen, L. J., Birn, H., Ladefoged, S. A., Randers, E., Rehling, M., Reinholdt, B. & Rossing, P., 23 mar. 2009, I: Ugeskrift for Laeger. 171, 13, s. 1090

Klinisk vurdering af ekskretorisk nyrefunktion dansk nefrologisk selskab

Petersen, L. J., Birn, H., Ladefoged, S. A., Randers, E., Rehling, M., Reinholdt, B. & Rossing, P., 1 mar. 2009, I: Ugeskrift for Laeger. 171, 13, 1 s.

YKL-40, a marker of inflammation and endothelial dysfunction, is elevated in patients with type 1 diabetes and increases with levels of albuminuria

Rathcke, C. N., Persson, F., Tarnow, L., Rossing, P. & Vestergaard, H., feb. 2009, I: Diabetes Care. 32, 2, s. 323-8 6 s.

Follow-up of intensive glucose control in type 2 diabetes

Lund, S. S., Rossing, P. & Vaag, A. A., 22 jan. 2009, I: The New England journal of medicine. 360, 4, s. 416; author reply 418

Optimal dose of lisinopril for renoprotection in type 1 diabetic patients with diabetic nephropathy: a randomised crossover trial

Schjoedt, K. J., Astrup, A. S., Persson, F. I., Frandsen, E., Boomsma, F., Rossing, K., Tarnow, L., Rossing, P. & Parving, H-H. D., 2009, I: Diabetologia. 52, 1, s. 46-9 3 s.

Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria

Persson, F., Rossing, P., Reinhard, H., Juhl, T., Stehouwer, C. D. A., Schalkwijk, C., Danser, A. H. J., Boomsma, F., Frandsen, E. & Parving, H-H. D., 2009, I: Diabetes Care. 32, 10, s. 1873-9 6 s.

Serum uric acid as a predictor for development of diabetic nephropathy in type 1 diabetes: an inception cohort study

Hovind, P., Rossing, P., Tarnow, L., Johnson, R. J. & Parving, H-H., 2009, I: Diabetes. 58, 7, s. 1668-71 3 s.

Is renal Na⁺,K⁺-ATPase a new target for renin-angiotensin blocking agents in diabetic nephropathy?

Rossing, P., 15 nov. 2008, I: The Journal of physiology. 586, 22, s. 5283

Plasma osteoprotegerin levels predict cardiovascular and all-cause mortality and deterioration of kidney function in type 1 diabetic patients with nephropathy

Jorsal, A., Tarnow, L., Flyvbjerg, A., Parving, H-H., Rossing, P. & Rasmussen, L. M., nov. 2008, I: Diabetologia. 51, 11, s. 2100-7 8 s.

Serum adiponectin predicts all-cause mortality and end stage renal disease in patients with type I diabetes and diabetic nephropathy

Jorsal, A., Tarnow, L., Frystyk, J., Lajer, M. S., Flyvbjerg, A., Parving, H-H., Vionnet, N. & Rossing, P., sep. 2008, I: Kidney International. 74, 5, s. 649-54 6 s.

Elevated levels of high-molecular-weight adiponectin in type 1 diabetes

Leth, H., Andersen, K. K., Frystyk, J., Tarnow, L., Rossing, P., Parving, H-H. & Flyvbjerg, A., aug. 2008, I: The Journal of clinical endocrinology and metabolism. 93, 8, s. 3186-91 6 s.

The urinary proteome in diabetes and diabetes-associated complications: New ways to assess disease progression and evaluate therapy

Rossing, K., Mischak, H., Rossing, P., Schanstra, J. P., Wiseman, A. & Maahs, D. M., jul. 2008, I: Proteomics - Clinical Applications. 2, 7-8, s. 997-1007 11 s.

Urinary proteomics in diabetes and CKD

Rossing, K., Mischak, H., Dakna, M., Zürlbig, P., Novak, J., Julian, B. A., Good, D. M., Coon, J. J., Tarnow, L., Rossing, P. & PREDICTIONS Network, jul. 2008, I: Journal of the American Society of Nephrology : JASN. 19, 7, s. 1283-90 8 s.

Long-term prevention of diabetic nephropathy: an audit

Schjoedt, K. J., Hansen, H. P., Tarnow, L., Rossing, P. & Parving, H-H., jun. 2008, I: Diabetologia. 51, 6, s. 956-61 6 s.

Markers of endothelial dysfunction and inflammation in type 1 diabetic patients with or without diabetic nephropathy followed for 10 years: association with mortality and decline of glomerular filtration rate

Astrup, A. S., Tarnow, L., Pietraszek, L., Schalkwijk, C. G., Stehouwer, C. D. A., Parving, H-H. & Rossing, P., jun. 2008, I: Diabetes Care. 31, 6, s. 1170-6 7 s.

Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy

Nguyen, T. Q., Tarnow, L., Jorsal, A., Oliver, N., Roestenberg, P., Ito, Y., Parving, H-H., Rossing, P., van Nieuwenhoven, F. A. & Goldschmeding, R., jun. 2008, I: Diabetes Care. 31, 6, s. 1177-82 6 s.

Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes

Persson, F., Rossing, P., Schjoedt, K. J., Juhl, T., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C., Boomsma, F., Frandsen, E. & Parving, H-H., jun. 2008, I: Kidney International. 73, 12, s. 1419-25 7 s.

ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy

Parving, H-H., de Zeeuw, D., Cooper, M. E., Remuzzi, G., Liu, N., Luncford, J., Shahinfar, S., Wong, P. H., Lyle, P. A., Rossing, P. & Brenner, B. M., apr. 2008, I: Journal of the American Society of Nephrology : JASN. 19, 4, s. 771-9 9 s.

Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy

Lajer, M. S., Tarnow, L., Jorsal, A., Teerlink, T., Parving, H-H. & Rossing, P., apr. 2008, I: Diabetes Care. 31, 4, s. 747-52 6 s.

Effect of adjunct metformin treatment in patients with type-1 diabetes and persistent inadequate glycaemic control. A randomized study

Lund, S. S., Tarnow, L., Astrup, A. S., Hovind, P., Jacobsen, P. K., Alibegovic, A. C., Parving, I., Pietraszek, L., Frandsen, M., Rossing, P., Parving, H-H. & Vaag, A. A., 2008, I: P L o S One. 3, 10, s. e3363

Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study

Persson, F., Rossing, P., Hovind, P., Stehouwer, C. D. A., Schalkwijk, C. G., Tarnow, L. & Parving, H-H., 2008, I: Scandinavian Journal of Clinical & Laboratory Investigation. 68, 8, s. 731-8 8 s.

Predictors of mortality in patients with type 2 diabetes with or without diabetic nephropathy: a follow-up study

Astrup, A. S., Nielsen, F. S., Rossing, P., Ali, S., Kastrup, J., Smidt, U. M. & Parving, H-H., dec. 2007, I: Journal of Hypertension. 25, 12, s. 2479-85 7 s.

Pregnancy-associated plasma protein A in a large cohort of Type 1 diabetic patients with and without diabetic nephropathy-a prospective follow-up study

Astrup, A. S., Tarnow, L., Christiansen, M., Hansen, P. R., Parving, H-H. & Rossing, P., dec. 2007, I: Diabetic Medicine. 24, 12, s. 1381-5 5 s.

Diabetic nephropathy: worldwide epidemic and effects of current treatment on natural history

Rossing, P., dec. 2006, I: Current Diabetes Reports. 6, 6, s. 479-83 5 s.

Irbesartan treatment reduces biomarkers of inflammatory activity in patients with type 2 diabetes and microalbuminuria: an IRMA 2 substudy

Persson, F., Rossing, P., Hovind, P., Stehouwer, C. D. A., Schalkwijk, C., Tarnow, L. & Parving, H-H., dec. 2006, I: Diabetes. 55, 12, s. 3550-5 6 s.

Renoprotection by blocking the RAAS in diabetic nephropathy—fact or fiction?

Rossing, P., Parving, H-H. & de Zeeuw, D., sep. 2006, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 21, 9, s. 2354-7; discussion 2357-8

Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy

Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Tarnow, L., Rossing, P. & Parving, H-H., aug. 2006, I: Kidney International. 70, 3, s. 536-42 7 s.

Impact of renin angiotensin system blockade on night to day blood pressure ratio in diabetic nephropathy

Jacobsen, P. K., Rossing, P. & Parving, H-H., jul. 2006, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 21, 7, s. 2030-1 2 s.

Monitoring kidney function in type 2 diabetic patients with incipient and overt diabetic nephropathy

Rossing, P., Rossing, K., Gaede, P., Pedersen, O. & Parving, H-H., maj 2006, I: Diabetes Care. 29, 5, s. 1024-30 7 s.

ACE-hæmmere og AT-II-antagonister—beskytter de mod nyresygdom?

Rossing, P. & Parving, H-H., 10 apr. 2006, I: Ugeskrift for Læger. 168, 15, s. 1564; author reply 1564-5

Renoprotective effects of renin-angiotensin-system inhibitors

Parving, H-H. & Rossing, P., 18 mar. 2006, I: Lancet. 367, 9514, s. 898-9; author reply 900-2

Comparison of the effects of vitamins and/or mineral supplementation on glomerular and tubular dysfunction in type 2 diabetes

Rossing, P., Cooper, M. E. & Parving, H-H., mar. 2006, I: Diabetes Care. 29, 3, s. 747-8; author reply 748-9

Cardiac autonomic neuropathy predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy

Astrup, A. S., Tarnow, L., Rossing, P., Hansen, B. V., Hilsted, J. & Parving, H-H., feb. 2006, I: Diabetes Care. 29, 2, s. 334-9 6 s.

Prediction, progression and prevention of diabetic nephropathy. The Minkowski Lecture 2005

Rossing, P., jan. 2006, I: Diabetologia. 49, 1, s. 11-9 9 s.

Aldosterone synthase (CYP11B2)-344T/C polymorphism and renoprotective response to losartan treatment in diabetic nephropathy

Schjoedt, K. J., Lajer, M., Andersen, S., Tarnow, L., Rossing, P. & Parving, H-H., 2006, I: Scandinavian Journal of Clinical and Laboratory Investigation. 66, 3, s. 173-80 8 s.

Beneficial impact of spironolactone in diabetic nephropathy

Schjoedt, K. J., Rossing, K., Juhl, T. R., Boomsma, F., Rossing, P., Tarnow, L. & Parving, H-H., dec. 2005, I: Kidney International. 68, 6, s. 2829-36 8 s.

Progression of microalbuminuria in type 1 diabetes: ten-year prospective observational study

Rossing, P., Hougaard, P. & Parving, H-H., okt. 2005, I: Kidney International. 68, 4, s. 1446-50 5 s.

Improved prognosis in type 1 diabetic patients with nephropathy: a prospective follow-up study

Astrup, A. S., Tarnow, L., Rossing, P., Pietraszek, L., Riis Hansen, P. & Parving, H-H., sep. 2005, I: Kidney International. 68, 3, s. 1250-7 8 s.

Oral contraceptives, angiotensin-dependent renal vasoconstriction, and risk of diabetic nephropathy

Ahmed, S. B., Hovind, P., Parving, H-H., Rossing, P., Price, D. A., Laffel, L. M., Lansang, M. C., Stevanovic, R., Fisher, N. D. L. & Hollenberg, N. K., aug. 2005, I: Diabetes Care. 28, 8, s. 1988-94 7 s.

The changing epidemiology of diabetic microangiopathy in type 1 diabetes

Rossing, P., aug. 2005, I: Diabetologia. 48, 8, s. 1439-44 6 s.

Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy

Andersen, S., van Nieuwenhoven, F. A., Tarnow, L., Rossing, P., Rossing, K., Wieten, L., Goldschmeding, R. & Parving, H-H., jun. 2005, I: Kidney International. 67, 6, s. 2325-9 5 s.

Renoprotection with and without blood pressure reduction

Laverman, G. D., Andersen, S., Rossing, P., Navis, G., de Zeeuw, D. & Parving, H-H., apr. 2005, I: Kidney International, Supplement. 94, s. S54-9

Telmisartan vs. enalapril in type 2 diabetes

Parving, H-H., Hovind, P. & Rossing, P., 24 feb. 2005, I: The New England journal of medicine. 352, 8, s. 835-6; author reply 835-6

Risikofaktorer for udvikling af mikro- og makroalbuminuri ved type 1-diabetes: et incidenskohortestudie—en sekundaerpublikation

Hovind, P., Tarnow, L., Rossing, P., Jensen, B. R., Graae, M., Torp, I., Binder, C. & Parving, H-H., 2005, I: Ugeskrift for Laeger. 167, 1, s. 57-60 4 s.

Aldosterone escape during blockade of the renin-angiotensin-aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate

Schjoedt, K. J., Andersen, S., Rossing, P., Tarnow, L. & Parving, H-H., nov. 2004, I: Diabetologia. 47, 11, s. 1936-9 4 s.

Angiotensin receptor blockers in diabetic nephropathy: renal and cardiovascular end points

Parving, H-H., Andersen, S., Jacobsen, P., Christensen, P. K., Rossing, K., Hovind, P., Rossing, P. & Tarnow, L., 2004, I: Seminars in Nephrology. 24, 2, s. 147-57 11 s.

Improved survival in patients obtaining remission of nephrotic range albuminuria in diabetic nephropathy

Hovind, P., Tarnow, L., Rossing, P., Carstensen, B. & Parving, H-H., 2004, I: Kidney International. 66, 3, s. 1180-6 7 s.

Predictors for the development of microalbuminuria and macroalbuminuria in patients with type 1 diabetes: inception cohort study

Hovind, P., Tarnow, L., Rossing, P., Jensen, B. R., Graae, M., Torp, I., Binder, C. & Parving, H-H., 2004, I: BMJ. 328, 7448, s. 1105

Progression of nephropathy in type 2 diabetic patients

Rossing, K., Christensen, P. K., Hovind, P., Tarnow, L., Rossing, P. & Parving, H-H., 2004, I: Kidney International. 66, 4, s. 1596-605 10 s.

Birth weight—a risk factor for progression in diabetic nephropathy?

Jacobsen, P., Rossing, P., Tarnow, L., Hovind, P. & Parving, H-H., mar. 2003, I: Journal of Internal Medicine. 253, 3, s. 343-50 8 s.

Time course of the antiproteinuric and antihypertensive effect of losartan in diabetic nephropathy

Andersen, S., Jacobsen, P., Tarnow, L., Rossing, P., Juhl, T. R. & Parving, H-H., feb. 2003, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 18, 2, s. 293-7 5 s.

Decreasing incidence of severe diabetic microangiopathy in type 1 diabetes

Hovind, P., Tarnow, L., Rossing, K., Rossing, P., Eising, S., Larsen, N., Binder, C. & Parving, H-H., 2003, I: Diabetes Care. 26, 4, s. 1258-64 7 s.

Long-term renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen, S., Tarnow, L., Cambien, F., Rossing, P., Juhl, T. R., Deinum, J. & Parving, H-H., 2003, I: Diabetes Care. 26, 5, s. 1501-6 6 s.

Smoking and progression of diabetic nephropathy in type 1 diabetes

Hovind, P., Rossing, P., Tarnow, L. & Parving, H-H., 2003, I: Diabetes Care. 26, 3, s. 911-6 6 s.

Optimal dose of losartan for renoprotection in diabetic nephropathy

Andersen, S., Rossing, P., Juhl, T. R., Deinum, J. & Parving, H-H., aug. 2002, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 17, 8, s. 1413-8 6 s.

Risk factors for development of incipient and overt diabetic nephropathy in type 1 diabetic patients: a 10-year prospective observational study

Rossing, P., Hougaard, P. & Parving, H-H., maj 2002, I: Diabetes Care. 25, 5, s. 859-64 6 s.

Pregnancy and progression of diabetic nephropathy

Rossing, K., Jacobsen, P., Hommel, E., Mathiesen, E., Svenningsen, A., Rossing, P. & Parving, H-H., jan. 2002, I: Diabetologia. 45, 1, s. 36-41 6 s.

Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/deletion genotype?

Andersen, S., Tarnow, L., Cambien, F., Rossing, P., Juhl, T. R., Deinum, J. & Parving, H-H., 2002, I: Kidney International. 62, 1, s. 192-8 7 s.

Progression of diabetic nephropathy: role of plasma homocysteine and plasminogen activator inhibitor-1

Hovind, P., Tarnow, L., Rossing, P., Teerlink, T., Stehouwer, C. D., Emeis, J. J. & Parving, H. H., dec. 2001, I: American journal of kidney diseases : the official journal of the National Kidney Foundation. 38, 6, s. 1376-80 5 s.

Remission of nephrotic-range albuminuria in type 1 diabetic patients

Hovind, P., Rossing, P., Tarnow, L., Toft Sorensen, H., Parving, J. & Parving, H. H., nov. 2001, I: Diabetes Care. 24, 11, s. 1972-7 6 s.

Remission and regression in the nephropathy of type 1 diabetes when blood pressure is controlled aggressively

Hovind, P., Rossing, P., Tarnow, L., Smidt, U. M. & Parving, H. H., jul. 2001, I: Kidney International. 60, 1, s. 277-83 7 s.

Attitudes towards diabetes and its care: Evaluation before, immediately post-course and ≥ 1 year after a practical, international inter-disciplinary course for diabetes teams

Rossing, P., Andersen, H., Hesselholdt, L., Thorsteinsson, B., Reimers, J., Binder, C., Nerup, J. & Mandrup-Poulsen, T., 24 apr. 2001, I: Practical Diabetes International. 18, 2, s. 39-44 6 s.

Prolonged QTc interval predicts mortality in patients with Type 1 diabetes mellitus

Rossing, P., Breum, L., Major-Pedersen, A., Sato, A., Winding, H., Pietersen, A., Kastrup, J. & Parving, H. H., mar. 2001, I: Diabetic Medicine. 18, 3, s. 199-205 7 s.

Progression of diabetic nephropathy

Hovind, P., Rossing, P., Tarnow, L., Smidt, U. M. & Parving, H. H., feb. 2001, I: Kidney International. 59, 2, s. 702-9 8 s.

Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes

Parving, H. H. & Rossing, P., jan. 2001, I: Diabetes Care. 24, 1, s. 177-80 4 s.

Lack of effect of fish oil supplementation on coagulation and transcapillary escape rate of albumin in insulin-dependent diabetic patients with diabetic nephropathy

Myrup, B., Rossing, P., Jensen, T., Parving, H. H., Hølmer, G., Gram, J., Kluff, C. & Jespersen, J., 2001, I: Scandinavian Journal of Clinical and Laboratory Investigation. 61, 5, s. 349-56 8 s.

Preventing diabetic nephropathy: an audit

Hansen, H. P., Lund, S. S., Rossing, P., Tarnow, L., Nielsen, F. S., Jensen, T. & Parving, H. H., 2001, I: Scandinavian Journal of Clinical and Laboratory Investigation. 61, 6, s. 471-7 7 s.

Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy

Tarnow, L., Rossing, P., Jensen, C., Hansen, B. V. & Parving, H. H., dec. 2000, I: Diabetes Care. 23, 12, s. 1725-30 6 s.

Risikofaktorer for progression af diabetisk nefropati

Rossing, P., 18 sep. 2000, I: Ugeskrift for Laeger. 162, 38, s. 5057-61 5 s.

QTc interval length and QT dispersion as predictors of mortality in patients with non-insulin-dependent diabetes

Christensen, P. K., Gall, M. A., Major-Pedersen, A., Sato, A., Rossing, P., Breum, L., Pietersen, A., Kastrup, J. & Parving, H. H., jul. 2000, I: Scandinavian Journal of Clinical and Laboratory Investigation. 60, 4, s. 323-32 10 s.

Role of patient factors in therapy resistance to antiproteinuric intervention in nondiabetic and diabetic nephropathy

Bos, H., Andersen, S., Rossing, P., De Zeeuw, D., Parving, H. H., De Jong, P. E. & Navis, G., apr. 2000, I: Kidney International, Supplement. 75, s. S32-7

Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy

Andersen, S., Tarnow, L., Rossing, P., Hansen, B. V. & Parving, H. H., feb. 2000, I: Kidney International. 57, 2, s. 601-6 6 s.

Cardiovascular morbidity and early mortality cluster in parents of type 1 diabetic patients with diabetic nephropathy

Tarnow, L., Rossing, P., Nielsen, F. S., Fagerudd, J. A., Poirier, O. & Parving, H. H., jan. 2000, I: Diabetes Care. 23, 1, s. 30-3 4 s.

Increased sympathetic activity during sleep and nocturnal hypertension in Type 2 diabetic patients with diabetic nephropathy

Nielsen, F. S., Hansen, H. P., Jacobsen, P., Rossing, P., Smidt, U. M., Christensen, N. J., Pevet, P., Vivien-Roels, B. & Parving, H. H., jul. 1999, I: Diabetic Medicine. 16, 7, s. 555-62 8 s.

Progression of diabetic nephropathy in normotensive type 1 diabetic patients

Jacobsen, P., Rossing, K., Tarnow, L., Rossing, P., Mallet, C., Poirier, O., Cambien, F. & Parving, H. H., jul. 1999, I: Kidney International, Supplement. 71, s. S101-5

Natural course of kidney function in Type 2 diabetic patients with diabetic nephropathy

Christensen, P. K., Rossing, P., Nielsen, F. S. & Parving, H. H., maj 1999, I: Diabetic Medicine. 16, 5, s. 388-94 7 s.

Cyclosporine nephrotoxicity in type 1 diabetic patients. A 7-year follow-up study

Parving, H. H., Tarnow, L., Nielsen, F. S., Rossing, P., Mandrup-Poulsen, T., Osterby, R. & Nerup, J., mar. 1999, I: Diabetes Care. 22, 3, s. 478-83 6 s.

Effects of nisoldipine and lisinopril on left ventricular mass and function in diabetic nephropathy

Tarnow, L., Sato, A., Ali, S., Rossing, P., Nielsen, F. S. & Parving, H. H., mar. 1999, I: Diabetes Care. 22, 3, s. 491-4 4 s.

Concentration changes during venous occlusion of proteins with affinity for extracellular matrix in insulin-dependent diabetes mellitus A sign of vascular damage in patients with diabetic nephropathy?

Myrup, B., Rossing, P., Jensen, T., Gram, J., Kluff, C. & Jespersen, J., 1 jan. 1999, I: Fibrinolysis. 13, 3, s. 142-147 6 s.

Effects of nisoldipine and lisinopril on microvascular dysfunction in hypertensive Type I diabetes patients with nephropathy

Sørensen, V. B., Rossing, P., Tarnow, L., Parving, H., Nørgaard, T. & Kastrup, J., dec. 1998, I: Clinical science (London, England : 1979). 95, 6, s. 709-17 9 s.

Improved visual function in IDDM patients with unchanged cumulative incidence of sight-threatening diabetic retinopathy

Rossing, K., Jacobsen, P., Rossing, P., Lauritzen, E., Lund-Andersen, H. & Parving, H. H., nov. 1998, I: Diabetes Care. 21, 11, s. 2007-15 9 s.

Promotion, prediction and prevention of progression of nephropathy in type 1 diabetes mellitus

Rossing, P., nov. 1998, I: Diabetic Medicine. 15, 11, s. 900-19 20 s.

Diabetes and risk of adverse events with calcium antagonists

Parving, H. H. & Rossing, P., okt. 1998, I: Diabetes Care. 21, 10, s. 1779-80 2 s.

Promotion, prediction, and prevention of progression in diabetic nephropathy

Rossing, P., sep. 1998, I: Danish Medical Bulletin (Online). 45, 4, s. 354-69 16 s.

Betydningen af deletionspolymorfi i ACE-genet for progression af ACE-hæmmerbehandlet diabetisk nyresygdom

Tarnow, L., Parving, H. H., Jacobsen, P., Rossing, P., Lecerf, L., Poirier, O. & Cambien, F., 17 aug. 1998, I: Ugeskrift for Laeger. 160, 34, s. 4886-9 4 s.

Assessment of glomerular filtration rate in diabetic nephropathy using the plasma clearance of ⁵¹Cr-EDTA

Hansen, H. P., Rossing, P., Mathiesen, E. R., Hommel, E., Smidt, U. M. & Parving, H. H., aug. 1998, I: Scandinavian Journal of Clinical and Laboratory Investigation. 58, 5, s. 405-13 9 s.

Angiotensin converting enzyme gene polymorphism and ACE inhibition in diabetic nephropathy

Jacobsen, P., Rossing, K., Rossing, P., Tarnow, L., Mallet, C., Poirier, O., Cambien, F. & Parving, H. H., apr. 1998, I: Kidney International. 53, 4, s. 1002-6 5 s.

Risikofaktorer for død hos insulinkrævede diabetikere

Rossing, P., Hougaard, P., Borch-Johnsen, K. & Parving, H. H., 23 feb. 1998, I: Ugeskrift for Laeger. 160, 9, s. 1315-9 5 s.

Doubling of serum creatinine: is it sensitive and relevant?

Rossing, P., feb. 1998, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 13, 2, s. 244-6 3 s.

Differences between the effect of nisoldipine and lisinopril on microvascular dysfunction in hypertensive IDDM patients with nephropathy

Sørensen, V. B., Rossing, P., Tarnow, L., Parving, H. H., Nørgaard, T. & Kastrup, J., 1 dec. 1997, I: Scandinavian Cardiovascular Journal, Supplement. 31, 45, 1 s.

Kidney function after withdrawal of long-term antihypertensive treatment in diabetic nephropathy

Hansen, H. P., Nielsen, F. S., Rossing, P., Jacobsen, P., Jensen, B. R. & Parving, H. H., dec. 1997, I: Kidney International, Supplement. 63, s. S49-53

Lisinopril improves endothelial dysfunction in hypertensive NIDDM subjects with diabetic nephropathy

Nielsen, F. S., Rossing, P., Gall, M. A., Smidt, U. M., Chen, J. W., Sato, A. & Parving, H. H., aug. 1997, I: Scandinavian Journal of Clinical and Laboratory Investigation. 57, 5, s. 427-34 8 s.

Left ventricular hypertrophy in non-insulin-dependent diabetic patients with and without diabetic nephropathy

Nielsen, F. S., Ali, S., Rossing, P., Bang, L. E., Svendsen, T. L., Gall, M. A., Smidt, U. M., Kastrup, J. & Parving, H. H., jul. 1997, I: Diabetic Medicine. 14, 7, s. 538-46 9 s.

Long-term effect of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy

Nielsen, F. S., Rossing, P., Gall, M. A., Skøtt, P., Smidt, U. M. & Parving, H. H., jul. 1997, I: Diabetes. 46, 7, s. 1182-8 7 s.

Polymorphisms in the interleukin-1 gene cluster do not contribute to the genetic susceptibility of diabetic nephropathy in Caucasian patients with IDDM

Tarnow, L., Pociot, F., Hansen, P. M., Rossing, P., Nielsen, F. S., Hansen, B. V. & Parving, H. H., jun. 1997, I: Diabetes. 46, 6, s. 1075-6 2 s.

Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment

Rossing, P., Tarnow, L., Boelskifte, S., Jensen, B. R., Nielsen, F. S. & Parving, H. H., mar. 1997, I: Diabetes. 46, 3, s. 481-7 7 s.

Renal protection in diabetes—an emerging role for calcium antagonists

Parving, H. H., Tarnow, L. & Rossing, P., 1997, I: Cardiology. 88 Suppl 3, s. 56-62 7 s.

Lav fødselsvægt—øget risiko for diabetisk nefropati?

Rossing, P., Tarnow, L., Nielsen, F. S., Hansen, B. V., Brenner, B. M. & Parving, H. H., 30 dec. 1996, I: Ugeskrift for Laeger. 159, 1, s. 41-4 4 s.

Genetics of diabetic nephropathy

Parving, H. H., Tarnow, L. & Rossing, P., dec. 1996, I: Journal of the American Society of Nephrology : JASN. 7, 12, s. 2509-17 9 s.

Increased plasma apolipoprotein (a) levels in IDDM patients with diabetic nephropathy

Tarnow, L., Rossing, P., Nielsen, F. S., Hansen, B. V., Dyerberg, J. & Parving, H. H., dec. 1996, I: Diabetes Care. 19, 12, s. 1382-7 6 s.

Macro-microangiopathy and endothelial dysfunction in NIDDM patients with and without diabetic nephropathy

Parving, H. H., Nielsen, F. S., Bang, L. E., Smidt, U. M., Svendsen, T. L., Chen, J. W., Gall, M. A. & Rossing, P., dec. 1996, I: Diabetologia. 39, 12, s. 1590-7 8 s.

Fish oil in diabetic nephropathy

Rossing, P., Hansen, B. V., Nielsen, F. S., Myrup, B., Hølmer, G. & Parving, H. H., nov. 1996, I: Diabetes Care. 19, 11, s. 1214-9 6 s.

Renal protection in diabetes: an emerging role for calcium antagonists

Parving, H. H., Tarnow, L. & Rossing, P., nov. 1996, I: Journal of Hypertension, Supplement. 14, 4, s. S21-5

Diabetisk nefropati. Uændret forekomst hos patienter med insulinkrævende diabetes mellitus

Rossing, P., Rossing, K., Jacobsen, P. & Parving, H. H., 14 okt. 1996, I: Ugeskrift for Laeger. 158, 42, s. 5940-3 4 s.

Predictors of mortality in insulin dependent diabetes: 10 year observational follow up study

Rossing, P., Hougaard, P., Borch-Johnsen, K. & Parving, H. H., 28 sep. 1996, I: British Medical Journal. 313, 7060, s. 779-84 6 s.

Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study

Parving, H. H., Jacobsen, P., Tarnow, L., Rossing, P., Lecerf, L., Poirier, O. & Cambien, F., 7 sep. 1996, I: British Medical Journal. 313, 7057, s. 591-4 4 s.

Circadian rhythm of arterial blood pressure and albuminuria in diabetic nephropathy

Hansen, H. P., Rossing, P., Tarnow, L., Nielsen, F. S., Jensen, B. R. & Parving, H. H., aug. 1996, I: Kidney International. 50, 2, s. 579-85 7 s.

Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy

Tarnow, L., Cambien, F., Rossing, P., Nielsen, F. S., Hansen, B. V., Ricard, S., Poirer, O. & Parving, H. H., jun. 1996, I: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 11, 6, s. 1019-23 5 s.

Benefits of long-term antihypertensive treatment on prognosis in diabetic nephropathy

Parving, H. H., Jacobsen, P., Rossing, K., Smidt, U. M., Hommel, E. & Rossing, P., jun. 1996, I: *Kidney International*. 49, 6, s. 1778-82 5 s.

Increased tissue factor pathway inhibitor activity in IDDM patients with nephropathy

Yokoyama, H., Myrup, B., Rossing, P. & Ostergaard, P. B., maj 1996, I: *Diabetes Care*. 19, 5, s. 441-5 5 s.

Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy

Tarnow, L., Cambien, F., Rossing, P., Nielsen, F. S., Hansen, B. V., Ricard, S., Poirier, O. & Parving, H. H., mar. 1996, I: *Diabetes*. 45, 3, s. 367-369 3 s.

Elevated fibrinogen and the relation to acute phase response in diabetic nephropathy

Myrup, B., de Maat, M., Rossing, P., Gram, J., Klufft, C. & Jespersen, J., 15 feb. 1996, I: *Thrombosis Research*. 81, 4, s. 485-90 6 s.

Fibrinolysis in insulin-dependent diabetic patients with and without nephropathy

Myrup, B., Rossing, P., Jensen, T., Gram, J., Klufft, C. & Jespersen, J., 1 jan. 1996, I: *Fibrinolysis*. 10, 5-6, s. 331-335 5 s.

Prevention and treatment of diabetic nephropathy with blood pressure lowering drugs

Parving, H. H., Rossing, P., Tarnow, L., Hommel, E. & Mathiesen, E., 1996, I: *Nephrology*. 2, s. 45-48

Correlation between microalbuminuria and height

Rossing, P., 1 dec. 1995, I: *Biomedicine and Pharmacotherapy*. 49, 9, 1 s.

Low birth weight. A risk factor for development of diabetic nephropathy?

Rossing, P., Tarnow, L., Nielsen, F. S., Hansen, B. V., Brenner, B. M. & Parving, H. H., dec. 1995, I: *Diabetes*. 44, 12, s. 1405-7 3 s.

Angiotensin-converting enzyme inhibition in diabetic nephropathy: ten years' experience

Parving, H. H., Rossing, P., Hommel, E. & Smidt, U. M., jul. 1995, I: *American journal of kidney diseases : the official journal of the National Kidney Foundation*. 26, 1, s. 99-107 9 s.

Insertion/deletion polymorphism in the angiotensin-I-converting enzyme gene is associated with coronary heart disease in IDDM patients with diabetic nephropathy

Tarnow, L., Cambien, F., Rossing, P., Nielsen, F. S., Hansen, B. V., Lecerf, L., Poirier, O., Danilov, S., Boelskifte, S. & Borch-Johnsen, K., jul. 1995, I: *Diabetologia*. 38, 7, s. 798-803 6 s.

On the mechanisms of blunted nocturnal decline in arterial blood pressure in NIDDM patients with diabetic nephropathy

Nielsen, F. S., Rossing, P., Bang, L. E., Svendsen, T. L., Gall, M. A., Smidt, U. M. & Parving, H. H., jul. 1995, I: *Diabetes*. 44, 7, s. 783-9 7 s.

Unchanged incidence of diabetic nephropathy in IDDM patients

Rossing, P., Rossing, K., Jacobsen, P. & Parving, H. H., jul. 1995, I: *Diabetes*. 44, 7, s. 739-43 5 s.

Increased glomerular filtration rate after withdrawal of long-term antihypertensive treatment in diabetic nephropathy

Hansen, H. P., Rossing, P., Tarnow, L., Nielsen, F. S., Jensen, B. R. & Parving, H. H., jun. 1995, I: *Kidney International*. 47, 6, s. 1726-31 6 s.

Lack of relationship between an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene and diabetic nephropathy and proliferative retinopathy in IDDM patients

Tarnow, L., Cambien, F., Rossing, P., Nielsen, F. S., Hansen, B. V., Lecerf, L., Poirier, O., Danilov, S. & Parving, H. H., maj 1995, I: *Diabetes*. 44, 5, s. 489-94 6 s.

Short stature and diabetic nephropathy

Rossing, P., Tarnow, L., Nielsen, F. S., Boelskifte, S., Brenner, B. M. & Parving, H. H., 4 feb. 1995, I: British Medical Journal. 310, 6975, s. 296-7 2 s.

Procoagulant activity and intimal dysfunction in IDDM

Myrup, B., Rossing, P., Jensen, T., Gram, J., Klufft, C. & Jespersen, J., jan. 1995, I: Diabetologia. 38, 1, s. 73-8 6 s.

Prevalence of arterial hypertension in diabetic patients before and after the JNC-V

Tarnow, L., Rossing, P., Gall, M-A., Nielsen, F. S. & Parving, H. H., nov. 1994, I: Diabetes Care. 17, 11, s. 1247-51 5 s.

Impact of lisinopril and atenolol on kidney function in hypertensive NIDDM subjects with diabetic nephropathy

Nielsen, F. S., Rossing, P., Gall, M. A., Skøtt, P., Smidt, U. M. & Parving, H. H., sep. 1994, I: Diabetes. 43, 9, s. 1108-13 6 s.

Monitoring kidney function in diabetic nephropathy

Rossing, P., Astrup, A. S., Smidt, U. M. & Parving, H. H., jul. 1994, I: Diabetologia. 37, 7, s. 708-12 5 s.

Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment

Rossing, P., Hommel, E., Smidt, U. M. & Parving, H. H., maj 1994, I: Diabetologia. 37, 5, s. 511-6 6 s.

The use of antihypertensive agents in prevention and treatment of diabetic nephropathy

Parving, H. H. & Rossing, P., maj 1994, I: Current opinion in nephrology and hypertension. 3, 3, s. 292-300 9 s.

Glomerular size- and charge selectivity in type 2 (non-insulin-dependent) diabetic patients with diabetic nephropathy

Gall, M. A., Rossing, P., Kofoed-Enevoldsen, A., Nielsen, F. S. & Parving, H. H., feb. 1994, I: Diabetologia. 37, 2, s. 195-201 7 s.

Reduction in albuminuria predicts diminished progression in diabetic nephropathy

Rossing, P., Hommel, E., Smidt, U. M. & Parving, H. H., feb. 1994, I: Kidney International, Supplement. 45, s. S145-9

The effect of the relationship between tissue-type plasminogen activator and plasminogen activator inhibitor type 1 on tissue-type plasminogen activator activity in insulin-dependent diabetes mellitus

Myrup, B., Rossing, P., Jensen, T., Gram, J., Klufft, C. & Jespersen, J., 1 jan. 1994, I: Fibrinolysis and Proteolysis. 8, SUPPL. 2, s. 22-24 3 s.

Effective antihypertensive treatment postpones renal insufficiency in diabetic nephropathy

Parving, H. H., Smidt, U. M., Hommel, E., Mathiesen, E. R., Rossing, P., Nielsen, F. & Gall, M. A., jul. 1993, I: American journal of kidney diseases : the official journal of the National Kidney Foundation. 22, 1, s. 188-95 8 s.

Calcium antagonists and the diabetic hypertensive patient

Parving, H. H. & Rossing, P., jun. 1993, I: American journal of kidney diseases : the official journal of the National Kidney Foundation. 21, 6 Suppl 3, s. 47-52 6 s.

Apolipoprotein(a) and cardiovascular disease in type 2 (non-insulin-dependent) diabetic patients with and without diabetic nephropathy

Nielsen, F. S., Voldsgaard, A. I., Gall, M. A., Rossing, P., Hommel, E., Andersen, P., Dyerberg, J. & Parving, H. H., maj 1993, I: Diabetologia. 36, 5, s. 438-44 7 s.

Impact of arterial blood pressure and albuminuria on the progression of diabetic nephropathy in IDDM patients

Rossing, P., Hommel, E., Smidt, U. M. & Parving, H. H., maj 1993, I: Diabetes. 42, 5, s. 715-9 5 s.

Effekten af captopril-, metoprolol- og hydroklortiazidbehandling hos ikke-insulinkrævende diabetikere (NIDDM) med primær hypertension. En dobbeltblind, randomiseret overkrydsningsundersøgelse

Gall, M. A., Rossing, P., Skøtt, P., Hommel, E. E., Mathiesen, E. R., Gerdes, L. U., Lauritzen, M., Vølund, A., Faergeman, O. & Beck-Nielsen, H., 1 mar. 1993, I: Ugeskrift for Læger. 155, 9, s. 636-41 6 s.

Apolipoprotein(a) in insulin-dependent diabetic patients with and without diabetic nephropathy

Gall, M. A., Rossing, P., Hommel, E., Voldsgaard, A. I., Andersen, P., Nielsen, F. S., Dyerberg, J. & Parving, H. H., okt. 1992, I: Scandinavian Journal of Clinical and Laboratory Investigation. 52, 6, s. 513-21 9 s.

Placebo-controlled comparison of captopril, metoprolol, and hydrochlorothiazide therapy in non-insulin-dependent diabetic patients with primary hypertension

Gall, M. A., Rossing, P., Skøtt, P., Hommel, E., Mathiesen, E. R., Gerdes, L. U., Lauritzen, M., Vølund, A., Faergeman, O. & Beck-Nielsen, H., maj 1992, I: American Journal of Hypertension. 5, 5 Pt 1, s. 257-65 9 s.

Plasma lipoproteins and renal function during simvastatin treatment in diabetic nephropathy

Hommel, E., Andersen, P., Gall, M. A., Nielsen, F., Jensen, B., Rossing, P., Dyerberg, J. & Parving, H. H., maj 1992, I: Diabetologia. 35, 5, s. 447-51 5 s.

3. Comparison of captopril, metoprolol and hydrochlorothiazide in hypertensive type-2 (non-insulin-dependent) diabetic patients

Rossing, P., Gall, M., Skott, P., Hommel, E., Mathiesen, E. R., Gerdes, U., Beck-Nielsen, H. & Parving, H. H., 1 jan. 1992, I: Journal of Hypertension. 10, 8, 1 s.

Prevalence of micro- and macroalbuminuria, arterial hypertension, retinopathy and large vessel disease in European type 2 (non-insulin-dependent) diabetic patients

Gall, M. A., Rossing, P., Skøtt, P., Damsbo, P., Vaag, A., Bech, K., Dejgaard, A., Lauritzen, M., Lauritzen, E. & Hougaard, P., sep. 1991, I: Diabetologia. 34, 9, s. 655-61 7 s.

Red cell Na⁺/Li⁺ countertransport in non-insulin-dependent diabetics with diabetic nephropathy

Gall, M. A., Rossing, P., Jensen, J. S., Funder, J. & Parving, H. H., jan. 1991, I: Kidney International. 39, 1, s. 135-40 6 s.

Aktiviteter

Atrial Fibrillation and Diabetes

Peter Rossing (Foredragsholder)
14 apr. 2021

New treatments for Diabetic Kidney Disease

university copenhagen (Foredragsholder)
14 jan. 2021

DIABETESBEHANDLING AF DEN NYRESYGE PATIENT

Peter Rossing (Foredragsholder)
20 jan. 2020

56th EASD Annual Meeting of the European Association for the Study of Diabetes

Peter Rossing (Arrangør)
2020

CKD in Patients With T2D

Peter Rossing (Foredragsholder)
2020

DAPA CKD background

Peter Rossing (Foredragsholder)
2020

Diabetes and atrial fibrillation
Peter Rossing (Foredragsholder)
2020

DIABETESBEHANDLING AF DEN NYRESYGE PATIENT
Peter Rossing (Foredragsholder)
2020

Empagliflozin: cardiorenal benefits in patients with type 2 diabetes, beyond glycemic control
Peter Rossing (Foredragsholder)
2020

Intervention and monitoring of diabetic nephropathy in 2020
Peter Rossing (Foredragsholder)
2020

ISN-ISE Webinar: Current management of diabetes in patients with kidney diseases
Peter Rossing (Foredragsholder)
2020

KDIGO diabetes management guideline
Peter Rossing (Foredragsholder)
2020

KDIGO DKD Guideline
Peter Rossing (Foredragsholder) & Peter Rossing (Foredragsholder)
2020

KDIGO guideline for Diabetes
Peter Rossing (Foredragsholder)
2020

KDIGO guideline for management of diabetes in CKD
Peter Rossing (Foredragsholder)
2020

Management of Diabetes in CKD
Peter Rossing (Foredragsholder)
2020

Mechanisms That Matter: CKD and T2D."
Peter Rossing (Foredragsholder)
2020

Metabolic Determinants of Cardiac and Renal Complications in Type 1 Diabetes
Peter Rossing (Foredragsholder)
2020

Navigating through the treatment options after metformin
Peter Rossing (Foredragsholder)
2020

New Treatment Options for Kidney Disease in Diabetes

Peter Rossing (Foredragsholder)
2020

Novel Mineralocorticoid Receptor Antagonists and cardio-renal protection in diabetes— Beyond SGLT2 Inhibitors and GLP-1 Receptor Agonists

Peter Rossing (Foredragsholder)
2020

Patient eligible for finerenone

Peter Rossing (Foredragsholder)
2020

Patient for SGLT2i

Peter Rossing (Foredragsholder)
2020

Patients with AF and Diabetes: Is it Possible to Avoid Irreversible Complications?

Peter Rossing (Foredragsholder)
2020

Recommendations for Glycemia Monitoring and Targets in CKD

Peter Rossing (Foredragsholder)
2020

Results and Sub-Analysis of DAPA-CKD Trial

Peter Rossing (Foredragsholder)
2020

Results and Sub-Analysis of DAPA-CKD Trial

Peter Rossing (Foredragsholder)
2020

Role of SGLT2 Inhibitors for Management of Cardiorenal Syndrome in Diabetes: From Prevent to Treatment

Peter Rossing (Foredragsholder)
2020

Seeing the forest for the trees

Peter Rossing (Foredragsholder)
2020

suPAR and Complications of Diabetes Mellitus

Peter Rossing (Foredragsholder)
2020

Targeting the mineralocorticoid receptor to reduce CKD in T2D: is it time for a new treatment paradigm?

Peter Rossing (Foredragsholder)
2020

Targeting the Mineralocorticoid Receptor to Reduce the Risk of Chronic Kidney Disease Progression in Type 2 Diabetes/

Peter Rossing (Foredragsholder)
2020

Translational research and management leadership

Peter Rossing (Andet)

2020 → ...

What is next after Metformin? Understanding the guidelines

Peter Rossing (Foredragsholder)
2020

Where are we now, and how should we move forward Update guideline from KDIGO 2020 DM in CKD

Peter Rossing (Foredragsholder)
2020

Linking kidney and cardiovascular complications - impact on prognosis and treatment

Peter Rossing (Foredragsholder)
14 dec. 2019

Echocardiography in Diabetes and Heart Failure

Peter Rossing (Foredragsholder)
5 dec. 2019

Management of hyperglycemia in type 2 diabetes

Peter Rossing (Konsulent)
5 dec. 2019

GLP 1 in diabetic kidney disease

Peter Rossing (Foredragsholder)
4 dec. 2019

Pathophysiology of diabetic kidney disease

Peter Rossing (Foredragsholder)
27 nov. 2019

EASD Scientist training course 2019

Peter Rossing (Arrangør)
18 nov. 2019

KDIGO guideline on Diabetic Nephropathy

Peter Rossing (Foredragsholder)
17 okt. 2019

Diabetic Kidney Disease

Peter Rossing (Foredragsholder)
11 okt. 2019

Diabetic Nephropathy

Peter Rossing (Foredragsholder)
7 okt. 2019

Diabetic Nephropathy update

Peter Rossing (Foredragsholder)
21 sep. 2019

Metformin safety and efficacy in CKD

Peter Rossing (Foredragsholder)
19 sep. 2019

Proteomic prediction and renin angiotensin aldosterone system inhibition prevention of early diabetic nephropathy in type 2 diabetes with normoalbuminuria (PRIORITY) study

Peter Rossing (Foredragsholder)
19 sep. 2019

Mechanisms of Kidney Disease Progression: Understanding the role of inflammation and fibrosis

Peter Rossing (Foredragsholder)
16 sep. 2019

Steering group member

Peter Rossing (Konsulent)
1 aug. 2019 → 31 jan. 2021

Diabetic kidney disease: Learnings so far

Peter Rossing (Foredragsholder)
14 jun. 2019

Edwin Bierman award: The link between the kidney and heart

Peter Rossing (Foredragsholder)
8 jun. 2019

Diabetic Kidney Disease

Peter Rossing (Foredragsholder)
26 mar. 2019

Sonar Study of Atrasentan in diabetic kidney disease

Peter Rossing (Foredragsholder)
13 mar. 2019

Guidelines for diabetes

Peter Rossing (Foredragsholder)
10 mar. 2019

New EASD ADA guidelines, and Nephroprotection with Type 2 DMtreatment

Peter Rossing (Foredragsholder)
27 jan. 2019

International Diabetes Federation 2019

Peter Rossing (Arrangør)
1 jan. 2019 → 6 dec. 2019

steering group member

Peter Rossing (Konsulent)
1 jan. 2019 → 31 dec. 2019

Myocardial Flow Reserve Assessed by Cardiac 82Rb PET/CT Is Associated with Albumin Excretion in Patients with Type 1 Diabetes

Emilie Hein Zobel (Foredragsholder), Signe Abitz Winther (Andet), Bernt Johan von Scholten (Andet), Lene Holmvang (Andet), Andreas Kjær (Andet), Peter Rossing (Andet) & Tine Willum Hansen (Andet)
26 okt. 2018

EASD ADA guideline on treatment of hyperglycaemia in Type 2 Diabetes

Peter Rossing (Foredragsholder)
5 okt. 2018

Diabetes and Hypertension

Peter Rossing (Foredragsholder)
10 aug. 2018

Steering group member

Peter Rossing (Konsulent)
1 aug. 2018 → 31 jan. 2021

ADA EASD position paper on treatment of hyperglycaemia in Type 2 Diabetes

Peter Rossing (Foredragsholder)
25 jun. 2018

Diabetes and Hypertension

Peter Rossing (Foredragsholder)
27 maj 2018

Urine proteome - is there a role in predicting and monitoring diabetic nephropathy

Peter Rossing (Foredragsholder)
26 maj 2018

New Treatments in Diabetic Kidney Disease

Peter Rossing (Foredragsholder)
24 maj 2018

Prognosis and treatment of diabetic nephropathy :recent advances and perspectives

Peter Rossing (Foredragsholder)
22 apr. 2018

KDIGO guideline on Diabetic Kidney Disease

Peter Rossing (Konsulent)
20 jan. 2018 → 1 maj 2020

Steering group member

Peter Rossing (Konsulent)
1 jan. 2018 → 31 jan. 2021

IDF Congress 2017

Allan Flyvbjerg (Deltager), Peter Rossing (Deltager), Ingrid Willaing (Deltager), Tina Vilsbøll (Deltager), Nana Folmann Hempler (Deltager), Mette Andersen Nexø (Deltager) & Bryan Cleal (Deltager)
4 dec. 2017 → 8 dec. 2017

ASN Kidney Week 2017

Peter Rossing (Deltager), Marie Frimodt-Møller (Deltager), Tine Wilum Hansen (Deltager), Mie Klessen Eickhoff (Deltager), Nete Tofte (Deltager) & Curovic Viktor Rotbain (Deltager)
31 okt. 2017 → 5 nov. 2017

53rd Annual Meeting of the European Association for the study of Diabetes EASD

Allan Flyvbjerg (Deltager), Birgitte Brock (Deltager), Peter Rossing (Deltager), Marit Eika Jørgensen (Deltager), Susanne Engberg (Deltager), Marie Frimodt-Møller (Deltager), Narges Safai (Deltager), Nete Tofte (Deltager), Tina Vilsbøll (Deltager), Viktor Rotbain Curovic (Deltager), Bryan Cleal (Deltager) & Kasper Olesen (Deltager)
11 sep. 2017 → 15 sep. 2017

American Diabetes Association's 77th Scientific Sessions, ADA 2017

Allan Flyvbjerg (Deltager), Peter Rossing (Deltager), Birgitte Brock (Deltager) & Tommi Suvitaival (Deltager)

9 jun. 2017 → 13 jun. 2017

30th Annual General Meeting of the European Diabetic Nephropathy Study Group, EDNSG

Peter Rossing (Deltager)

19 maj 2017 → 20 maj 2017

Diabetic Nephropathy

Peter Rossing (Foredragsholder)

2017 → ...

Treatment of Diabetes in CKD

Peter Rossing (Foredragsholder)

2017 → ...

Priser

Claus Bruun Honorary Lecture

Rossing, Peter (Modtager), 2010

Dandy foundation honorary award

Rossing, Peter (Modtager), 2000

Edward Bierman Award

Rossing, Peter (Modtager), 9 jun. 2019

GOLGI prize

Rossing, Peter (Modtager), 2016

Knud Lundbæk award

Rossing, Peter (Modtager), 2017

Minkowski Prize

Rossing, Peter (Modtager), 2005

Niels A Lassen prize

Rossing, Peter (Modtager), 2015

Niels Schwartz-Sørensen Prize

Rossing, Peter (Modtager), 2008

Novartis Young Investigator Award

Rossing, Peter (Modtager), 2008

Professor Vishvanathans Honorary Award

Rossing, Peter (Modtager), 2012

Ruth Østerby Honorary Award

Rossing, Peter (Modtager), 2013

Projekter

Deep phenotyping of the heart with advanced imaging modalities in type 2 diabetes – implications for pathophysiology and prognosis (DIA-HEART study)

Kjær, A., Ribel-Madsen, R., Hasbak, P., Rasmussen, I. K. B., Zobel, E. H., Rossing, P. & Holmvang, L.
01/08/2019 → 01/08/2024

GALAXY: Gut-and-liver axis in alcoholic liver fibrosis

Rossing, P. & Trost, K.
01/01/2016 → 31/12/2021

Personalizing Treatment of Diabetic Nephropathy

Rossing, P.
01/06/2015 → 30/06/2021

Prevention of early renal function decline

Rossing, P.
20/12/2012 → 02/11/2019

PRIMETIME

Rossing, P., Persson, F. & Hansen, D.
31/12/2019 → 31/12/2024

PRIORITY: Proteomic prediction and Renin angiotensin aldosterone system Inhibition prevention Of early diabetic nephropathy In TYpe 2 diabetic patients with normoalbuminuria

Rossing, P., Persson, F. & Tofte, N.
02/01/2012 → 31/12/2018